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1.1 Heterochromatin and epigenetics 
1.1.1 Heterochromatin 
In eukaryotic cells, genomic DNA is folded with histone and non-histone proteins to form 
chromatin. Chromatin is divided into two major compartments called euchromatin and 
heterochromatin. Euchromatin or “true” chromatin is referred as the transcriptionally active 
region of chromatin where heterochromatin is considered to be transcriptionally inert, 
consisting primarily of highly repetitive sequences, such as satellite sequences, transposable 
elements, centromeric and telomeric sequences which participate critically in the formation of 
chromosomal structures essential for proper chromosome function (Hughes and Hawley, 2009). 
Heterochromatin itself is further classified into two distinct groups as constitutive and 
facultative (Brown, 1966). Facultative heterochromatin is defined as euchromatic regions that 
become packaged into a compact heterochromatin-like form generated in a developmental 
manner (e.g. autosomal imprinted genomic loci) which retain the potential to interconvert 
between heterochromatin and euchromatin (Gilbert et al., 2003) whereas constitutive 
heterochromatin describes large segments of the genome, primarily arrays of tandemly 
repeated sequences which are packaged in a permanently inactive form (Gilbert and Allan, 2001).  
It was Emil Heitz who first distinguished heterochromatin from euchromatin 82 years ago on 
the basis of a series of cytogenetic observations (Heitz, 1928). He stained cells from several 
species of moss with carmine acetic acid and observed a type of chromatin in the nucleus that 
remained condensed throughout the cell cycle, which was different from euchromatin that 
underwent cycles of condensation and decondensation at different stages of the cell cycle. His 
observations were followed by those of Hermann Joseph Muller’s, who first described the 
phenomenon of position effect variegation (PEV) in Drosophila (Muller, 1930). Muller used X-
rays as a mutagen and observed, in mutant flies, a variegating eye phenotype with some 
patches of red and some patches of white facets. Variegation was due to the change in the 
position of a typically distal gene, “white” to a more proximal position within the pericentric 
heterochromatin due to an X-ray induced chromosomal inversion. The evidence that genes 
that were more proximal to heterochromatin were silenced first, with subsequent silencing of 
Introduction 
 
8 
 
distal genes later came from the studies of Demerec, Slisynska (Demerec and Slisynska, 1937) and 
Schultz (Schultz, 1939) and led eventually to the idea of linear spreading of heterochromatin 
along the chromosomes, an idea that still has an influence on the theories of chromatin-
mediated silencing. Genetic screens for dominant second-site mutations on flies exhibiting a 
PEV phenotype were extremely useful for the identification of loci likely to encode (hetero-) 
chromatin components or enzymes that modify those components (Reuter and Spierer, 1992).  As a 
result of these analyses, about 30 modifiers of PEV have been isolated and characterized so far 
that are either suppressors (Su(var)) or enhancers (E(var)) of PEV. Heterochromatin protein 
1 (HP1 – Su(var)2-5) and the histone methyltransferase Su(var)3-9 are among the most 
important chromatin components revealed by this approach, which will be explained in more 
detail below (James and Elgin, 1986; Tschiersch et al., 1994). 
1.1.2 Epigenetics 
The word epigenetics was coined by Conrad Hal Waddington (1905-1975) in 1942 as “the 
branch of biology which studies the causal interactions between genes and their products, which bring 
the phenotype into being” (Waddington, 1942) although the root term “epigenesis” dates back to 
Aristotle (384-322 BC) where he used it in opposition to “preformation” and argued that 
there were no preformed equivalents in the fertilized egg for later developing structures. 
Waddington elegantly put these terms into the context of development in his 1939 book “An 
Introduction to Modern Genetics” (Waddington, 1939) where he wrote that as “the interaction of 
these constituents [of the fertilized egg] gives rise to new types of tissue and organ which were not 
present originally,...development must be considered as ‘epigenetic’.” In light of many more 
discoveries that have dramatically increased our understanding of the molecular mechanisms 
underlying regulation of eukaryotic gene expression, the current definition of epigenetics has 
been evolved into: “the study of mitotically and/or meiotically heritable changes in gene function 
that cannot be explained by changes in DNA sequence” (Riggs et al., 1996). 
Several interrelated epigenetic mechanisms have been identified so far including noncoding 
RNAs, chromatin remodelling, histone variant composition, DNA methylation and histone 
modifications, which will be further explained below. 
Introduction 
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1.1.2.1 Noncoding RNAs 
The RNAi machinery (e.g. dicer, argonaute, siRNA, miRNA) is an evolutionarily conserved 
set of proteins that breaks down double-stranded RNA (dsRNA) species into smaller siRNA 
molecules (short interfering RNA). These small siRNAs inhibit mRNA translation into 
proteins and thereby reduce gene expression. Notably, a transcriptional gene silencing 
mechanism has been discovered in fission yeast S. pombe, where mutations of any component 
of the RNAi machinery resulted in defects in chromosome segregation that is likely due to a 
defect in centromeric heterochromatin (Hall et al., 2002; Reinhart and Bartel, 2002; Volpe et al., 2002). 
Further work in yeast and fruit flies has indicated strongly a role for the RNAi machinery in 
the assembly of silent heterochromatin domains (Grewal, 2010). 
1.1.2.2 Chromatin remodelling and histone variants 
According to current concepts, chromatin composition can be changed by the recruitment of 
chromatin “remodelling” complexes (Ho and Crabtree, 2010). These remodelling complexes are 
able to mobilize nucleosomes and/or alter nucleosomal structure resulting in conformational 
changes that regulate the accessibility of several transcriptional factors and regulators to 
DNA. Remodelers can be generalized into two families, namely ISWI and SWI/SNF (Ho and 
Crabtree, 2010); ISWI complexes are thought to mobilize nucleosomes, allowing them to move 
along the DNA, while SWI/SNF complexes are thought to alter the structure of the 
nucleosome itself (Tsukiyama et al., 1995; Varga-Weisz et al., 1997). There are also other remodelling 
complexes like Swr1 (Mizuguchi et al., 2004) and SRCAP (Ruhl et al., 2006) that are dedicated to the 
replacement of core histones with specialized histone variants. Some examples the histone 
variants known today include histone H3.3 that replaces histone H3.1 in regions of high 
transcriptional activity, CENP-A which is the centromere specific H3 variant, H2A.Z which 
is correlated with open promoters in yeast and H2A.X which is primarily associated with 
sensing DNA damage and augments the recruitment of DNA repair complexes (Sarma and 
Reinberg, 2005; Cairns, 2009). 
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1.1.2.3 DNA methylation 
The methylation of the cytosines in CpG dinucleotides in mammalian genomic DNA 
represents the archetypal epigenetic mechanism, having been studied for many decades since 
it was posited that DNA methylation could regulate gene activity (Riggs, 1975; Holliday and Pugh, 
1975). DNA methylation involves the addition of a methyl group at cytosine residues of the 
DNA template by DNMTs (DNA methyltransferases). This modification does not change 
the primary DNA sequence but impacts on gene activity and expression in a heritable fashion 
(Razin and Riggs, 1980). The addition of a methyl group in vertebrates occurs mostly on the 
cytosine within CG dinucleotides (CpG) although there is evidence that also non-CpG 
methylation exists, primarily within CA nucleotides, which is detected mainly in stem cells 
(Schübeler, 2009). 60-90 % of all CpGs are methylated in mammals whereas “CpG islands”, 
CpG-enriched sequences that frequently coincide with gene promoter regions, are generally 
unmethylated (Bird, 1986). In higher eukaryotes, CpG methylation is associated with a repressed 
chromatin environment and is involved in various processes such as gene repression, 
imprinting, X-chromosome inactivation, suppression of repetitive genomic elements, and 
carcinogenesis (Bird, 2002). 
1.1.2.4 Histone modifications 
The fundamental chromatin unit, or nucleosome, contains 146 bp of DNA, which is wrapped 
around an octamer of histones (Luger et al., 1997). All higher order levels of compaction (e.g. the 
30 nm fibre) are assembles out of this fundamental nucleosome particle. Accordingly, there is 
a current high interest how post-translational modifications of the constituent histones of the 
nucleosome might be involved in the epigenetic regulation of gene activity. It is known that 
histones are modified by covalent modifications at specific positions within the amino-
terminus of the core histones (the “histone tails”) that protrude from the nucleosome (Figure 
1). These modifications include lysine acetylation, methylation, ubiquitination and 
sumoylation, arginine methylation, serine and threonine phosphorylation, glutamate ADP-
ribosylation, and proline isomerization. Lysine residues can be mono-, di- or tri- methylated  
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Figure 1 Some of the most studied covalent modifications and their positions on histones are depicted. 
 
Lysine 
acetylation 
Serine & threonine 
phosphorylation 
Arginine 
methylation 
Lysine 
methylation 
Establishers HATs Kinases PRMTs HKMTs 
Examples 
Gcn5, Src1, TAF1, CBP 
& p300, Sas3, MOZ & 
MORF, PCAF & hGcn5, 
Rtt109, Esa1, Hat1, 
HBO1, Mof, Sas2 
Snf1, Jil-1, Rsk2, Msk1, 
lp11, Aurora B, Sps1, 
CKII, Mst1, Haspin, 
ATM, DNA-PK 
CARM1, PRMT1 
Set1, SET7/SET9, 
SUV39H1&SUV39H2, 
G9a, Eu-HMTase1, 
ESET&SETDB1, 
Clr4, EZH2, DOT1, 
SUV420, SET9 
Removers HDACs PPtases Deiminases 
Amine oxidases, 
hydroxylases 
Examples RPD3, Hda1, HDAC1-10 Glc7, PP1, PP2A JMJD6 
JARID1A-C, LSD1, 
Lid, UTX, JMJD3, 
JHDM1-3 
 
Table 1 Enzymes that are responsible for site specific histone modifications. “Establishers” are the enzymes that are 
responsible for the transfer of the stated modifications on the amino acids, whereas “removers” remove these 
modifications. HAT: Histone acetyltransferase, PRMT: Protein arginine methyltransferase, HKMT: Histone lysine 
methyltransferase, HDAC: Histone deacetylase, PPtase: Protein phosphatase. 
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whereas arginine residues can be modified into symmetric or asymmetric dimethylated states, 
or into a monomethylated state (Gelato and Fischle, 2008). These modifications can also be reversed 
and many enzymes and complexes have been identified and characterized that modify 
histones or return histone residues to an unmodified state (Bhaumik et al., 2007) (Table 1).  
Existence of such distinct histone modifications are thought to generate synergistic or 
antagonistic interaction affinities for chromatin-associated proteins that in turn dictate 
dynamic transitions between transcriptionally active (on) or transcriptionally silent (off) 
chromatin states. In general, histone acetylation and H3K4, –K36, -K79 methylation are 
related to a transcriptionally active state, whereas H3K9, -K27 and H4K20 methylation are 
indicative of a silent state. This notion has led to the proposal of a “histone code” hypothesis 
where histone modifications are thought to change higher order chromatin structures and 
thus regulate accessibility of genomic information (Strahl and Allis, 2000). Although an interesting 
hypothesis, it remains unproven particularly because generalisations are somewhat difficult to 
make as histone modification patterns vary considerably between organisms (especially 
between lower and higher eukaryotes). 
1.2 Heterochromatin protein 1 (HP1) 
In addition to enzymatic activities that can reversibly modify the histones, the “histone code” 
hypothesis posits that there are “adapter” proteins that recognize the modifications and 
“translate” the code into biological function. Of these adapter proteins, one of the first to be 
characterized was the non-histone chromosomal protein, heterochromatin protein 1 (HP1) 
(Eissenberg and Elgin, 2000). HP1 was first identified in D. melanogaster as a mutation Su(var)205, 
that dominantly suppresses PEV (James and Elgin, 1986; Eissenberg et al., 1990). The subsequent 
cloning of the wild type gene product showed it to be a chromatin protein that predominantly 
localizes to pericentromeric heterochromatin (James et al., 1989). HP1 is a phylogenetically highly 
conserved protein with homologues in diverse organisms including both plants and animals 
(Singh et al., 1991) with the exception of budding yeast, in which PEV relies on silent information 
regulatory (SIR) proteins. Studies in many organisms have shown that HP1 homologues are 
involved in the establishment and maintenance of higher-order chromatin structures by 
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specifically recognizing and binding to (tri- and di-) methylated histone H3K9 (Bannister et al.,  
2001; Lachner et al., 2001). Artificial recruitment of HP1 to a gene promoter region results in gene 
repression in many organisms, establishing the role of HP1 in gene silencing (Ayyanathan et al., 
2003; Li et al., 2003).  
The HP1 family of proteins are encoded by a class of genes known as the chromobox (Cbx) 
genes. In mammals, there are three homologues of D. melanogaster HP1, termed HP1α 
(Cbx5), HP1β (Cbx1), and HP1γ (Cbx3) (Jones et al., 2000). They share a high degree of sequence 
similarity and localize, to a lesser or greater extent, to constitutive heterochromatin: 
HP1α and HP1β are usually found enriched at sites of constitutive heterochromatin such as 
centromeres and telomeres, whereas HP1γ has a more uniform distribution (Minc  et al., 1999; 
Minc  et al., 2000; Dialynas et al., 2007). Although HP1 proteins are concentrated at pericentric 
heterochromatin in most organisms, they are also found at euchromatin, where their binding 
correlates with the repression of genes (Fanti et al., 2003; Grewal and Moazed, 2003). For example, 
HP1α and HP1γ were shown to be recruited by the hormone-induced repression of a viral 
promoter fused to a transgene reporter inserted into mouse euchromatin (Ayyanathan et al., 2003). 
HP1γ has also been found to associate with actively transcribed gene regions and to play a role 
in efficient transcriptional elongation (Vakoc et al., 2005; Lomberk et al., 2006). 
HP1 proteins are part of a larger superfamily of proteins containing chromatin organization 
modifier (chromo) domain (CD), which is an evolutionarily conserved region of 30-60 amino 
acids found in the amino-terminal half of these proteins. Many members of this superfamily 
are known to function in gene regulation and heterochromatin formation, such as the 
Polycomb protein PC1, a silencer of homeotic genes (Paro and Hogness, 1991).  The CD of HP1 
shares greater than 60 % amino acid sequence identity with the Polycomb CD and 
substitution of these chromodomains in HP1 and PC1 with each other changes their nuclear 
localization patterns indicating a role of the CD in both target-site binding and target 
preference (Platero et al., 1995). HP1 proteins are also characterized by the presence of a second 
unique conserved domain in the C-terminal half of the protein, known as the chromoshadow 
domain (CSD) (Aasland and Stewart, 1995). CSD shares amino-acid sequence identity with the 
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CD, but has different functions. It can dimerize to form a hydrophobic pocket that can 
accommodate a pentapeptide PxVxL sequence motif, found in several HP1-interacting 
partners such as such as transcriptional intermediary factors (TIFs) and chromatin assembly 
factor 1 (CAF1) (Brasher et al., 2000; Thiru et al., 2004; Nielsen et al., 1999; Murzina et al., 1999) (Figure 2).  
1.2.1 HP1β 
Among the three mammalian HP1 isoforms HP1β is the best characterized. It is a small 
protein of around 25 kDa and has the typical N-terminal CD/C-terminal CSD structure with 
a poorly conserved hinge region in between. Although the structure of the intact HP1β has 
not yet been determined, three dimensional structures of the CD and CSD have been 
elucidated by NMR spectroscopy and X-ray crystallography (Figure 2) (Ball et al., 1997; Brasher et 
al., 2000; Huang et al., 2006). The similarity of the CD and CSD at the level of the primary 
sequence (identity 24 %) is reflected in a concomitant similarity at the tertiary level with each 
globule consisting of an anti-parallel, three-stranded, β-sheet that backs onto one (CD) or 
two (CSD) α-helices. Recombinant HP1β CSD dimerizes in solution with the dimer focused 
upon helix α2, which interacts symmetrically and at an angle of 35° with helix α2 of the 
adjacent CSD subunit and forms a non-polar pit that can accommodate pentapetides with the 
consensus sequence motif PxVxL that is found in several HP1-interacting proteins (Figure 2).  
Chromoshadow domain Chromoshadow domain dimer Chromodomain 
Figure 2 Tertiary structures of HP1β chromodomain (green), chromoshadow domain (pink) and the chromoshadow domain 
dimer (pink & blue) are depicted (Billur et al., 2010). At the level of primary sequence, CD and CSD are 24 % identical and 
this similarity is also reflected upon the tertiary level with each globule consisting of an anti-parallel, three-stranded, β-sheet 
that backs onto one (CD) or two (CSD) α-helices. The CSD dimer interface centers on helix α2, which interacts 
symmetrically and at an angle of 35° with helix α2 of a neighboring subunit and forms a ‘‘nonpolar’’ pit that can 
accommodate pentapeptides with the consensus sequence motif PxVxL. 
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HP1β localizes to constitutive heterochromatin through a variety of interactions with 
chromatin. One involves a dynamic interaction of the HP1β CD with the H3K9me3 
determinant of the histone code with a KD of 1.9 µM that results from the enzymatic 
activities of Suv39h1/h2 histone methyltransferases (Rea et al., 2000, Cheutin et al., 2003, Festenstein et al., 
2003). In cells taken from Suv39h1/h2 double-null mutant mice, the enrichment of both 
H3K9me3 and H4K20me3 at centromeric heterochromatin is lost, and HP1β is found 
homogeneously distributed throughout both the eu- and heterochromatin (Peters et al., 2001; 
Kourmouli et al., 2004; Kourmouli et al., 2005; Schotta et al., 2004). Enrichment of HP1β at heterochromatin 
could be reconstituted in these cells by exogenously expressed Suv39h1 but not by a Suv39h1 
mutant that lacks H3K9 histone methyltransferase activity. Together with other studies, this 
has led to the development of a model where HP1β–H3K9me3 binding leads to further 
methylation of H3K9 on adjacent nucleosomes through the interaction of HP1β with 
Suv39h1, thereby resulting in the spreading of a repressive heterochromatic chromosomal 
domain (Bannister et al., 2001). The NMR solution structure of the HP1β CD–H3K9me3 
complex and the crystal structure of D. melanogaster HP1 CD with the H3 tail peptide 
revealed that the binding site for the H3K9me3 peptide is the groove in the HP1β CD and 
that a short stretch of amino acids in the histone tail (E5 - S10) were involved in this binding 
(Jacobs et al., 2002; Nielsen et al., 2002). An induced fit mechanism has been shown to be utilized 
where the HP1β N-terminus wraps around the H3K9me3 peptide as binding takes place. As 
a result of this, three conserved aromatic residues (Y21, W42 and F45) are brought together 
to form a notional “aromatic cage” in which the positively charged methylammonium 
functional moiety of H3K9me3 fits in largely through electrostatic interactions forming a 
cation-π bond (Figure 3) (Dougherty, 2007). Non-conservative substitutions at any of these 
Figure 3 A notional “aromatic cage” is formed from three conserved aromatic residues: 
Y21, W42 and F45. The interaction between the methylammonium moiety and the 
aromatic cage is largely electrostatic and mediated by cation-π interactions where the 
positively charged (cation) moiety is attracted to the negative electrostatic potential of 
the aromatic groups’ π-system (Billur et al., 2010). 
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aromatic residues have been shown to cause a 200-500 fold reduction in the binding affinity 
of HP1 CD for the H3K9me3 peptide (Jacobs et al., 2002). It has been shown that the 
phosphorylation of the adjacent serine residue (S10) in the H3K9me3 peptide also reduces 
the affinity of HP1β CD for the histone tail by 100 fold and this is probably caused by the 
interference of this residue with the side chains of T51 and E53. As a result of this 
phosphorylation, most of the chromatin-bound HP1β is excluded into the cytoplasm at 
metaphase and this is thought to be required for chromatin to undergo maximal compaction 
during formation of metaphase chromosomes (Fischle et al., 2005; Hirota et al., 2005). 
Another key interaction of HP1β which has been studied in some detail is the binding to 
histone H3 histone-fold domain. The binding of HP1β to the histone-fold region (amino 
acids 48–136) of recombinant, non-modified, histone H3 has been shown to be resistant to 
0.6 M NaCl concentration and is not perturbed by a 200-fold excess of H3K9me3 peptide 
(Nielsen et al., 2001; Dialynas et al., 2006). Mutational analysis on HP1β and D. melanogaster HP1 
indicates that a single residue, valine 23, is probably responsible for both H3K9me3 and 
histone H3 binding (Nielsen et al., 2002; Jacobs et al., 2001). Binding to histone H3 fold probably 
occurs only if the histone H3 fold is accessible and the fact that HP1β binds poorly to 
mononucleosomes but strongly to oligonucleosomal arrays that contain various nucleosome 
assembly/disassembly intermediates is in support of this hypothesis (Dialynas et al., 2006). Passage 
through S-phase seems to be required for the stable incorporation of HP1β into 
heterochromatin as evidenced by the failure of cells blocked in S-phase to incorporate HP1β 
into heterochromatin (Dialynas et al., 2006). S-phase results in the disruption of chromatin and 
may explain the observation that HP1β preferentially binds to H3-H4 subparticles in S-phase 
extracts. H3-H4 subparticles can also be isolated from bulk heterochromatin using GST-
HP1β “pull downs” and have been shown being not to be particularly enriched in the 
H3K9me3 determinant of the histone code (Dialynas et al., 2006) indicating that the binding of 
HP1β to histone H3 fold does not require the presence of H3K9me3 on the same histone. 
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1.2.2 HP1β, centromeres and sister chromatid cohesion 
Centromeres were originally defined by Flemming in 1880 as a cytologically visible “primary” 
constriction in the chromosome (Flemming, 1880). The current definition is that the centromere 
consists of the DNA plus chromatin proteins that are responsible for kinetochore formation 
(Torras-Llort et al., 2009). The kinetochore itself defines a small, transiently assembled structure 
whose function is to attach chromosomes to spindle microtubules, generate force for 
chromosome movements, and produce a signal that delays anaphase onset until all 
chromosomes are attached to the spindle microtubules (Figure 4) (Pidoux and Allshire, 2005). In 
most eukaryotes the kinetochore forms only on a subset of the long arrays of repetitive DNA 
associated with centromeres and these ‘regional’ centromeres are specified by epigenetic 
mechanisms instead of the primary DNA sequence. It has been shown that the centromeric 
heterochromatin in humans has a conserved organization with a typical association with 
specific histone methylation patterns, high levels of DNA methylation, low recombination 
frequency and repression of transcription (Blower et al., 2002). Both centromeric chromatin and 
flanking pericentromeric heterochromatin are required for chromosome segregation and de 
novo chromosome assembly and they are distinct epigenetic entities with their own 
characteristics. Whereas centromeric chromatin is continuous and contains the histone variant 
CENP-A as well as H3K4me2, the flanking pericentric heterochromatin is defined by 
H3K9me2 and H3K9me3 and exerts a repressive effect on gene transcription, which appears 
to be relevant for the activity of the centromere (Sullivan and Karpen, 2004; Lam et al., 2006). The HP1 
and Su(var)3-9 proteins are also located at the heterochromatic pericentromeric regions in 
Drosophila and mammals (James et al., 1989; Wreggett et al., 1994; Aagaard et al., 1999; Minc et al., 1999). In 
fission yeast, the absence of either Swi6 (HP1) or Clr4 (Su(var)3-9) has been shown to result 
Telomere 
Centromeric chromatin 
Perientromeric heterochromatin 
Outer kinetochore 
Inner kinetochore 
Spindle microtubules 
Cohesin Figure 4. The structural organization of a mitotic, metacentric chromosome. 
Centromeric chromatin underlies the kinetochore, which contains inner and 
outer plates that form microtubule attachment sites. Pericentromeric 
heterochromatin flanks centromeric chromatin, and contains a high density of 
cohesin, which mediates sister chromatid cohesion (redrawn from Allshire and 
Karpen, 2008). 
Introduction 
 
18 
 
in the alleviation of outer repeat (and mating type) silencing, and Swi6 is specifically located 
at these regions (Allshire et al., 1995; Ekwall et al., 1995; Partridge et al., 2000; Nakayama et al., 2000; Noma et al., 
2001). 
 Sister chromatid cohesion is required to ensure faithful chromosome segregation by ensuring 
biorientation of chromosomes on the mitotic or meiotic spindle (Lee and Orr-Weaver, 2001). 
Cohesion depends on a multi-subunit, ring-shaped cohesin complex which consists of a 
heterodimer of structural maintenance of chromosomes (SMC) subunits, SMC1 and SMC3, 
the kleisin subunit SCC1 (also known as Mcd1/Rad21), and SCC3 (also known as 
SA/STAG) (Peters et al., 2008) (Figure 5). Loading of this complex on chromatin occurs in early 
G1 in vertebrates which establishes cohesion during S phase (Uhlmann and Nasmyth, 1998; Watrin et 
al., 2006). As a result of the so-called prophase pathway that involves Aurora B and Polo 
kinases, as well as a number of additional cohesin-interacting factors, most cohesin dissociates 
from chromatin at the onset of mitosis (Losada et al., 2002; Dai et al., 2006). However, a small 
population of cohesin, enriched mainly at the centromeric region, remains on chromatin until 
the onset of anaphase when it is finally removed through the cleavage of the SCC1 N-
terminus by separase (Waizenegger et al., 2000; Wirth et al., 2006). Protection of centromeric cohesin 
from the prophase pathway is established by the centromere-specific SGO1 protein, a 
member of a class of proteins known as shugoshins (means “guardian spirit” in Japanese), 
whose founding member is the Mei-S332 protein in D. melanogaster (Kerrebrock et al., 1995; Kitajima 
et al., 2005; McGuinness et al., 2005; Salic et al., 2004). SGO1 proteins possess a conserved coiled-coil 
domain that binds the ABC PP2A holoenzyme (ATP binding cassette protein phosphatase 
SMC3 SMC1 
SCC1 
SCC3 
N C 
Separase 
Hinge 
Figure 5. The structure of the cohesin complex (yeast nomenclature) which is a 
heterodimer formed between SMC1 and SMC3 subunits. Each subunit composed of a ca. 
50 nm long intramolecular antiparallel coiled coil, forms a rod-shaped protein with a 
globular “hinge” domain at one end and an ATP nucleotide-binding domain at the other. 
At the onset of anaphase, separase cleaves the SCC1 subunit and removes cohesin from 
chromosomes. 
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2A), which is also localized to centromeres in mitotic cells and is required for maintaining 
cohesion in early mitosis in human cells and in meiosis I in yeast (Kitajima et al., 2006; Riedel et al., 
2006; Tang et al., 2006). It is thought that PP2A counteracts cohesin phosphorylation by Polo 
thereby preventing the cohesin’s release. An additional mechanism that has evolved in 
eukaryotes to prevent chromosome missegregation is the spindle assembly checkpoint (SAC). 
SAC activity delays the metaphase-to-anaphase transition until all chromosomes establish 
proper attachments to spindle microtubules and align at the metaphase plate. There are 
several evolutionary conserved core components of the SAC, including:  BUB1, BUB3, 
MAD1, MAD2, BUBR1 (MAD3 in yeast), MPS1 and Aurora B. It has been shown that the 
proper localization of SGO1 at centromeres requires both the spindle checkpoint protein 
BUB1, Aurora B and also HP1α (Kitajima et al., 2005; Tang et al., 2004; Yamagishi et al., 2008). In human 
cells treated with an siRNA against HP1α, SGO1 localization was abolished and the 
centromeric cohesin was largely dissociated in the SGO1-lacking chromosomes (Yamagishi et al., 
2008). Besides SGO1 has also been shown to directly interact with GST-tagged HP1α, HP1β 
and HP1γ indicating a role for HP1 proteins in the localization of SGO1 (Serrano et al., 2009). 
Recently, Kawashima et al. have shown that Bub1 is responsible for the phosphorylation of a 
conserved serine residue at position 121 of histone H2A in fission yeast and demonstrated 
that this single phosphorylation event is required for the correct localization and function of 
SGO1 and that this pathway is conserved from yeast to human (Kawashima et al., 2010; Javerzat, 
2010). 
As explained, the role of heterochromatin in cohesion formation and proper sister chromatid 
segregation has been under investigation for some time. However, there have been conflicting 
results concerning the role of HP1 proteins in regulating chromosome cohesion. In fission 
yeast, the methyltransferase Clr4 (Suv39h1 homologue) and Swi6 (HP1 homologue) have 
been shown to be required for the enrichment of cohesin at centromeres in interphase and to 
be essential for centromeric cohesion in both mitosis and meiosis (Bernard et al., 2001; Nonaka et al., 
2002; Kitajima et al., 2003). Specifically, Swi6 mutants lack cohesin in the outer centromeric repeat 
region and, as a consequence, show chromosome segregation defects. Supporting the 
conservation of this mechanism in higher eukaryotes, mouse cells deficient for Suv39h1 and 
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Suv39h2 histone methyltransferases, in which there is no apparent enrichment of HP1 in 
pericentric heterochromatin, showed reduced cohesion in the pericentric major satellite (Peters 
et al., 2001; Guenatri et al., 2004). However another group, using the same Suv39h1/h2 deficient cells, 
showed that neither the association of cohesin with major satellite repeats in interphase nor 
the enrichment of cohesin on mitotic centromeres is detectably reduced compared to wt cells 
(Koch et al., 2008). Moreover, mutants of Su(var)39 in Drosophila show a slight reduction in the 
amount of cohesin in the 1.688 pericentric satellite (Peng and Karpen, 2007) but Drosophila larvae 
expressing reduced or mutant versions of HP1 show no apparent defects in pericentromeric 
cohesion (Fanti et al., 1998). Finally, Serrano et al. showed that depletion of all three HP1 
isoforms by siRNA in human cells did not perturb cohesin loading onto chromatin in 
interphase and the presence of cohesin in the pericentric regions of metaphase chromosomes 
(Serrano et al., 2009). Thus, the role of mammalian HP1 proteins in chromosome cohesion 
remains an open question. 
1.2.3 HP1β and telomeres  
Telomeres are nucleoprotein structures with two specific functions: they ensure that DNA 
replication includes the very ends of the chromosomes, overcoming the “end-replication 
problem”, and also form a protective “cap” to prevent the natural ends of linear chromosomes 
from degradation and from being detected as double-strand DNA breaks by the DNA repair 
machinery (Lue, 2004; Chan and Blackburn, 2004; Palm and de Lange; 2008). In mammals, telomeres consist 
of double-stranded G-rich repeats ending in a single-stranded 3´overhang (the G-strand 
overhang), which provides the substrate for telomerase. The G-strand overhang can also fold 
back and invade the double-stranded region of telomeres, forming a protective structure 
known as the T-loop (Griffith et al., 1999; de Lange, 2004) (Figure 6). The majority of eukaryotes, 
including mammals, use the repeated sequence TTAGGG at their chromosome ends and the 
length of these repeats varies greatly between different mammals. Human telomeres are 
around 10–15 kilobases (kb) long at birth, whereas the telomeres of laboratory mice and rats 
are 20–50 kb long (de Lange et al., 1990; Hastie et al., 1990; Kipling and Cooke, 1990; Lejnine et al., 1995). The 
length of the telomeres is maintained by the enzyme telomerase, which is a reverse 
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transcriptase that adds telomeric repeats de novo after each cell division, counteracting the 
end-replication problem in those cell types in which it is expressed (Chan and Blackburn, 2002; 
Collins and Mitchell, 2002). An alternative way of maintaining telomere length has also been 
described, such as ALT (alternative lengthening of telomeres), which relies on homologous 
recombination between telomeric sequences (Dunham et al., 2000; Muntoni and Reddel, 2005).  
The protective cap function of telomeres is essential for organisms as the slightest defect in 
this structure results in a damage response that leads to a cell cycle checkpoint arrest and/or 
attempts to repair the chromosome end by non-homologous end joining leading to end-to-
end fusion of chromosomes followed by chromosome breakage (Riha et al., 2006). In order to 
maintain this function, a number of proteins have evolved that bind to telomeres and play 
vital roles. This complex is termed “shelterin” in mammals and consists of six specialized 
proteins: telomeric repeat binding factor 1-2 (TRF1-TRF2), repressor and activator protein 1 
(RAP1), TRF1 interacting nuclear protein 2 (TIN2), protection of telomeres 1 (POT1) and 
TPP1 (formerly known as TINT1, PTOP, or PIP1) (Figure 6) (Palm and de Lange, 2008; O'Sullivan 
and Karlseder, 2010). The components of shelterin specifically localize to telomeres; they are 
abundant at telomeres throughout the cell cycle and they do not function elsewhere in the 
nucleus. TRF1 and TRF2 bind the double stranded part of telomeres, whereas POT1 can 
bind the single stranded TTAGGG repeats present at the 3’ overhang and in the D-loop of 
the T-loop configuration. These TRF1 and TRF2 DNA binding modules are bridged by 
TPP1 and TIN2 and are crucial for chromosome end protection and telomere length 
regulation. TRF1 and TRF2 are constitutively present at telomeres and the proportion of 
TRF1 and TRF2 loaded on telomeres is important for telomere length regulation. RAP1 
does not bind TTAGGG repeats and its telomeric localization is dependent on interaction 
Figure 6 Mammalian telomeres end in a 3′ overhang of the G-
rich strand that is the substrate for telomerase-mediated telomere 
elongation. The G-strand overhang can fold back and invade the 
double-stranded region of the telomere, thereby generating a 
looped structure known as the telomere loop (T-loop). The 
overhang then forms base pairs with the C-rich strand, displacing 
the G-strand at this site into a displacement loop (D-loop). 
D-loop 
T-loop 
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with TRF2. RAP1 has recently been implicated in the inhibition of non-homologous end 
joining in vitro and in vivo (Bae and Baumann, 2007; Sarthy et al., 2009). There are two paralogues of 
POT1 in mouse: POT1a and POT1b. Disruption of these two genes in mouse embryonic 
ﬁbroblasts has been shown to result in reduced proliferation, a severe telomeric DNA damage 
response, chromosome reduplication, increased sister telomere recombination and resection of 
the telomeric C-strand to give long G-overhangs (Hockemeyer et al., 2006; Wu et al., 2006). TPP1, on 
the other hand, connects POT1 with TIN2 through its centrally located POT1 interaction 
domain and depletion of TPP1 leads to removal of all detectable POT1 from telomeres. 
Furthermore, impaired TPP1 function leads to unprotected telomeres and telomere length 
phenotypes like the ones seen in POT1 deficient cells (Hockemeyer et al., 2007; Lazzerini and de Lange, 
2007; Liu et al., 2004; Xin et al., 2007; Ye et al., 2004). 
In addition to the shelterin complex, telomeric sequences are also bound by nucleosomes that 
are enriched in histone modifications characteristic of constitutive heterochromatin domains 
(García-Cao et al., 2004; Makarov et al., 1993) including trimethylation of H3K9 and H4K20 by the 
histone methyltransferases Suv39h1/h2 and Suv420h1/h2 and are therefore rich in 
heterochromatin proteins HP1α, HP1β and HP1γ. The overexpression of HP1β in human 
cells has been shown to result in reduced association of human telomerase reverse 
transcriptase with the telomere and a higher frequency of end-to-end chromosomal fusions, 
indicating that the concentration of HP1β in the nucleus can affect telomere function (Sharma 
et al., 2003). Similar telomere dysfunction and enhanced genomic instability has previously been 
observed in Drosophila larvae that are null mutant for HP1 (Perrini et al., 2004). It has also been 
shown that the reduction of all three isoforms of HP1 proteins in mice causes abnormal 
telomere elongation (Garcia-Cao et al., 2004) indicating a potential regulatory function of these 
proteins at the ends of mammalian chromosomes.  
1.2.4 HP1β and oncogene-induced senescence (OIS)  
Cellular senescence was originally described as the process of cell cycle arrest that accompanies 
the exhaustion of replicative potential in cultured human fibroblasts (Hayflick and Moorhead, 1961). 
It is now defined as an irreversible proliferation arrest that occurs in response to various cell 
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stresses, including activated oncogenes (oncogene-induced senescence), critically short 
telomeres (replicative senescence) or DNA damage. Senescence is also thought to be an 
important tumour suppression mechanism with a distinct role in organismal ageing. 
Senescence can be distinguished from quiescence, a form of cell cycle arrest that is reversible 
following exposure to appropriate cellular signals, by its irreversibility. Senescent cells have a 
typical flat and enlarged morphology (Serrano et al., 1997), are positive for senescence-associated 
β-galactosidase (SA-β-Gal) (Dimri et al., 1995) and have a characteristically changed pattern of 
gene expression particularly in genes involved in regulation of the cell cycle, extra-cellular 
matrix remodelling, cytokine signalling and inflammation (Fridman and Tainsky, 2008). Most 
strikingly, senescent cells possess senescence-associated heterochromatic foci (SAHF) that are 
manifest as large blocks of HP1-containing heterochromatin domains in the nucleus (Narita et 
al., 2003). 
Oncogene-induced senescence (OIS) was initially described more than a decade ago when a 
senescence phenotype was unexpectedly observed on overexpression of an oncogenic version 
of H-ras (H-rasG12V) in normal cells grown in vitro (Serrano et al., 1997). These cells stopped 
dividing and suffered morphological and molecular changes that were indistinguishable from 
senescence. In OIS there was also an upregulation of p16INK4A and p19ARF tumour suppressors 
which are thought to be responsible for the cell cycle arrest. It is now known that OIS in 
primary cells is mediated by the two main tumour suppressor pathways of the cell: the 
p19ARF/p53 and/or the p16INK4A/Retinoblastoma (pRb) pathways (Gil and Peters, 2006; Kim and 
Sharpless, 2006). In vivo evidence for this tumour suppressor mechanism was found when cellular 
senescence, with the concomitant increase in senescence markers, was observed in a variety of 
mouse and human premalignant tumours while malignant tumours lack the markers and 
continued to proliferate (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Lazzerini Denchi et al., 2005; 
Michaloglou et al., 2005). These data placed senescence as a tumour suppressor mechanism 
operating in the premalignant stages of tumorigenesis to prevent progression of oncogenically 
stressed cells. In particular, Collado and colleagues showed that the expression of oncogenic 
K-ras (KrasV12) triggered senescence during the early stages of tumorigenesis driven by this 
oncogene and identified premalignant (adenomas) as well as malignant (adenocarcinomas) 
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tumours in the lungs of these mice (Guerra et al., 2203; Collado et al., 2005). They showed that 
premalignant lesions in the lung contained abundant senescent cells positive for OIS markers 
(SA-β-gal, p15, p16, Dec1, DcR2 and HP1γ) and concluded that a substantial number of 
cells in premalignant tumours undergo OIS. In contrast, cells in malignant adenocarcinomas 
continued to proliferate and did not express these OIS markers. Subsequent studies using 
similar mouse models based on endogenous K-ras have produced contradictory results. 
Therefore more studies are needed for the accurate role of K-ras oncogene in OIS (Collado and 
Serrano, 2010). 
A specific role for p16 in OIS is the maintenance of the growth arrest through activation of 
pRb. This p16INK4A/pRb pathway has been shown to be crucial for the formation of SAHF, 
highly condensed regions of chromatin with a typical accumulation of H3K9me3 and 
heterochromatin proteins, including HP1, high-mobility group A (HMGA) proteins and 
macroH2A (Narita et al., 2003; Narita et al., 2006; Zhang et al., 2005). It has been reported that access of 
the transcription factor E2F to its target genes is prevented by SAHF formation resulting in a 
stable repression of the transcription of S-phase promoting genes and thereby contributing to 
a robust cell cycle arrest (Narita et al., 2003; Narita et al., 2006; Dimova and Dyson, 2005). Besides, Suv39h1 
histone methyltransferase activity was shown to be required for Ras-induced OIS in 
lymphocyte cells; in Suv39h1-deficient lymphomas, pRb was not able to activate the 
senescence pathway and promote senescence. The fact that pRb physically interacts with both 
HP1 and Su(var)39h1 suggests a role of HP1 proteins in OIS (Nielsen et al., 2001; Trimarchi and Lees, 
2002).  
1.2.5 HP1β knockout mice 
In a first attempt to elucidate the function of HP1β in vivo, the murine Cbx1 gene encoding 
HP1β was disrupted in the Singh laboratory using gene targeting which resulted in a perinatal 
lethal phenotype (Aucott et al., 2008). Cbx1-/- neonates exhibited no gross morphological 
abnormalities in the major organs. However, it was observed that the lung alveoli remained 
collapsed after birth due to the inability of the diaphragm to respond to the activating signals 
from the intramuscular nerve as evidenced by a significant reduction in the number of 
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acetylcholine receptor clusters per µm of the nerve. Cbx1-/- mutant brains showed aberrant 
cerebral cortex development, reduced proliferation of neuronal precursors, widespread cell 
death and edema. In vitro cultures of neurospheres from Cbx1-/- mutant brains revealed a 
dramatic genomic instability as evidenced by a statistically significant increase in premature 
centromere division, increased ploidy, micronuclei formation and diplochromosomes 
compared to WT cells. Strikingly, the Cbx1-/- phenotype is more severe than the viable double 
null Suv39h1/h2 phenotype and, in addition, the overall H3K9me3 and H4K20me3 levels 
and distribution are unchanged in Cbx1-/- neurons. Based on these observations, it has been 
proposed that the essential interaction of HP1β, whose loss results in the lethality, lies outside 
its interaction with the H3K9me3 determinant of the “histone code” that is imposed by the 
Suv39h1/h2 HMTases. Instead, it has been posited that the loss of an immobile fraction of 
HP1β that binds tightly to the H3 histone fold might be responsible for the dramatic 
genomic instability seen in Cbx1-/- cortical neurons (Billur et al., 2010). It would seem that despite 
many years of study on HP1β, its true physiological function still remains to be elucidated. 
1.3 The goal of the study 
This study builds on the observations on the Cbx1 (gene encoding the HP1β protein) null 
mutant mice. Cbx1 function is essential for organismal survival. The null mutants die at 
around birth and in vitro cultures of neurospheres from Cbx1-/- brains revealed a dramatic 
genomic instability as evidenced by a statistically significant increase in premature centromere 
division, increased ploidy, micronuclei formation and diplochromosomes compared to WT 
cells (Aucott et al., 2008). Based on this phenotype one major goal of this study is to describe, in 
concrete cellular and molecular terms, the role of HP1β on genomic stability. To that end, the 
effects of Cbx1 null mutation on telomere function and sister chromatid cohesion are 
investigated. A second goal is to investigate the role of HP1β in OIS, using both in vivo and 
in vitro model systems. Finally, in order to characterise the critical interaction of HP1β, 
which is likely to result in the lethality seen in the Cbx1 mutants, the binding affinity of 
HP1β (and its mutants), to recombinant histone H3 is measured using isothermal titration 
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calorimetry (ITC) and this binding affinity is compared to the affinity of HP1β to the 
H3K9me3 peptide. 
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2.1 Materials 
2.1.1 Primers 
All primers were purchased from Eurofins MWG Operon (Ebersberg, Germany). 
 
 
 
 
 
 
 
 
 
 
2.1.2 Plasmids 
GST-HP1α:  Expresses full length mouse heterochromatin protein-1 α as a GST fusion protein in 
pGEX-4T-1 vector (provided by Dr. P. B. Singh, see Appendix for sequence) 
GST-HP1β:  Expresses full length mouse heterochromatin protein-1 β as a GST fusion protein in 
pGEX-3X vector (provided by Dr. P. B. Singh, see Appendix for sequence) 
GST-HP1γ:  Expresses full length mouse heterochromatin protein-1 γ as a GST fusion protein in 
pGEX-3X vector (provided by Dr. P. B. Singh, see Appendix for sequence) 
His-HP1β:  Expresses full length mouse heterochromatin protein-1 β as a hexahistidin fusion 
protein in pQE-30 vector (provided by Dr. P. B. Singh, see Appendix for sequence) 
pCAG-EGFP-TPP1: Expresses TPP1 as fused to EGFP (kindly provided by Dr. Y. Shinkai, Kyoto, Japan) 
pCAG-EGFP-POT1a: Expresses POT1a as fused to EGFP (as above) 
pCAG-EGFP-POT1b: Expresses POT1b as fused to EGFP (as above) 
2.1.3 Antibodies 
  Primer Name   Primer Sequence (5’ – 3’) 
CPAU2 GCCGCAGACATGATAAGATACATTGATG 
CPAL2 AAAACCTCCCACACCTCCCCCTGAA 
RNA3 GTCAGTACACATACAGACTT 
ERT2 TCCATGGAGCACCCAGTGAA 
POL3 TGAGCGAACAGGGCGAA 
UTR-K-RAS-1 CACTGGACACTGAGGGTCA 
UTR-K-RAS-2 CATACTGGGTCTGCCTTA 
CLNEO GATGCCTGCTTGCCGAATAT 
M31genoty2.for ACAGTCAGAAAAGCCACGAGGC 
M31genoty3.rev GTCAGGCCGAGGGTCACTATCG 
K-ras V12 for CTGCTGAAAATGACTGAGTATAAA 
K-ras V12 rev TCCTTGCTAACTCCTGAGCC 
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2.1.3.1 Primary antibodies 
Anti-H3K9me3:  Rabbit polyclonal antibody against trimethylated lysine 9 on histone H3 (Abcam, 
Cambridge, UK) 
Anti-H3K9me2:  Mouse monoclonal antibody against dimethylated lysine 9 on histone H3 (Abcam, 
Cambridge, UK) 
Anti-H4K20me3:  Rabbit polyclonal antibody against trimethylated lysine 20 on histone H4 (Abcam, 
Cambridge, UK) 
Anti-SMC3:  Rabbit polyclonal antibody against SMC3 (Abcam, Cambridge, UK) 
Anti-BUB1:  Rabbit polyclonal antibody against human BUB1 (kindly provided by J. M. van 
Deursen, Rochester, USA) 
Anti-SGO1:  Rabbit polyclonal antibody against SGO1 (kindly provided by Dr. J. Peters, Vienna, 
Austria) 
Anti-CREST:  Human antiserum against CREST (kindly provided by Dr. A. Kromminga, 
Hamburg, Germany) 
Anti-HP1α:  Mouse monoclonal antibody against HP1α (Millipore, Schwalbach, Germany) 
Anti-HP1β:  Rat polyclonal antibody against HP1β (Dr. P. B. Singh, Borstel, Germany)  
Anti-HP1γ:  Mouse monoclonal antibody against HP1γ (Millipore, Schwalbach, Germany) 
Anti-pKi67:  Rabbit polyclonal antibody against pKi-67 (kindly provided by Prof. H. Zentgraf, 
Heidelberg, Germany) 
Anti-p16:  Rabbit polyclonal antibody against p16 (Santa Cruz biotechnology, Heidelberg, 
Germany) 
Anti-DcR2:  Rabbit polyclonal antibody against human DcR2 (Assay Designs, Michigan, USA) 
Anti-TIN2:  Rabbit polyclonal antibody against TIN2 (Abcam, Cambridge, UK) 
Anti-GFP:  Rabbit polyclonal antibody against green fluorescent protein (MBL, MA, USA). 
Anti-TRF1:  Rabbit polyclonal antibody against TRF1 (Abcam, Cambridge, UK) 
Anti-TRF2:  Rabbit polyclonal antibody against TRF2 (Abcam, Cambridge, UK) 
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2.1.3.2 Secondary antibodies 
Alexa Fluor 488: Goat anti rabbit IgG (H+L) alexa fluor 488 dye conjugate (Invitrogen, Carlsbad/CA, 
USA) 
Alexa Fluor 594: Goat anti rabbit IgG (H+L) alexa fluor 594 dye conjugate (Invitrogen, Carlsbad/CA, 
USA) 
Anti-human-FITC: Goat anti human IgG (H+L) FITC conjugate (Serotec, Martinsried, Germany) 
Anti-mouse-PO: Goat anti mouse IgG (H+L) horseradish peroxidase conjugate (Dianova, Hamburg, 
Germany) 
Anti-rabbit-PO: Goat anti rabbit IgG (H+L) horseradish peroxidase conjugate (Dianova, Hamburg, 
Germany) 
Anti-goat-PO: Rabbit anti goat IgG (H+L) horseradish peroxidase conjugate (Dianova, Hamburg, 
Germany) 
Anti-Rat-PO: Rabbit anti rat IgG (H+L) horseradish peroxidase conjugate (Dianova, Hamburg, 
Germany) 
2.1.4 Buffers, media and solutions 
All fine chemicals were purchased from Merck (Darmstadt, Germany) unless otherwise stated.  
2.1.4.1 Standard media and solutions 
Phosphate buffered saline (PBS)  
150 mM NaCl, 8 mM Na2HPO4, 2 mM KH2PO4, (pH 7.5). Stored at RT. 
Tris-buffered saline (TBS) 
150 mM NaCl, 10 mM Tris-HCl, (pH 7.5). Stored at RT. 
LB medium 
1 % (w/v) Tryptone (Roth, Karlsruhe, Germany), 0.5 % (w/v) yeast extract (Roth, Karlsruhe, Germany), 1 % 
(w/v) NaCl (pH 7.5). Stored at 4 °C. 
LB agar 
0.5 % (w/v) Agar in LB medium. Stored at 4 °C. 
SOC medium 
Invitrogen (Carlsbad/CA, USA). Stored at 4 °C. 
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NZY+ medium 
0.96 % (w/v) NZ amine (casein hydrolysate), 0.48 % (w/v) yeast extract, 0.48 % (w/v) NaCl, 0.11 % (w/v) 
MgCl2, 0.14 % (w/v) MgSO4, 0.34 % (w/v) glucose, (pH 7.5). Stored at 4 °C. 
Psi Medium 
0.48 % (w/v) MgSO4, 0.75 % (w/v) KCl in LB medium. Stored at 4 °C. 
2.1.4.2 Flow-FISH solutions 
Cell suspension buffer 
0.1 % BSA, 10 mM Hepes-bufffer (Roth, Karlsruhe, Germany), 5 % Glucose (Sigma-Aldrich, Munich, 
Germany). Stored at 4 °C. 
Hybridization mix „unst“ and „tel“  
20 mM Tris-Base, 20 mM NaCl, 1 % BSA, 75 % deionized formamide (Sigma-Aldrich, Munich, Germany), 
0.3 µg/ml Telo-PNA-FITC (Panagene, Daejeon, Korea) (only in tel). Freshly prepared. 
Wash buffer 1  
75 % formamide, 20 mM Tris-Base, 1 % BSA, 1 % Tween-20 (Sigma-Aldrich, Munich, Germany). Freshly 
prepared. 
Wash buffer 2  
1 % BSA, 1 % Tween-20 (Sigma-Aldrich, Munich, Germany), 10 mM Hepes (Roth, Karlsruhe, Germany), 5 % 
Glucose (Sigma-Aldrich, Munich, Germany) Freshly prepared. 
LDS solution  
0.1 µg/ml LDS751 (Invitrogen, Carlsbad/CA, USA), 10 µg/ml RNase  A (Roth, Karlsruhe, Germany), 0.1 % 
BSA, in PBS. Freshly prepared. 
2.1.4.3 Telomere-FISH and Giemsa staining solutions 
Hybridization buffer 
10 mM NaH2PO4, (pH 7.4), 10 mM NaCl, 20 mM Tris, (pH 7.5), 70 % formamide 
Fixative solution 
Methanol:glacial acetic acid (3:1). Freshly prepared. 
Pepsin solution 
2.5 ml of 10 % Pepsin stock in 50 ml 10 mM HCl (0.005 % solution). 
Washing solution 
Washing Solution 1: PBS/0.1 % (v/v) Tween-20 
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Washing Solution 2 : 2×SSC/0.1 % (v/v) Tween-20 
Trypsin solution 
0.015 g Trypsin in 100 ml PBS 
Giemsa solution 
5 % (v/v) Giemsa in H2O, freshly prepared and sterile filtrated. 
2.1.4.4 ChIP solutions 
Fixation solution 
1 % (w/v) formaldehyde in DMEM (Sigma-Aldrich, Munich, Germany). Freshly prepared. 
20/2 TE buffer  
2 mM EDTA (Sigma-Aldrich, Munich, Germany), 20 mM Tris-HCl (pH 8.0). Stored at 4 °C. 
ChIP dilution buffer  
0.01 % (w/v) SDS, 1.1 % (v/v) Triton X-100, 1.2 mM Tris-HCl (pH 8.0), 167 mM NaCl. Stored at 4 °C. 
Elution buffer  
0.1M NaHCO3, 1 % SDS. Freshly prepared. 
High salt buffer   
0.1 % (w/v) SDS, 1 % (v/v) Triton X-100, 2 mM EDTA (Sigma-Aldrich, Munich, Germany), 20 mM Tris-
HCl (pH 8.0), 500 mM NaCl. Stored at 4 °C. 
Low salt buffer  
0.1 % (w/v) SDS, 1 % (v/v) Triton X-100, 2 mM EDTA (Sigma-Aldrich, Munich, Germany), 20 mM Tris-
HCl (pH 8.0), 150 mM NaCl. Stored at 4 °C.     
LiCl buffer  
0.25M LiCl, 1 % (v/v) NP-40, 1 % (w/v) Sodium deoxycholate, 1 mM EDTA (Sigma-Aldrich, Munich, 
Germany), 10 mM Tris-HCl (pH 8.0). Stored at 4 °C. 
SDS lysis buffer  
1 % (w/v) SDS, 10 mM EDTA (Sigma-Aldrich, Munich, Germany), 50 mM Tris-HCl (pH 8.0). Stored at 4 °C 
2.1.4.5 GST pull down solutions 
0.3 M assay buffer  
20 mM Tris-HCl, 0.3 M NaCl, 0.1 mM EGTA (Sigma-Aldrich, Munich, Germany), 2 mM MgCl2, 1 mM 
PMSF (Sigma-Aldrich, Munich, Germany), 0.5 % (v/v) Triton X-100, Complete Protease inhibitors (Roche, 
Mannheim, Germany) and 0.5 % (v/v) Gelatine (Sigma-Aldrich, Munich, Germany), (pH 7.6).  
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Bead washing and blocking buffer  
150 mM NaCl, 20 mM Tris-HCl, 1 % (v/v) Gelatine (Sigma-Aldrich, Munich, Germany) (pH 7.6).  
2.1.4.6 Protein purification solutions 
Lysis buffer 
1 mM PMSF (Sigma-Aldrich, Munich, Germany), 1 mM DTT (Sigma-Aldrich, Munich, Germany), 100 mM 
MgCl2, 1 mg/ml lysozyme (Fluka, St.Gallen, Switzerland), 2500 U/l culture Benzonase (Sigma-Aldrich, 
Munich, Germany), NP-40 (0.5 %, v/v) in PBS (pH 7.3). Freshly prepared. 
Elution buffer 
50 mM Tris-HCl, 10 mM reduced glutathione (Sigma-Aldrich, Munich, Germany) (pH 8.0). Freshly prepared. 
NPI-10 
50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, (pH 8.0). 
NPI-20 
50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, (pH 8.0). 
NPI-300 
50 mM NaH2PO4, 300 mM NaCl, 300 mM imidazole, (pH 8.0). 
2.1.4.7 Coomassie stain solutions 
Coomassie stain solution 
0.25 % (w/v) Coomassie brilliant blue (BioRad, Munich, Germany), 45 % (v/v) methanol, 10 % (v/v) acetic acid. 
Coomassie destain solution 
30 % (v/v) methanol, 10 % (v/v) acetic acid. 
Coomassie fixative solution 
30 % (v/v) methanol, 3 % (v/v) glycerol. 
2.1.4.8 SDS-PAGE and western blotting solutions 
SDS sample buffer  
25 mM Tris-HCl, 50 mM DTT (Sigma-Aldrich, Munich, Germany), 10 % (v/v) glycerol, 2 % (w/v) SDS, 
0.02 % (w/v) Bromphenol blue (Sigma-Aldrich, Munich, Germany) (pH 6.8). 
Electrophoresis buffer  
25 mM Tris-HCl, 192 mM glycin, 0.1 % (w/v) SDS. 
Upper tris buffer  
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0.4 % (v/v) SDS, 0.5 M Tris-HCl (pH 6.8). 
Lower tris buffer  
0.4 % SDS, 1.5 M Tris-HCl (pH 8.8). 
Transfer buffer  
 20 mM Tris, 15 mM glycin, 20 % (v/v) methanol, (pH 8.3). 
AP buffer  
 1 M Tris/HCl, 1 M NaCl, 50 mM MgCl2, (pH 9.5). 
Ponceau-S solution 
 0.2 % (w/v) Ponceau-S, 0.2 % (v/v) acetic acid. 
2.1.4.9 Metaphase spread preparation solutions 
Hypotonic buffer 
75 mM KCl, 0.1 % Tween-20. 
Potassium chromosome medium (KCM)  
120 mM KCl, 20 mM NaCl, 10 mM Tris-HCl, 0.5 mM EDTA, 0.1 % (v/v) Triton X-100 (pH 7.5). 
2.1.5 Bacterial strains  
Name            Genotype                 Manufacturer 
                  
                     
              
                
 
2.1.6 Kits  
QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany), Plasmid Midi Kit (Qiagen, Hilden, Germany), 
QiaQuick PCR purification kit (Qiagen, Hilden, Germany), QuikChange II XL Site-Directed Mutagenesis Kit 
(Stratagene, Santa Clara, USA), Ladderman Labeling Kit (Takara Bio, Saint-Germain-en-Laye, France), DC 
Protein Assay Kit (BioRad, Munich, Germany). 
 
TetrRΔ (mcrA)183 Δ(mcrCB-hsdSMR-mrr) 173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac The [F’ 
proAB lacIqZΔM15 Tn10  (TetR) Amy CamR] 
Kmr, rpsL, rpoB, gyrA, NaIs, Strs, Rifs, Thi-, Mtl-, 
Ara+, Gal+,Mtl-, F-, RecA+, Uvr+, Lon+ 
 
B F– ompT hsdS(rB– mB–) dcm+ Tetr gal 
endA Hte [argU ileY leuW Camr] 
E.coli M15[pREP4] 
E.coli XL-10 Gold 
E.coli BL21-CodonPlus-RIL 
Stratagene 
Stratagene 
 Qiagen 
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2.2 Methods 
2.2.1 Molecular biology 
2.2.1.1 Preparation of plasmid DNA 
Small scale plasmid DNA was prepared using “QiaprepSpin Miniprep” kit from a 2 ml ON culture in LB 
medium, following the manufacturer’s instructions. Plasmid was eluted in 50 µl water and stored at -20 °C. 
Large scale plasmid DNA was prepared using “Plasmid Midi” kit from a 100 ml ON culture in LB medium, 
following the manufacturer’s instructions. Plasmid DNA was eluted in 50 µl water and stored at -20 °C. 
2.2.1.2 Isolation of total RNA from tissue 
Lung tissues were grinded using a mortar, and total RNA from the tissue was prepared using “RNeasy Mini” kit 
following the manufacturer’s instructions. RNA was eluted in 30 µl water and stored at -20 °C. 
2.2.1.3 Measuring concentration of nucleic acids 
The concentration of nucleic acids was determined by measuring the OD at 260 nm with spectrophotometer 
Ultraspec 1000 (Pharmacia Biotech, Uppsala, Sweden). A measured OD260 value of 1 equals a double stranded 
DNA concentration of 50 µg/ml. A measured OD260 value of 1 equals a RNA concentration of 40 µg/ml. To 
determine the protein contamination in the samples, OD280 nm value was also measured in parallel. For DNA 
samples the OD260 / OD280 value must ≥1.8 and for RNA samples ≥2.0. 
2.2.1.4 Reverse transcription of RNA (cDNA synthesis) 
3 µg of freshly purified total-RNA and 1 µg Oligo-dT18-primer were added to 10 µl water and were incubated 
for 10 min at 70 °C. After briefly cooling on ice, RNase-inhibitors, RT-Buffer, DTT, dNTPs and 200 U 
Reverse Transcriptase Superscript II (Invitrogen, Carlsbad/CA, USA), were added to the reaction mixture 
following the manufacturer’s protocol and were incubated at 42 °C for 1 h. The enzyme was deactivated by 
3 min incubation at 95 °C, cDNA was diluted 1:10 in water and stored at -20 °C. 
2.2.1.5 Transformation of plasmid DNA into E.coli 
XL-10 Gold: After gently thawing the cells on ice, 2 µl of β-mercaptoethanol was added to 45 µl bacteria and 
incubated 10 min on ice with gentle swirling every 2 min 2 µl of Dpn-I treated DNA was added to this mix and 
incubated further for 30 min on ice. The cells were heat-shocked by 30 s incubation in a 42 °C water bath 
following 2 min incubation on ice. 0.5 ml NZY+ Broth preheated to 42 °C was added following 1 h incubation 
at 37 °C on a shaker. The reaction was then spread on LB agar plates with appropriate antibiotics. 
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M15[pREP4]: After gently thawing the cells on ice, 2 µl of DNA were added to 40 µl of bacteria and incubated 
20 min on ice. The cells were heat-shocked by 90 s incubation a in 42 °C water bath following with 2 min 
incubation on ice. 0.5 ml Psi Broth preheated to 42 °C was then added following 1 h incubation at 37 °C on a 
shaker. The reaction was then spread on LB agar plates with appropriate antibiotics. 
BL21-CodonPlus-RIL: After gently thawing the cells on ice, 2 µl of β-mercaptoethanol was added to 100 µl 
bacteria and incubated 10 min on ice with gentle swirling every 2 min 1–50 ng of expression plasmid DNA 
containing the gene of interest was added to this mix and incubated further for 30 min on ice. The cells were 
heat shocked with 20 s incubation in 42 °C water bath following 2 min incubation on ice. 0.9 ml SOC medium 
preheated to 42 °C was then added following 1 h incubation at 37 °C on a shaker. The reaction was then spread 
on LB agar plates with appropriate antibiotics. 
2.2.1.6 Agarose gel electrophoresis 
For the separation of nucleic acid fragments, agarose gels based on TAE-Buffer system were used. 0.4 µg/ml 
ethidium bromide was added to the gel mixture for the visualization of DNA on a UV transilluminator (Intas, 
Göttingen, Germany). Samples were mixed with 10 % (v/v) DNA sample buffer (10X) and loaded on a gel. The 
gel was run with 5 V/cm in horizontal electrophoresis equipment (Bio-Rad, Munich, Germany). 1 kb and 100 
bp ladders (Fermentas, St. Leon-Rot, Germany) were used as standards. 
2.2.1.7 Restriction digest 
250 ng – 1 µg DNA was mixed with 4-10 U restriction endonuclease in the suitable buffer (as stated by the 
manufacturer) and incubated for 10 min – 1 h at 37 °C on a shaker.  
2.2.1.8 Site-directed mutagenesis 
Single and double amino acid mutations of HP1β proteins were done using “QuikChange II XL Site-Directed 
Mutagenesis Kit” following manufacturer’s instructions. The basic procedure utilizes a supercoiled double-
stranded DNA vector with an insert of interest and two synthetic oligonucleotide primers, both containing the 
desired mutation, which were designed using manufacturer’s primer design software. The oligonucleotide 
primers, each complementary to opposite strands of the vector, are extended during temperature cycling by Pfu 
Ultra HF DNA polymerase, without primer displacement. Extension of the oligonucleotide primers generates a 
mutated plasmid containing staggered nicks. Following temperature cycling, the product is treated with Dpn I. 
The Dpn I endonuclease is specific for methylated and hemimethylated DNA and is used to digest the parental 
DNA template and to select for mutation containing synthesized DNA. DNA isolated from almost all E. coli 
strains is dam methylated and therefore susceptible to Dpn I digestion. The nicked vector DNA incorporating 
the desired mutations was then transformed into XL10-Gold ultracompetent cells. 
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2.2.1.9 Genotyping PCR 
Genomic DNA from transgenic mice was prepared by the lysis of ear tissue samples in DirectPCR reagent 
(Peqlab, Erlangen, Germany) following the manufacturer’s instructions. 
HP1β genotyping PCR: K-ras+/V12;RERTn+/ERT mice were screened for Cbx1+/- mutation with M31genoty2.for 
and M31genoty3.rev primers and “Expand LT PCR” Kit (Roche, Mannheim, Germany) using the following 
conditions: 
K-ras genotyping PCR: K-ras(+V12);RERT(ert/ert) mice were screened for K-Ras mutation with UTR-K-
RAS-1, UTR-K-RAS-2 and CLNEO primers using following conditions: 
RERT genotyping PCR: K-ras(+V12);RERT(ert/ert) mice were screened for RERT mutation with RNA3, 
ERT2 and POL3 primers using following conditions: 
94°C – 2 min 
94°C – 40 s 
60°C – 40 s 
72°C – 1 min 
72°C – 10 min 
4°C –      ∞ 
 
34X 
MgCl2 (25 mM) 2 µl 
Buffer TAQ (10X) 5 µl 
UTR-K-RAS-1 10 µM 2.5 µl 
UTR-K-RAS-2 10 µM 5 µl 
CLNEO 10 µM 2.5 µl 
dNTPs 2.5 mM 1 µl 
Taq enzyme 0.25 µl 
H2O 29.75 µl 
Template 1 µl 
 
PCR products were run on a 2 % 
agarose gel. WT genotype, gave a 
band of 270 bp, K-rasV12 
homozygous genotype gave a 
band of 500 bp and K-rasV12 
heterozygous genotype gave 2 
bands of 500 bp and 270 bp. 
 
 
94°C – 2 min 
94°C – 40 s 
55°C – 40 s 
72°C – 1 min 
72°C – 10 min 
4°C –      ∞ 
 
34X 
MgCl2 (25 mM) 2 µl 
Buffer TAQ (10X) 5 µl 
RNA3 10 µM 5 µl 
POL3  10 µM 2.5 µl 
ERT2  10 µM 2.5 µl 
dNTPs 2.5 mM 1 µl 
Taq enzyme 0.25 µl 
H2O 29.75 µl 
Template 1 µl 
 
PCR products were run on a 2 % 
agarose gel. WT genotype, gave a 
band around 400 bp, RERT 
homozygous genotype gave a 
band around 700 bp and RERT 
heterozygous genotype gave 2 
bands around 400 bp and 700 bp. 
 
 
94°C – 2 min 
94°C – 1 min 
62°C – 1 min 
72°C – 4 min 
72°C – 15 min 
16°C – 10 min 
 
Buffer 3 2 µl 
M31genoty2.for (20 pmol/µl) 1 µl 
M31genoty3.rev (20 pmol/µl) 1 µl 
dNTPs  (20 mM stock) 0.2 µl 
Taq enzyme 0.1 µl 
H2O 14.7 µl 
Template 1 µl 
 
PCR products were run on a 
1,2 % agarose gel. WT genotype, 
gave a band of 258 bp and 
HP1β+/- genotype gave a band of 
1,36 kb. 
 
 
33X 
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Crosslink DNA and proteins 
 
Sonicate chromatin 
 
Immunoprecipitate with Ab 
of interest, reverse crosslink 
and purify DNA 
 
Figure 7 Steps involved in a typical ChIP experiment. 
2.2.1.10 Chromatin immunoprecipitation (ChIP) 
 ChIP assay was performed as described by Bullwinkel et al., 2006 (Figure 7). Mouse embryonic fibroblasts 
grown to sub-confluency were washed twice with PBS, cross-linked for 10 min by 1 % formaldehyde in serum-
free medium at 37 °C, washed again with ice-cold PBS containing complete EDTA free protease inhibitor 
cocktail, scraped off the culture dish and resuspended in 2.5 ml SDS lysis buffer containing the same protease 
inhibitors. The cell lysate was sonicated six times for 10 s on ice (in 2 min intervals) with a microtip on a 
Branson sonifier 250 (Branson Ultrasonics Corporation, CT, USA) at an output setting of 3–4, resulting in 
DNA fragments with an average length of 
approximately 800 bp. Insoluble material was 
removed by centrifugation (5 min at 1000 g followed 
by 5 min at 13000 g) and the supernatant was diluted 
1:10 in ChIP dilution buffer containing protease 
inhibitors. Protein G sepharose slurry was prepared 
by equilibration of protein G sepharose 4 Fast Flow, 
(GE Healthcare, Munich, Germany) in PBS, 
containing 0.75 mg/ml BSA and 0.1 mg/ml baker’s 
yeast RNA (Sigma-Aldrich, Munich, Germany) with 
a final bead volume content of 20 %. Preclearing of 
the ChIP samples was performed for 2 h by addition 
of 60 µl protein G sepharose slurry. 75 µl of the 
precleared lysate (equals to 0.3 % of the initial 
sonicated cell lysate) was transferred into a new tube 
and labelled as input DNA which was kept at 4 °C 
until reverse crosslinking step, whereas 1 ml of this 
precleared lysate was used for the experimental samples and incubated ON at 4 °C with appropriate antibodies or 
no antibody as control. The DNA-protein-antibody complex was precipitated with 60 µl protein G sepharose 
slurry for 1 h. After washing once with wash buffer containing 150 mM NaCl, once with wash buffer containing 
500 mM NaCl, once with lithium chloride buffer and twice with TE, complexes were eluted twice in 100 µl 
elution buffer and 150 µl of the eluted sample supernatant (equals to 3 % of the initial sonicated cell lysate) was 
transferred into a new tube and 5 M NaCl was added to a final concentration of 0.2 M. Finally, crosslinks were 
removed by incubation for 4 h at 65 °C. After addition of EDTA (10 mM final concentration) and Tris-HCl 
(pH 6.5, 40 mM final concentration) proteins were digested by 1 µl (10 mg/ml) proteinase K (Sigma-Aldrich, 
Munich, Germany). DNA was recovered by QiaQuick PCR purification columns (Qiagen, Hilden, Germany). 
For the quantification of precipitated ChIP DNA, input DNA was used. 
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2.2.1.11 Dot/Slot-blotting of ChIP DNA  
ChIP DNA was dot/slot-blotted on Hybond N+ nylon membranes (GE Healthcare, Munich, Germany) with an 
apparatus (Schleicher & Schuell, Dattel, Germany) using a modified protocol implementing the manufacturer’s 
protocol. Briefly, a piece (10 cm x 13 cm) of positively charged nylon membrane and Whatman filter paper (GE 
Healthcare, Munich, Germany) was cut and soaked for 10 min in distilled water in a glass dish of 0.5 cm depth. 
The blotting manifold was assembled with the filter paper and nylon membrane on top, and the membrane was 
prewashed with distilled water by pipetting 500 µl of water per well. Samples were prepared in a buffer with a 
final concentration of 0.4 M NaOH and 10 mM EDTA and denatured by boiling at 100 °C for 10 min. After a 
brief chill on ice, samples were centrifuged briefly to collect evaporated water and applied to the membrane while 
the dot-blot manifold was connected to vacuum pump. The wells were then rinsed with 500 µl 1 M NaOH, the 
manifold dismantled and the nylon membrane was UV crosslinked with the autocrosslink option of the UV 
Stratalinker 1800 (Stratagene, CA, USA). 
2.2.1.12 Random primer end labelling of telomeric DNA with radioactive 32P-dCTP 
The random primer labelling was done using the “Ladderman Labelling Kit” using the manufacturer’s 
instructions. Removal of unincorporated 32P labeled dCTP (GE Healthcare, Munich, Germany) was done using 
Illustra MicroSpin S-200 HR Columns (GE Healthcare, Munich, Germany) following manufacturer’s 
instructions. Briefly, 1 µg template DNA and 2 µl random primer were mixed and distilled water was added to a 
total volume of 14 µl. The mixture was heated at 95 °C for 3 min and cooled on ice for 5 min. 1 µl of Bca DNA 
polymerase was then added and the mixture was incubated at 53 °C for 10 min followed by the addition of 
EDTA to a final concentration of 30 mM. Reaction mixture was then added on illustra MicroSpin S-200 HR 
columns and centrifuged for 2 min at 2700 rpm. The eluate was used for the hybridization experiments. 
2.2.1.13 Hybridization of dot-blotted ChIP DNA with a 32P-labelled telomeric probe and image analysis 
After a brief rinse in 6X SSC, nylon membrane with dot-blotted ChIP DNA was preincubated in 10 ml Church 
buffer for 10 min at 68 °C. After this preincubation step, the buffer was removed, nylon membrane was put in a 
hybridization bag whose 3 sides were sealed and 4 ml of fresh Church buffer together with 32P-labelled telomeric 
probe was added to the membrane. The open side of the bag was heat-sealed using the heat sealing machine 
Polystar 100 GE (Rische+Herfurth GmbH, Hamburg, Germany) and hybridized overnight at 68 °C with gentle 
shaking in a water bath. Next day, nylon membrane was washed 3 times in 2X SSC/0.1 % SDS for 5 min at RT 
followed by two washes in 2XSSC/0.1 % SDS for 10 min at 68 °C. After final wash, the nylon membrane was 
exposed overnight to a storage phosphor screen (GE Healthcare, Munich, Germany), in an X-Omatic Regular 
intensifying cassette (Kodak, Stuttgart, Germany). Next day, the phosphor screen was scanned with 
Phosphorimage SI (GE Healthcare, Munich, Germany) using manufacturer’s software with 50 µm resolution. 
Materials & Methods 
 
40 
 
The image was analyzed using Image Quant 6.0 Software (GE Healthcare, Munich, Germany) for the 
quantification of signal intensities. Final values were calculated by subtracting “No antibody control” intensity (as 
background signal) from all samples and by normalizing (dividing by input DNA value), which then gave the 
final value of “Telomeric DNA in ChIP” in arbitrary units. 
Telomeric DNA in ChIP [a.u.] = (Sample intensity - background intensity) / Input DNA intensity 
2.2.1.14 Measurement of telomere length by FLOW-FISH 
These experiments have been done in collaboration with Dr. U. Brassat and Prof. T. Brummendorf (UKE, 
Hamburg). The mean telomere lengths were measured using FLOW-FISH technique which basically 
implements the use of FITC-labelled telomeric PNA probes (CCCTAA3) (Panagene, Daejeon, Korea) for the 
hybridization to the telomeres of cells to be measured. In principal this technique involves the discrimination of 
2N interphase cells from 4N cells by using the DNA stain LDS751 (Invitrogen, Carlsbad/CA, USA) and 
including only 2N cells in the measurement of mean telomere length by FACS. As internal control, bovine 
thymocytes were used as these control cells are easily distinguished from the murine test cells due to their size 
and therefore provide a convenient reference point for telomere fluorescence measurements. The telomere 
lengths of the control cells were previously measured using telomere restriction fragment (TRF) analysis, and 
found to be 19.515 kb. Comparison of the fluorescence signals obtained from control cells and experimental cells 
made it possible to measure the absolute mean telomere length. In this procedure, cells were harvested and 
resuspended in cell suspension buffer. Frozen and fixed bovine thymocytes were also thawed out and 
resuspended in cell suspension buffer. For each sample, 2x105 MEFs and 1x105 bovine thymocytes (thy) were 
counted and used. Each measurement was done in triplicates in 1.5 ml reaction tubes, with (“tel”) and without 
(“unst”) FITC-labelled telomeric probe in order to allow subtraction of autofluorescence of cells in the same 
light scatter window. The cells were then centrifuged at 20000 g for 30 s, supernatants discarded and the pellets 
were resuspended in 300 µl (=100 µl/1x105) hybridization mix “tel” or “unst”. DNA was denatured by incubating 
the samples at 87 °C for 15 min in water bath, with a following 1,5 h incubation in the dark at RT for the 
hybridization of telomeric probe. The samples were then washed 4 times with 1 ml wash buffer 1 for the removal 
of excess probe. Between the washes, the cells were resuspended well by pipetting up and down, centrifuged at 
2000 g for 5 min at 4 °C and the supernatants were discarded. After final wash step, samples were washed for the 
last time in wash buffer 2, centrifuged at 900 g for 10 min at 4 °C and all but 50 µl of the supernatant was 
discarded. Thereafter, DNA was stained by adding 300 µl LDS solution to the samples and incubating in the 
dark for 20 min at RT in FACS tubes. The samples were kept on ice until the measurement was done. The 
fluorescent signal emitted from LDS751 was measured in Fl3 and the signal emitted from FITC was measured 
in Fl1 channel of the FACSCalibur (Beckman-Coulter, CA, USA). For the calculation of the absolute mean 
telomere length, the following formula has been used: 
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Mean Telomere Length [kb] = ( (MEF „tel“ – MEF – „unst“) / (Thy „tel“ – Thy „unst“) ) x 19.515 (TL of thymocytes) 
2.2.1.15 Telomere-FISH and Giemsa staining 
Telomere FISH was done in collaboration with Prof. T. Pandita (WUSM, St. Louis) using manufacturer’s 
(Panagene, Daejeon, Korea) protocol. Briefly, one day before the experiment, cells were passaged at a split ratio 
of 1:5 to achieve maximal cell division rate. On the next day, Colcemid (PAA, Pasching, Austria) was added to 
flasks to a final conc. of 0.1 µg/ml and incubated for 3 h. The cells at metaphase were then shaken off by hitting 
the bottom of the cell culture dish a couple of times and the supernatant including cells at metaphase was 
transferred into 50 ml tubes. Following centrifugation at 1200 rpm for 10 min at 4 °C, supernatant was discarded 
and the cell pellet was resuspended in 30 ml 75 mM KCl and incubated at RT for 30 min. The cells were fixed 
initially by adding 2 ml of fixative solution (4 °C) twice and mixing carefully by turning the tube. After 
harvesting the cells at 1500 rpm for 5 min, 10 ml of fixative solution was added twice followed by centrifugation 
at 1500 rpm for 5 min. Following last centrifugation step, 700 µl of fixative solution was added to cell pellet and 
suspension was dropped on slides. Preparation of metaphases until this step was same for telomere FISH and 
Giemsa staining. After this point, for Giemsa staining slides were then heated up to 100 °C on a heating plate 
and incubated in trypsin solution for 40 s. Following a brief wash in H2O and PBS, slides were then incubated 
for 10 min in Giemsa solution. Chromosomal abnormalities were analyzed using a light microscope. 200 
metaphases per genotype were analyzed for the determination of chromosomal aberrations and Chi-squared tests 
were used to test the significance of the observed differences between the genotypes. For telomere FISH 
experiments, slides were dried at 67 °C for 10 min, incubated in PBS for 15 min, fixed in 4 % formaldehyde/PBS 
for 4 min, washed twice in PBS for 5 min, treated with pepsin solution for 4 min and washed three times in PBS 
for 5 min. Slides were then dehydrated using cold ethanol series (1 min each in 70 %, 80 %, 100 % ethanol) and 
dried on air. 15 µl of telomere PNA probe was then added to slides, which were then coverslipped and allowed 
to denature at 80 °C for 5 min. Hybridization was done at RT for 2 h. After hybridization, slides were washed in 
washing solution-1 for 20 min at 57 °C following a second wash in washing solution 2 at RT for 5 min. Slides 
were then coverslipped with a drop of Vectashield antifade medium with DAPI (Vector laboratories, 
Burlingame, USA). 
2.2.2 Protein biochemistry 
2.2.2.1 Protein expression in E.coli 
40 ml of LB medium containing appropriate antibiotics were inoculated with a freshly picked single bacterial 
colony and grown at 37 °C overnight with vigorous shaking in water bath. Next day, overnight culture was 
diluted 1:50 in 2 l of fresh LB medium and grown at 37 °C with vigorous shaking until an OD600 value of 0.6 
was reached. Expression was induced by adding IPTG (Fluka, St. Gallen, Switzerland) to the culture to a final 
concentration of 1 mM. Cultures were grown for 5 h at 37 °C with vigorous shaking followed by centrifugation 
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at 4000 g for 20 min at 4 °C. The supernatant was discarded and the bacterial pellets were stored at –80 °C until 
purification. 
2.2.2.2 GST fusion protein purification 
Bacterial pellets were allowed to thaw out for 15 min at RT and then completely resuspended by pipetting up 
and down in 30 ml cold lysis buffer on ice. After 30 min incubation on ice, samples were sonicated 4 x 10 s with 
a Branson sonifier 250 (50 % duty, level 3), with 20 s intervals on ice. The protein was then solubilized by 
15 min incubation on a roller at 4 °C. After a centrifugation step at 12000 rpm for 20 min at 4 °C, pellets were 
discarded and the supernatant was loaded on GSTrapFF 1 ml columns (GE Healthcare, Munich, Germany) 
which were already equilibrated with 5 ml of PBS (pH 7.3) using a microperpex peristaltic pump (LKB Broma, 
Sweden) with a flow rate of 0.2 ml/min while keeping the sample on ice. The column was then washed with 20 
ml of cold PBS with a flow rate of 1 ml/min and the GST-fusion protein was eluted with 5 ml elution buffer 
with a flow rate of 1 ml/min. 
2.2.2.3 Hexahistidin fusion protein purification 
Bacterial pellets were allowed to thaw out for 15 min at RT and then completely resuspended by pipetting up 
and down in 40 ml cold NPI-10 buffer together with 10 ml lysozyme (10 mg/ml) on ice. After 30 min 
incubation on ice, samples were sonicated 4 x 10 s on a Branson sonifier 250 (50 % duty, level 3), with 20 s 
intervals on ice. The protein was then solubilized by 15 min incubation on a roller at 4 °C. After a centrifugation 
step at 15000 g for 20 min at 4 °C, pellets were discarded and the supernatant was incubated with 2-4 ml Ni-
NTA Superflow Resin (Qiagen, Hilden, Germany) for 1 h at 4 °C. The beads were then loaded on a 
polypropylene plastic column (Qiagen, Hilden, Germany), washed twice with buffer NPI-20 and fusion protein 
was eluted using 5 ml NPI-300 buffer. 
2.2.2.4 Measuring protein concentration  
Protein concentrations were determined both by using “DC Protein Assay Kit” (BioRad, Munich, Germany) 
following the manufacturer’s instructions, which is a colorimetric assay similar to Lowry (Lowry et al., 1951), and 
by measuring the OD280 value of protein samples with the spectrophotometer Ultraspec 1000 (Pharmacia 
Biotech, Uppsala, Sweden) and using the Beer-Lambert formula:  
A = c x l x ε 
(A: OD280 value, ε: extinction coefficient, c: concentration in mol/l, l: optical path length in cm) 
 
Materials & Methods 
 
43 
 
2.2.2.5 SDS-PAGE 
Separation of proteins according to their molecular weight 
was done with SDS polyacrylamide gel electrophoresis 
(PAGE). Briefly, samples in SDS sample buffer were 
denatured by incubating at 95 °C for 10 min and loaded on 
3 % loading gel. Separation was done on a 5-15 % running 
gel depending on the molecular mass of the protein (for 
gel composition see Table 2). The gel was run using a 
vertical SDS-PAGE apparatus (BioRad, Munich, 
Germany) with a current of 20-25 mA. “Precision Plus 
Protein Standard All Blue” (BioRad, Philadelphia, USA) 
was used as molecular weight standard. 
2.2.2.6 Coomassie staining 
After SDS-PAGE, the gel was washed twice for 5 min in water followed by 10 min incubation in Coomassie 
staining solution at 85 °C. Excess Coomassie stain was then destained by incubating the gel in Coomassie 
destain solution for 3 h. The gel was then fixed by incubation in Coomassie fixing solution overnight. On the 
next day, the gel was dried between two cellophane sheets (BioRad, Munich, Germany) for long term storage. 
2.2.2.7 Western blotting 
After SDS-PAGE, proteins were transferred overnight onto a nitrocellulose membrane (Schleicher&Schuell, 
Dassel, Germany) using a Mini Protean II Blotting apparatus filled with transfer buffer (BioRad, Munich, 
Germany) with a constant current of 50 mA. After verification of the transfer with Ponceau-S staining for 
3 min, the unspecific binding was blocked by incubating the blot in 5 % skimmed milk powder/TBST for 
30 min. Following this step, the blot was incubated with primary antibodies in 0.5 % skimmed milk 
powder/TBST for 1 h and after washing 3x in TBST, AP-conjugated species specific secondary antibody 
incubation in 0.5 % skimmed milk powder/TBST for 30 min was done. The colour reaction indicating the 
binding of the antibody was visualized using NBT/BCIP (Promega, Madison, USA) diluted in AP buffer and 
the reaction was stopped with water after protein bands were visible. 
2.2.2.8 GST pull down assays 
Glutathione Sepharose 4B beads (75 % slurry) (GE Healthcare, Munich, Germany) were prepared by washing 
and blocking the beads three times in bead washing and blocking buffer following the manufacturer’s 
instructions and diluting the beads in the same buffer to make a 50 % slurry. 30 µl of the 50 % bead slurry was 
 
Loading gel 
3.3 % (w/v) 
polyacrylamide 
Running gel 
5-15 % (w/v) 
polyacrylamide 
40 % acrylamide/ 
bisacrylamide (1:29) 8.35 % (v/v) 
12.38 – 37.16 % 
(v/v) 
Lower tris buffer - 24.8 % (v/v) 
Upper tris buffer 26.1 % (v/v) - 
Ammonium persulfate 0.42 % (w/v) 0.82 % (w/v) 
TEMED 0.42 % (v/v) 0.08 % (v/v) 
 
   Table 2 Composition of SDS gels used. 
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= Sepharose 
= Glutathione 
=Bait Prot.(eg.HP1) 
=GST 
=Prey Prot.(eg.H3) 
2- Add prey protein 
3- Wash the complex 
and run on SDS gel 
1- Add bait GST fusion 
protein to glutathione 
sepharose beads 
Figure 8 Steps involved 
in a typical GST pull 
down experiment. 
then mixed with 5 µg of bait GST-fusion protein in 800 ml assay buffer and incubated in 1.5 ml tubes at RT for 
1 h on an end-to-end roller (LTF Labortechnik, Wasserburg, Germany). Following centrifugation for 10 min at 
500 g, supernatant was discarded and 5 µg of prey protein (recombinant X.laevis histone H3, kindly provided by 
Prof. Wolfgang Fischle, MPI-BPC, Göttingen) was added 
together with 800 ml fresh assay buffer. After incubating the 
mixture for 1 h at RT on an end-to-end roller, samples were 
washed 6 times in 1 ml fresh assay buffer. The tubes were 
centrifuged for 5 min at 500 g in between and the 
supernatant was discarded. After the final wash step, 30 µl 
SDS sample buffer were added to beads and incubated for 
10 min at 95 °C with 350 rpm shaking on a thermomixer 
(Eppendorf, Hamburg, Germany). The samples were then 
briefly cooled on ice, and loaded on SDS polyacrylamide 
gels for the separation and visualization of proteins. The 
NaCl concentration of the assay buffer has been adjusted as 
stated (0.3 M, 0.6 M or 0.75 M) (Figure 8). 
2.2.2.9 Preparation of paraffin sections and immunohistochemistry  
Mice lungs were fixed either in 4 % formalin or HOPE solution overnight and on the next day embedded in 
paraffin blocks with Hypercenter (Shandon, Pittsburgh, USA) using the automated program (70 % Ethanol-
30 min, 70 % Ethanol-1h, 85 % Ethanol-45 min, 2X 95 % Ethanol-45 min, 2X 100 % Ethanol-45 min, 2X 
100 % Xylene-2 h and 2X Paraffin-1 h). They were cut to 10 µm sections with Leica SM200R microtome 
(Leica Microsystems, Wetzlar, Germany). Lung sections were then stained using indirect immune-peroxidase 
staining. Briefly, slides were deparaffinated by 10 min incubation in xylene followed by 10 min serial incubations 
in 100 %, 70 % and 40 % acetone. Antigen retrieval was achieved by boiling the slides in 10 mM citric acid 
(pH 6.0), using a normal household pressure cooker for 2 min. After this step, the pressure cooker was 
immediately cooled under running cold tap water and slides were transferred to distilled water and incubated for 
5 min. For the blocking of endogenous peroxidase activity, slides were then incubated in 3 % H2O2 in TBS for 
20 min followed by 3 washes in TBS. For the reduction of background staining, slides were then incubated in 
Image-iT FX signal enhancer (Invitrogen, Carlsbad/CA, USA) for 30 min. Primary antibody incubation was 
done for 1 h followed by 30 min incubation with species specific horseradish-peroxidase coupled secondary 
antibodies. Primary and secondary antibodies were diluted in 10 % BSA/TBS. Finally, the PO staining was 
developed by incubating the slides in DAB developing solution (Sigma-Aldrich, Munich, Germany) for 10 min. 
The slides were counterstained with haematoxylin and coverslipped with a drop of Kaiser’s glycerol gelatine. 
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Pictures were taken on an Olympus BX41 microscope (Olympus, Hamburg, Germany) equipped with a Nikon 
DS-Ri1 camera (Nikon, Surrey, UK). 
2.2.2.10 Indirect immunofluorescence 
MEFs grown on „superfrost plus“ glass slides (R. Langenbrinck, Emmendingen, Germany) were washed twice 
with PBS and fixed in 2 % formaldehyde (w/v) (in PBS) solution for 10 min. Following the permeabilization in 
0.25 % Triton X-100 (in PBS) for 10 min, cells were incubated 1 h with primary antibody solution (in 10 % 
BSA/PBS). Cells were then washed three times in PBS for 5 min and incubated 1 h with secondary antibody 
solution (in 10 % BSA/PBS) and coverslipped with a drop of vectashield antifade medium with DAPI (Vector 
laboratories, Burlingame, USA) after washing three times for 5 min in PBS. All images were taken using a Leica 
SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany). 
2.2.2.11 Preparation of chromosome spreads and indirect immunofluorescence staining 
One day before the experiment, cells were passaged at a split ratio of 1:5 to achieve maximal cell division rate. 
On the next day, Colcemid (PAA, Pasching, Austria) was added to flasks to a final concentration of 0.1 µg/ml 
and incubated for 3 h. The cells at metaphase were then shaken off by hitting the bottom of the cell culture dish 
couple of times and the supernatant including cells at metaphase was transferred into 50 ml tubes. Following 
centrifugation at 1200 rpm for 10 min at 4 °C, the supernatant was discarded and the cell pellet was resuspended 
in 2 ml 4 °C cold PBS. After counting, cells were pelletted at 1200 rpm for 10 min at 4 °C and 4 ml 4 °C cold 
hypotonic buffer was added drop wise while mixing the cells gently. The cell suspension was then incubated at 
37 °C for 20 min and 5x104 cells were centrifuged on glass slides using a cytospin (Shandon, Pittsburgh, USA) 
for 5 min at 2000 rpm. Slides were then transferred immediately into KCM medium and incubated for 10 min 
at RT. After blocking for 30 min using ImageIT Signal Enhancer solution, primary antibody of interest in 10 % 
BSA/KCM was added and incubated for 1 h at RT in a humid chamber. Following 3 washes in KCM medium 
each for 5 min, secondary antibody solution in 10 % BSA/KCM was added and incubated for 1 h at RT in a 
humid chamber. The slides were then washed three times in KCM buffer and fixed in 4 % formaldehyde/KCM 
solution for 15 min at RT. After briefly rinsing in distilled water, slides were then coverslipped using Vectashield 
antifade medium with DAPI (Vector laboratories, Burlingame, USA). 
2.2.2.12 Isothermal titration calorimetry (ITC) 
For the determination of binding affinities, isothermal titration calorimetry was used which is the only technique 
that can directly measure the binding energetics of biological processes. A typical ITC instrument is a heat-flux 
calorimeter which measures the amount of power (µcal/s) required to maintain a constant temperature between 
the sample and reference cell (Figure 9). With the injection of ligand, a certain amount of macromolecule/ligand 
complex is formed which is accompanied by the release (exothermic reaction) or the absorption (endothermic 
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reaction) of heat that causes a difference in temperature between sample and reference cell which is then 
compensated by either lowering or raising the thermal power applied. After each injection, the system reaches 
equilibrium, and the temperature balance is restored, resulting in a signal in the form of a peak. The amount of 
heat associated with the injection is then provided by integrating the area under this curve. The heat signal 
reduces until only a background heat as the reactant becomes saturated. Thermodynamic parameters for histone 
H3-HP1β and H3K9me3-HP1β binding were determined using an ITC200 instrument ((Microcal) GE 
Healthcare, Munich, Germany) following manufacturer’s instructions and software. His tagged recombinant 
mouse HP1β, its T51A, V23M, F45E, I161E mutants and recombinant X. laevis histone H3 (kindly provided 
by Prof. H. Bartunik, MPG-ASMB, Hamburg) were all excessively dialyzed against 50 mM sodium phosphate, 
25 mM NaCl (pH 6.0). Lyophilized histone H3 tail peptide (Peptide Protein Research, Fareham, UK) was also 
dissolved in the same dialysis buffer. Histone H3 tail peptide used was H3K9me3 trimethylated at lysine 9 
(ARTKQTARKMe3STGGKAY) (underlining corresponds to a non native residue). The heats of binding 
reactions (µcal/s) were measured by 20 sequential injection of 1 mM ligand (histone H3, or H3K9me3), each 
2 µl, spaced at 3-5 min intervals, into 100 µM HP1β in the cell. Binding curves were analyzed using fitting 
parameter “one set of sites” of instrument’s software. All calculations were based on the Gibbs free energy 
equation:                                   ∆G = -RT  ln Ka  = ∆H - T∆S  
Figure 9 Schematic diagram of ITC200 instrument used in calorimetry experiments. This instrument uses a cell feedback 
network (CFN) to differentially measure and compensate for heat produced or absorbed between the sample and reference 
cell. A thermoelectric device measures the temperature difference between the two cells and a second device measures the 
temperature difference between the cells and the jacket. The temperature difference between the sample and reference cells 
(ΔT1) is kept at a constant value (i.e. baseline) by the addition or removal of heat to the sample cell, as appropriate, using 
the CFB system. The integral of the power required to maintain  ΔT1 constant over time is a measure of total heat resulting 
from the process being studied (redrawn from http://www.microcal.us/technology/itc.asp). 
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(∆G is the free energy of binding, R is the gas constant, T is the absolute temperature, Ka is the association 
constant, ∆H is the enthalpy and ∆S is the entropy).  
Based on this equation, it can be seen that two determinants of the binding affinity are enthalpy (∆H) and 
entropy (∆S). The strength of the interactions (e.g. hydrogen bond, van der Waals, electrostatic) between the 
target and the ligand is reflected by the binding enthalpy, whereas the entropy change primarily reflects two 
contributions: changes in solvation entropy and changes in conformational entropy. Binding of a ligand to the 
macromolecule results in desolvation and triggers the release of water molecules from the binding site and the 
ligand, which then increases the entropy of the system. 
2.2.3 Cell biology 
2.2.3.1 Production of primary mouse embryonic fibroblasts (MEFs)  
Cbx1 knock out (-/-) primary MEFs were derived from 13.5 day old embryos generated by crossing two Cbx1 
heterozygous (+/-) mice. Following removal of head and organs, embryos were rinsed with PBS, minced and 
digested with Trypsin/EGTA (PAA, Pasching, Austria) for 5 min at 37 °C, using 2 ml per embryo. Trypsin was 
inactivated by addition of MEF culture medium. Cells from single embryos were plated in one T75 cell culture 
dish and incubated at 37 °C in a cell culture incubator (Thermo Fisher Scientific, Bonn, Germany).  
2.2.3.2 MEF cell culture 
MEFs were cultured in medium containing 87 % (v/v) DMEM 
(Sigma-Aldrich, Munich, Germany), 10 % (v/v) FCS (Biochrome, 
Berlin, Germany), 1 % (v/v) L-glutamine (Biochrome, Berlin, 
Germany), 1 % (v/v) Non essential amino acids 100x (PAA, Pasching, 
Austria) and 1 % (v/v) Penicillin/Streptomycin 100x (PAA, Pasching, 
Austria). For the passaging of MEFs, 85-90 % confluent cells were 
washed twice in PBS, detached with Trypsin/EGTA medium, pH 7.6 
(TEG, see Table 3) for 5 min, centrifuged for 10 min at 1200 rpm at 
4 °C and split into a new culture dish with a 1:10 ratio. 
2.2.3.3 Cell counting 
Counting of cells was performed with exclusion of dead cells by trypan blue (Biochrom, Berlin, Germany). 
Trypan blue permeates the membrane of only dead cells, which appear blue. Working solution of trypan blue 
was prepared by diluting trypan blue 1:10 in 0.9 % NaCl. The cell suspension to be counted was diluted 1:10 in 
the working solution of trypan blue and cells were counted using a Neubauer counting chamber (Assistent, 
Sondheim, Germany) under an optical microscope. 
TEG 
KH2PO4 0.0216 % (w/v) 
NaCl 0.63 % (w/v) 
Na2HPO4 0.012 % (w/v) 
KCl 0.0333 % (w/v) 
D – Glucose 0.099 % (w/v) 
Tris 0.27 % (w/v) 
Phenol red (1%) 0.09 % (w/v) 
Trypsin (10 x) 10 % (w/v) 
EGTA 0.04 % (w/v) 
PVA 0.01 % (w/v) 
 
    Table 3 TEG medium composition 
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2.2.3.4 3T9 assay 
For the 3T9 assay, cells were maintained on a defined schedule: 9 x 105 cells per 60 mm diameter dish were 
trypsinized, counted and passaged every 3 days. Plating after disaggregation of embryo cells was considered 
passage 1 and the first replating three days later as passage 2. 
2.2.3.5 Transient transfection of EGFP-TPP1, -POT1a and -POT1b 
pCAG-EGFP-TPP1, -POT1a and -POT1b plasmids were transiently introduced into MEF cells by the 
transfection reagent “lipofectamine 2000” (Invitrogen, Carlsbad/CA, USA) following manufacturer’s 
instructions. Afterwards, cells were incubated for 48 h, and indirect immunofluorescence staining of cells was 
done as described. These experiments were performed in collaboration with Dr. K. Okamoto (Scripps, San 
Diego). 
2.2.4 Animal experiments 
2.2.4.1 Induction of K-rasV12 in K-ras+/V12;RERTn+/ERT;Cbx1+/- transgenic mice 
K-ras+/V12;RERTn+/ERT mice were provided by Dr. C. Guerra (cnio, Madrid, Spain). Cbx1+/- mutation was 
introduced into these mice by crossing K-ras+/V12;RERTn+/ERT with Cbx1+/- mice. Genotyping of the newborn 
mice was done using stated primers (see primers). Expression of KrasV12 oncogene in 3 weeks old mice was 
induced by intraperitoneal injection of 0.5 mg 4-hydroxytamoxifen (Sigma-Aldrich, Munich, Germany) in 
100 µl corn oil (Sigma-Aldrich, Munich, Germany) three times a week for two weeks. Expression of K-rasV12 
oncogene was screened by sequencing the cDNA obtained from mice with K-ras V12 for and K-ras V12 rev 
primers. 
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3.1 Investigation of the effect of Cbx1 mutation on genomic stability 
In order to investigate the effect of Cbx1 disruption on genome stability in mouse, primary 
MEFs from the three genotypes, WT, Cbx1+/- and Cbx1-/- were cultured, in duplicates, 
according to a 3T9 protocol, which is an established method for measuring the growth rate 
and immortalization frequency of mouse cells (Kamijo et al., 1997). Briefly, cells were passaged 
every three days, and 9x105 cells were plated per passage. As shown in figure 10, by passage 16 
the WT cells had undergone senescence crisis and died. In contrast, cultures of Cbx1+/- and 
Cbx1-/- MEFs either went through the crisis and continued to proliferate or simply continued 
to proliferate without any sign of having been through crisis. 
Having shown that Cbx1-/- MEFs exhibited an increased immortalization frequency, the next 
step was to determine the possible reasons underlying this observation. To this end, Giemsa 
staining and telomere FISH analysis were undertaken on metaphase chromosomes of early 
passage Cbx1-/- MEFs. Telomere FISH is a valuable technique that involves the hybridization 
of a fluorescent labelled telomeric PNA probe to the metaphase chromosomes, enabling the 
discrimination of individual chromosome ends. Analysis of metaphases prepared from 
exponentially growing early passage (passage 2-4, before senescence crisis) MEFs revealed 
Figure 10 3T9 assay of primary MEFs showing that homo- and heterozygous deletion of Cbx1 results in escape from 
senescence. WT MEFs are depicted as green lines with triangles, Cbx1+/- MEFs are depicted as blue lines with circles and 
Cbx1-/- MEFS are depicted as red lines with squares. 
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that there was an increase in aneuploid metaphases (Figure 11A) in Cbx1-/- cultures compared 
to Cbx1+/- and Cbx1+/+. A variety of other chromosomal aberrations were also present 
including premature chromosome separations (Figure 11B) as evidenced by presence of single 
chromatids, which is indicative of chromosome segregation defects, telomere-telomere fusions 
with loss (Figure 11D) and retention (Figure 11C) of telomere signals, chromosomal 
translocations (Figure 11E), formation of diplochromosomes (Figure 11F) and micronucleus 
formation (Figure 11G). 
Figure 11 Telomere FISH analysis on metaphases from Cbx1-/- primary MEFs reveals a variety of karyotypic aberrations.        
A. Example of an aneuploid metaphase seen in Cbx1-/- MEFs.  B. Some of the aneuploid Cbx1-/- metaphases exhibit 
premature chromosome separation.  C.  Chromosome end associations with retention of telomere signals.  D. Telomere-
telomere fusions with loss of telomere signals.  E. Chromosomal translocations, including ring chromosomes (arrow) and 
inversions (arrowhead).  F.  Diplochromosomes.  G. Micronucleus formation. Experiment was done in collaboration with 
Prof. T. Pandita (WUSOM, St. Louis). Scale bars: 10 µm. 
 
Genotype Chromosome gaps  and breaks Telomere associations Bridges 
Cbx1+/+ 5 31 7 
Cbx1+/- 6 29 10 
Cbx1-/-          24 (p<0.001)          88(p<0.001)          51(p<0.001) 
 
Table 4 Comparison of the frequencies of chromosome aberrations (chromosome gaps and breaks, telomere 
associations and anaphase bridges) per 200 cells analyzed. In all three categories, Cbx1-/- cells showed significantly 
increased numbers of aberrations compared to wild type controls. Experiment was done in collaboration with Prof. T. 
Pandita (WUSOM, St. Louis). 
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Statistical analysis (chi-squared test with 1 degree of freedom) showed that Cbx1-/- cells 
exhibited significantly more aberrations compared to Cbx1+/+ wild type controls (p<0.001). In 
Cbx1-/- cells, there were 5 times more chromosomal gaps and breaks, almost 3 times more 
telomere associations and more than 7 times more anaphase bridges than in wild type controls 
(Table 4). 
3.2 Investigation of the effect of Cbx1 null mutation on telomere function 
3.2.1 Investigation of the effect of Cbx1 null mutation on the telomeric “shelterin” 
The presence of chromosomal translocations including telomere-telomere fusions in 
chromosomes derived from Cbx1-/- MEFs indicated that telomere function had been affected 
by the Cbx1-/- mutation. It has been shown that mammalian telomeres are protected from 
being sensed as DNA damage by the “shelterin” protein complex, which is a complex of 6 
interacting proteins that form a protective cap at the end of mammalian chromosomes. When 
the shelterin complex is disrupted telomeres become “uncapped” and such uncapped telomeres 
elicit the DNA damage response that can trigger non-homologous end joining and 
consequent telomere-telomere fusions (Palm and de Lange; 2008). 
To address the question of whether the telomeric fusions and end associations observed in the 
chromosomes of Cbx1-/- MEFs were due to a disruption of the protective shelterin complex or 
changes in the telomeric heterochromatin itself, chromatin immunoprecipitation (ChIP) assay 
was undertaken using chromatin isolated from early passage WT and Cbx1-/- MEFs. ChIP 
assay is an established method for detecting the association of individual proteins with specific 
genomic regions. Briefly, chromatin from early passage WT and Cbx1-/- MEFs was 
precipitated with antibodies directed against known markers of heterochromatin, namely 
trimethylated lysine 9 on histone H3 (H3K9me3), dimethylated lysine 9 on histone H3 
(H3K9me2), and trimethylated lysine 20 on histone H4 (H4K20me3). ChIP was also 
performed with TRF1 and TRF2, which are components of the “shelterin” complex. DNA 
from the precipitated chromatin was then dot/slot blotted on nylon membrane, probed with 
32P labelled telomeric probe and the signals were quantified using the Imagequant software. 
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Figure 12 ChIP experiments were undertaken for the analysis of telomeric heterochromatin. Chromatin from early passage 
wild type and Cbx1-/- MEFs was immunoprecipitated with antibodies against several marks of heterochromatin and telomeric 
proteins. While there was no or very little change in the heterochromatic state of telomeres, there was a slight decrease in 
TRF1 found in the telomeres of Cbx1-/- cells compared to WT. Averages of three independent experiment are shown (n=3). 
a.u.: arbitrary units 
 
Cbx1-/- WT 
H3K9me3 
H3K9me2 
TRF1 
TRF2 
49.75 
24.20 
38.82 
145.17 
94.13 
55.04 
23.32 
36.89 
128.45 
92.06 
H4K20me3 
Mean values with standard deviations of 3 experiments are depicted in figure 12. As shown, 
there were little or no differences in the levels of the heterochromatin marks H3K9me3, 
H3K9me2, H4K20me3 and TRF2 protein, although a slight decrease in TRF1 association 
with the telomeres in Cbx1-/- MEFs was observed compared to WT MEFs. 
Guided by the observation that there was a decrease in TRF1 association with Cbx1-/- 
telomere (Figure 12) it has been investigated whether the cellular levels of TRF1 were 
changed due to removal of Cbx1 gene. To address this question, equal amounts of crude cell 
lysates obtained from early passage WT and Cbx1-/- MEFs were loaded on SDS 
polyacrylamide gels and western blotting using antibodies against HP1β, TRF1 and TRF2 
was performed. As expected, HP1β was not detectable in Cbx1-/- MEFs. There was no 
difference in the TRF1 (and TRF2) signal intensities in Cbx1-/- MEFs compared to WT 
(Figure 13). It was also observed that the molecular weight of the lower TRF1 band in Cbx1-/- 
MEFs had a slightly lower molecular weight than compared to same band in WT cells. 
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WT      Cbx1-/- 
HP1β 
TRF1 
 TRF2 
 
Figure 13 Equal amounts of crude cell lysates from early passage WT and 
Cbx1-/- MEFs were loaded on a 15 % SDS gel. Western blotting was then 
performed with antibodies against HP1β, TRF1 and TRF2.  
 
3.2.2 Investigation of the effect of Cbx1 null mutation on cellular distribution of “shelterin” 
proteins  
In order to explore the possibility that the telomeric phenotypes observed in Cbx1-/- MEFs 
were due to the mis-localisation of TPP1, POT1a and POT1b proteins, WT and Cbx1-/- 
MEFs were transiently transfected with pCAG-EGFP-TPP1, POT1a and POT1b EGFP 
fusion expression plasmids and immunofluorescence staining was performed using anti-GFP 
primary and Alexa-fluor-488 secondary antibodies for the enhancement of the GFP signal 
(green). As shown in figure 14, all three proteins gave a “dotty” nuclear staining pattern. 
WT                   Cbx1-/- 
POT1a 
 
 
 
POT1b 
 
 
 
TPP1 
Figure 14 Intracellular localizations of telomeric 
proteins POT1a, POT1b and TPP1 in G1 
interphase nuclei. Expression vectors encoding 
EGFP fusions of the proteins were transiently 
transfected into WT and Cbx1-/- MEFs. Following 
transfection, indirect immunofluorescence double 
staining was performed using anti-GFP(Rb) and 
anti-rabbit Alexa-fluor-488 antibodies in order to 
enhance the GFP signal (green). Cells were also 
counterstained with DAPI (blue) for the 
visualization of DNA. Note the slightly larger, 
more diffuse, blocks of Pot1b staining in Cbx1-/- 
Experiment was done in collaboration with Dr. K. 
Okamoto (Scripps, San Diego). 
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There were no differences in the pattern of TPP1, POT1a and POT1b staining in Cbx1-/- 
MEFs compared to WT MEFs although in some Cbx1-/- nuclei, POT1b was sometimes 
observed as slightly larger, more diffusely distributed dots (see the POT1b staining in the 
nucleus shown in figure 14). 
3.2.3 Investigation of the effect of Cbx1 null mutation on telomere length 
Mammalian telomeres are enriched for HP1 proteins and the heterochromatic marks 
H3K9me3, H4K20me3 (Blasco, 2007). Deletion of the Suv39h1/2 and Suv4-20h1/h2 histone 
methyltransferases that impose the H3K9me3 and H4K20me3 marks on heterochromatin 
results in the loss of the histone modifications, HP1α and HP1γ with only residual amounts 
of HP1β remaining at the telomeres (Garcia-Cao et al., 2004; Benetti et al., 2007). Notably, mutation in 
these enzymes also results in telomere recombination and in elongated telomeres.  
A critical role for HP1β in telomere physiology has been underscored by the overexpression of 
HP1β in human cells, which results in reduced association of human telomerase reverse 
transcriptase with the telomere and a higher frequency of end-to-end chromosomal fusions 
(Sharma et al., 2003). To investigate whether the genomic instability seen in Cbx1-/- MEFs was 
associated with a change in telomere lengths, FLOW-FISH analysis on early and late passage 
WT and Cbx1-/- MEFs was undertaken. FLOW-FISH is an established method for the 
measurement of mean telomere length (Baerlocher et al., 2006). Briefly, early passage (passages 1-3) 
and late passage (passages 30-35) WT and Cbx1-/- MEFs were hybridized with and without 
FITC-conjugated PNA probes specific for the telomeric sequences. After hybridisation, a 
flow cytometer was used to “gate” on G1 cells containing 2n DNA content for further analysis 
(Figure 15). Focussing on the 2n G1 cells, quantitative fluorescence values were obtained 
using the flow cytometer and mean telomere lengths of Cbx1-/- MEFs could be determined by 
first subtracting the autofluorescence levels obtained using unstained cells and then, second, 
by calculating the mean telomere length by comparison to the quantitative signals obtained 
from parallel analysis of cells with a known telomere length. 
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Figure 15 For measuring the lengths of telomeres, the FLOW-FISH technique was used. WT MEFs (R1) and bovine 
thymocytes (R3) in G1 phase, gated for the diploid content of DNA, were analysed by FACS. Quantitative fluorescence 
values were obtained for MEFs (R2) and bovine thymocytes (R4) respectively. Because bovine thymocytes have a known 
telomere length (~19.5 kb) it is possible to compare the fluorescence values obtained with the bovine thymocytes with those 
obtained from the MEFs and thus calculate the mean telomere length of experimental cells. Experiment was done in 
collaboration with Dr. U. Brassat (UKE, Hamburg). 
 
Figure 16 Mean telomere lengths of early and late passages of WT and Cbx1-/- MEFs measured by FLOW-FISH (n = 3) 
(1 TFU = 1 kb). Where telomeres of early passage WT and Cbx1-/- MEFs were of almost identical length, late passage 
Cbx1-/- MEFs had much longer telomeres (~20 kb longer) compared to WT controls. Experiment was done in 
collaboration with Dr. U. Brassat (UKE, Hamburg). 
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As shown in figure 16, there was very little or no difference found in the telomere lengths of 
early passage WT and Cbx1-/- cells. However, at late passage, the Cbx1-/- cells had telomeres 
that were longer (~20 kb) than the WT telomeres. 
3.3 Investigation of the effect of Cbx1 null mutation on sister chromatid cohesion  
Considering the role of HP1 proteins on cohesion in yeast, it has been investigated whether 
the genomic instability seen in Cbx1-/- MEFs was associated with defects in sister chromatid 
cohesion and kinetochore attachment. Consequently, indirect immunofluorescence staining 
experiments were performed on unfixed metaphase spreads from early passage WT and Cbx1-
/- MEFs. Accordingly, cells were arrested at metaphase by culturing cells in the presence of 
colcemid, incubated in a hypotonic medium for swelling and then centrifuged on glass 
objectives which resulted in the disruption of the cell membrane and enabled the visualization 
of metaphase chromosomes. Following this, slides were subjected to double indirect 
immunofluorescence staining without fixation with antibodies against SMC3, BUB1 and 
SGO1. Anti-CREST antibody was used in parallel for the localization of centromeres. DNA 
was counterstained with DAPI.  
As shown in figure 17, staining of chromosomes with an anti-SMC3 antibody revealed that 
there were no changes in SMC3 localization in early passage WT and Cbx1-/- MEFs. In both 
genotypes, SMC3 signal was present in between the two centromeric signals of CREST 
staining. The staining of unfixed metaphase chromosomes from early passage WT and Cbx1-/- 
MEFs with anti-BUB1 and anti-SGO1 antibodies are shown in figures 18 and 19, 
respectively. BUB1 signals in figure 18 perfectly colocalized with the centromeric signals 
obtained by the CREST staining with no change between WT and Cbx1-/- MEFs. The 
staining pattern of SGO1 in figure 19 was slightly different than the pattern observed by 
BUB1. SGO1 seemed to partially colocalize with centromeres, while some of the protein was 
localized around the centromeric signals of CREST staining. Notably, there were again no 
differences between the staining patterns obtained from WT and Cbx1-/- MEFs when an 
anti-SGO1 antibody was used. 
Results 
 
58 
 
 
Figure 17 Localization of cohesion subunit SMC3 on WT and Cbx1-/- metaphase chromosomes. SMC3 is shown in 
red, CREST in green and the DNA was counterstained with DAPI. Scale bars: 10 µm 
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Figure 18 Localization of spindle assembly checkpoint protein BUB1 on WT and Cbx1-/- metaphase chromosomes. BUB1 is 
shown in red, CREST in green and the DNA was counterstained with DAPI. Scale bars: 5 µm 
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Figure 19 Localization of SGO1 protein on WT and Cbx1-/- metaphase chromosomes. SGO1 is shown in red, CREST in 
green and the DNA was counterstained with DAPI. Scale bars: 5 µm 
 
CREST 
 
 
 
 
SGO1 
 
 
 
Merged 
WT                             Cbx1-/- 
Results 
 
61 
 
3.4 Investigation of the effect of Cbx1 mutation on oncogene-induced senescence in the K-
ras+/V12;RERTn+/ERT mouse model system  
K-ras+/V12;RERTn+/ERT transgenic mice carry the inducible K-rasV12 allele along with the wt 
allele. These mice express the oncogenic K-rasV12 upon 4-hydroxytamoxifen (4-OHT) i.p. 
injection, which results in the activation of the inducible Cre-ERT2 recombinase expression 
leading to removal of the STOP transcriptional sequences that prevent expression of the 
targeted K-rasV12 allele (Guerra et al., 2003). Oncogenic K-ras protein only differs from WT K-ras 
in one amino acid: the glycine 12 residue (GGT) is changed into the oncogenic valine 12 
(GTA). These animals have been shown to develop lung adenomas (premalignant tumours) 
and adenocarcinomas (malignant tumours). The premalignant adenomas exhibit characteristic 
features of OIS: they stain positive for SA-β-gal, p16 and DcR2 and are negative for pKi-67 
staining (Collado et al., 2005). In contrast, the malignant adenocarcinomas escape cellular 
senescence; they show a low expression of SA-β-gal, p16 and DcR2 and a concomitant 
increase in pKi-67 expression. 
In order to investigate the effects of Cbx1 mutation on oncogene-induced senescence, Cbx1 
heterozygous mutation was introduced into mice carrying the inducible K-rasV12 allele to 
create the strain K-ras+/V12;RERTn+/ERT;Cbx1+/-. Mice were then injected with 4-OHT to 
induce expression of the K-rasV12 oncogene. In our hands, these mice neither died nor showed 
severe breathing difficulties when they were around 8 months old as described in the original 
reference (Guerra et al., 2003); therefore they were not killed at month 8 and allowed to live 
longer. The experiment was eventually stopped and the mice were killed. Some of the mice 
were by then 22 months old. Lungs of these mice were analyzed for the expression of 
oncogenic K-rasV12 and examined for the presence of adenomas and adenocarcinomas by 
histopathological and immunohistochemical analysis of sections using markers for senescence 
(p16, DcR2) and proliferation (pKi-67). Histopathological analysis was done in collaboration 
with Prof. E. Vollmer (FZB). Analysis of the expression of oncogenic K-rasV12 was done by 
sequencing of RT-PCR products amplified from lung tissues with K-rasV12 specific primers. 
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As a result of this analysis, it was found that at the time the tissues were taken, K-rasV12 was 
expressed in 4 of the experimental (Cbx1+/-) and 6 of the control (WT) mice (Figure 20).  
16 mice were analyzed in total in these experiments (8 experimental and 8 control). In 5 out 
of 8 experimental mice, histopathological analyses revealed obvious malignant 
adenocarcinomas whereas in control group there was only one mouse with a small region of 
adenocarcinoma (Figure 21, Table 5). In contrast, there were surprisingly no premalignant 
adenomas found in any of the lungs dissected. 
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Figure 20.  RT-PCR products amplified using “K-ras V12 for” and “K-ras V12 rev” primers from lung tissues of K-
ras+/V12;RERTn+/ERT (WT control group on the right side, numbers 9-16) and K-ras+/V12;RERTn+/ERT;Cbx1+/-  
(experimental group on the left side, numbers 1-8) mice were sequenced. Chromatographs with codons 10-14 of K-ras 
gene, with codon 12 in black rectangle, are shown. Valine 12 (GTA) was considered as expressed when the 
chromatograph peaks had at least 10 % of the size of the WT allele (GGT). This analysis has revealed that oncogenic K-
rasV12 was expressed in 4/8 experimental and in 6/8 of WT mice (see also Table 5). 
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Mice No. Adenocarcinoma K-ras
V12  
expressed 
Age at time  
of death (weeks) 
K-ras+/V12;RERTn+/ERT;Cbx1+/- 
1-   82 
2-   92 
3-   73 
4-   65 
5-   92 
6-   86 
7-   84 
8-   84 
K-ras+/V12;RERTn+/ERT (Control group) 
9-   72 
10-   67 
11-   67 
12-   66 
13-   86 
14-   79 
15-   79 
16-   56 
 
Table 5 Analysis of lungs from WT and experimental mice. Each lung was screened for the presence of tumors and 
expression of oncogenic K-rasV12 by 4-OHT injection. Ages of mice when they were killed are also included. 
 
K-ras+/V12;RERTn+/ERT;Cbx1+/-   K-ras+/V12;RERTn+/ERT 
Figure 21 Number of adenocarcinomas found in K-ras+/V12;RERTn+/ERT;Cbx1+/- mice compared to WT (n= 8 for both 
genotypes). While the only adenocarcinoma from WT control mice was identified in only one of the many lung sections 
prepared, 5 of the experimental K-ras+/V12;RERTn+/ERT;Cbx1+/- mice had obvious malignant tumours with 4 of them present 
in multiple sections. 
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Immunohistochemical analysis on lung sections possessing adenocarcinomas was done with 
markers of senescence and proliferation. It was only possible to stain 4 of the 5 
adenocarcinomas found in K-ras+/V12;RERTn+/ERT;Cbx1+/- lungs as the fifth tumour was only 
seen in one of the sections prepared, and there were no sections left for further staining. 
Likewise, the staining of the only adenocarcinoma in control group lungs was also not 
possible due to same problem. All stainings shown in figures 22 - 27 were performed on 
adjacent sections of the same tumours for each mouse. 
As shown in figure 22, none of the tumours were positively stained for p16, which shows that 
the cells were unlikely to be senescent. DcR2 staining, another cellular marker of in vitro 
oncogene-induced senescence confirmed the result with p16 (Figure 23). The tumours from 
K-ras+/V12;RERTn+/ERT;Cbx1+/- lungs were also negative for DcR2 staining.  
Having shown that the tumours found in K-ras+/V12;RERTn+/ERT;Cbx1+/- lungs were negative 
for senescent markers, pKi-67 staining was performed next on the lung adenocarcinomas in 
order to assess the proliferation rate (Figure 24). As shown in figure 24, there was a strong 
positive staining for pKi-67 in all four lung sections with malignant tumours, which is 
indicative of strong cellular proliferation. Lung sections from WT mice were negative for 
pKi-67 staining.  
In order to investigate the expression levels and cellular distribution of HP1 isoforms, IHC 
staining with HP1α, HP1β and HP1γ antibodies was performed in parallel (Figures 25-27). 
All three isoforms gave strong nuclear staining patterns, typical for HP1 proteins. There were 
no obvious differences in the staining patterns observed between K-ras+/V12;RERTn+/ERT and 
K-ras+/V12;RERTn+/ERT;Cbx1+/- mice apart from HP1γ staining which was stronger in K-
ras+/V12;RERTn+/ERT;Cbx1+/- tumour sections. 
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Figure 22 Immunohistochemical staining of a WT tissue and lung tumours found in K-ras+/V12;RERTn+/ERT;Cbx1+/- lungs 
with the p16 antibody. Numbers on the left side are the numbers of mice as given in table 2. Black arrows indicate regions 
with adenocarcinomas. In the right columns, same tumour regions with a higher magnification are shown. * indicates 
adenocarcinomas existed in all over the section. Blue colour: Haematoxylin, Brown colour: PO staining. Scale bars: 250 µm 
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Figure 23 Immunohistochemical staining of a WT tissue and lung tumours found in K-ras+/V12;RERTn+/ERT;Cbx1+/- lungs 
with DcR2 antibody. Numbers on the left side are the numbers of mice as given in table 2. Black arrows indicate regions with 
adenocarcinomas. In the right columns, same tumour regions with a higher magnification are shown. * indicates 
adenocarcinomas existed in all over the section. Blue colour: Haematoxylin, Brown colour: PO staining. Scale bars: 250 µm 
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Figure 24 IHC staining of a WT lung tissue and lung tumours found in K-ras+/V12;RERTn+/ERT;Cbx1+/- lungs with pKi-67 
antibody. Numbers on the left side are the numbers of mice as given in table 2. Black arrows indicate regions with 
adenocarcinomas. In the right columns, same tumour regions with a higher magnification are shown.  * indicates 
adenocarcinomas existed in all over the section. Blue colour: Haematoxylin, Brown colour: PO staining. Scale bars: 250 µm 
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Figure 25 Immunohistochemical staining of a WT tissue and lung tumours found in K-ras+/V12;RERTn+/ERT;Cbx1+/- lungs 
with HP1α antibody. Numbers on the left side are the numbers of mice as given in table 2. Black arrows indicate regions 
with adenocarcinomas. In the right columns, same tumour regions with a higher magnification are shown. * indicates 
adenocarcinomas existed in all over the section. Blue colour: Haematoxylin, Brown colour: PO staining. Scale bars: 250 µm 
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Figure 26 Immunohistochemical staining of a WT tissue and lung tumours found in K-ras+/V12;RERTn+/ERT;Cbx1+/- lungs 
with HP1β antibody. Numbers on the left side are the numbers of mice as given in table 2. Black arrows indicate regions 
with adenocarcinomas. In the right columns, same tumour regions with a higher magnification are shown. * indicates 
adenocarcinomas existed in all over the section. Blue colour: Haematoxylin, Brown colour: PO staining. Scale bars: 250 µm 
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Figure 27 Immunohistochemical staining of a WT tissue and lung tumours found in K-ras+/V12;RERTn+/ERT;Cbx1+/- lungs 
with HP1γ antibody. Numbers on the left side are the numbers of mice as given in table 2. Black arrows indicate regions with 
adenocarcinomas. In the right columns, same tumour regions with a higher magnification are shown.  * indicates 
adenocarcinomas existed in all over the section. Blue colour: Haematoxylin, Brown colour: PO staining. Scale bars: 250 µm 
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Figure 28 Growth curve analysis of the cells transduced with an 
empty control vector or a ras expression vector. Graph shows the 
averages of 3 independent experiments. Experiments were done 
in collaboration with Dr. M. Balabanov (UKE, Hamburg). 
 
day 0 day 2 day 4 day 6 day 8 
Re
lat
ive
 ce
ll n
um
be
r (
x1
04 )
 
3.5 Investigation of the effect of Cbx1 mutation on oncogene-induced senescence in vitro 
Guided by the observation (detailed in last section) that a reduction in Cbx1 gene dosage 
likely resulted in escape from senescence and increased proliferation followed by the formation 
of malignant adenocarcinomas in the K-ras mouse model, it has been tested whether this 
effect was also reproducible in vitro using the well established H-rasV12 oncogene model 
(Serrano et al., 1997). Previously, it has been shown that cells transduced with an H-rasV12 
expression plasmid undergo cellular senescence as evidenced by a cessation of proliferation 
and positivity for SA-β-gal staining. In collaboration with Dr. M. Balabanov (UKE, 
Hamburg), retroviral transduction experiments on WT, Cbx1+/- and Cbx1-/- MEFs were 
performed using an empty control vector pBabe-puro and pBabe-Ras-puro expressing an H-
rasV12 cDNA. Upon selection with puromycin (2.5 µg/ml) for 3 days, cells were plated at low 
density and allowed to proliferate for 8 days while counting them on days 2, 4, 6 and 8 
respectively for growth curve analysis. 
As seen in figure 28, WT MEFs 
transduced with an empty control 
vector (red circles with a continuous 
line) continued to proliferate until day 
8, same cells transduced with the ras 
expression vector (red circles with a 
dotted line) showed a proliferation 
arrest, as previously shown (Serrano et al., 
1997). When Cbx1-/- MEFs were 
transduced with the H-rasV12 
expression vector (blue triangles with 
a dotted line), there was also a growth 
arrest compared to Cbx1-/- MEFs 
transduced with empty vector (blue triangles with a continuous line), indicating that the 
Cbx1-/- MEFs behave similar to the WT MEFs when challenged by oncogenic virus.  
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Next, in order to investigate whether the cells with proliferation arrest were also positive for 
senescent, SA-β-gal staining was performed on MEFs 7 days after transduction. 100 cells 
from each genotype were counted and the averages of three independent experiments were 
taken. As shown in figure 29, cells transduced with the empty control vector were not 
senescent, while cells transduced with oncogenic ras expressing pBabe-ras-puro were stained 
positive for SA-β-gal. WT, Cbx1+/- and Cbx1-/- MEFs were stained positively 91 %, 94 % and 
80 %, respectively. The percentages of positively stained cells correlated well with the growth 
curve analysis of the individual genotypes shown in figure 18. 
3.6 Investigation of the binding of HP1β to Histone H3  
The binding of HP1β to trimethylated lysine 9 of histone H3 and SUV39H1 histone 
methyltransferase is thought to be the key interaction of HP1β (Lachner et al., 2001 and Bannister et 
al., 2001). However, in the light of rapidly increasing evidence, originally stemming from 
biophysical studies, a more complex picture has emerged which cannot easily be explained by a 
simple binary H3K9me3-HP1β interaction (Festenstein et al., 2003; Cheutin et al., 2003; Schmiedeberg et al., 
2004 and Dialynas et al., 2007; see introduction). Notably, the striking fact that Suv39h1/h2 knock 
out animals live whereas Cbx1 knock out animals die, suggests that the essential function of 
HP1β must lie outside the Suv39h1/h2 dependent heterochromatic H3K9me3-HP1β 
interaction. One key candidate for this interaction is HP1β binding to the histone H3 
histone-fold, which has been studied in some detail (Nielsen et al., 2001 and Dialynas et al., 2006). A few 
HP1β residues have been tested for their affinities to H3K9me3 peptide and histone H3. 
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) Figure 29 WT, Cbx1+/- and Cbx1-/- MEFs were transduced either 
with an empty vector or a ras expression vector. 7 days after 
transduction, cells were then exposed to SA-β-gal staining and 
positively stained cells for each genotype were counted. 100 cells 
for each genotype were analyzed and averages of three 
independent experiments are shown. Experiments were done in 
collaboration with Dr. M. Balabanov (UKE, Hamburg). 
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However, it remains to be identified whether there are specific residues that may play a role in 
the interaction of HP1β with histone H3. 
In order to investigate the interaction of HP1β with histone H3 in vitro, GST pull down 
experiments with recombinant, unmethylated histone H3 were undertaken. Recombinant 
WT mouse HP1β was expressed as a GST fusion protein along with several mutant forms 
harbouring mutations in the chromo and chromoshadow domains (Figure 30). The type of 
mutation was decided upon from a review of the literature and aimed at addressing the 
interaction of HP1β with recombinant, unmethylated histone H3. The rationale for the 
experiments was to incubate WT and mutant GST-HP1β proteins with histone H3 in 
increasing NaCl concentrations so that the affinity of the interaction could be gauged.  
 
The results obtained in GST pull down experiments are shown in figure 31 and table 6. All 
full length recombinant HP1β mutant proteins (Figure 31, left and right section) tested were 
able to pull down recombinant histone H3 at all NaCl concentrations except for the I161E 
mutant which lost its binding to histone H3 at 0.6 M and 0.75 M NaCl. In case of N-
terminal HP1β mutants lacking amino acids 115-185 (Figure 31, middle section), the WT 
N-terminal HP1β and N-terminal T51A, V23M and K33Q mutants all lost binding to 
histone H3 at 0.6 M and 0.75 M NaCl. This binding was surprisingly rescued at 0.6 M in 
F45E mutant and at both 0.6/0.75 M in R29/30Q mutant. C-terminal HP1β lacking amino 
acids 1-115 was also able to pull down histone H3 in all three NaCl concentrations tested. 
1 115 HP1β N-terminal mutant 
HP1β C-terminal mutant R29/30Q 
Figure 30 An overview of mutations and recombinant HP1β 
proteins used in pull down experiments is shown. Single letter 
codes of the substituted amino acids are shown and their 
position in the mouse HP1β sequence was drawn to scale. CD 
and CSD depict to chromo domain and chromoshadow 
domain, respectively. 
115 185 
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Figure 31 Coomassie stained SDS gels, showing the results of GST pull down experiments done with several HP1β 
mutants and histone H3. The higher band seen in each gel is HP1β and the lower band is histone H3. Experiments 
using the same proteins were repeated in increasing NaCl concentration (three rows in each section). In the left section, 
pull down experiments are shown in which full length recombinant HP1β  mutants were used. In the middle section, 
proteins used were either N-terminal HP1β mutants expressing amino acids 1-115, or C-terminal HP1β expressing 
amino acids 115-185. In the right section, full length recombinant HP1β mutants with an additional I161E mutation are 
shown. In each experiment histone H3 was also incubated with glutathione sepharose beads only and GST protein 
without fusion partner (left, bottom corner) as controls.  
1       2 
1: Only beads control+ histone H3 
2: Only GST control+ histone H3 
WT HP1β 
+ histone H3 
HP1β T51A  
+ histone H3 
HP1β V23M  
+ histone H3 
HP1β F45E  
+ histone H3 
HP1β K33Q  
+ histone H3 
HP1β R29/30Q  
+ histone H3 
NaCl Concentration 
0.3 M   0.6 M  0.75 M 
Nterm-HP1β K33Q  
+ histone H3 
Nterm-HP1β R29/30Q  
+ histone H3 
WT Nterm-HP1β 
+ histone H3 
Nterm-HP1β T51A  
+ histone H3 
Nterm-HP1β V23M  
+ histone H3 
Nterm-HP1β F45E  
+ histone H3 
WT Cterm-HP1β 
+ histone H3 
NaCl Concentration 
0.3 M   0.6 M  0.75 M 
HP1β I161E  
+ histone H3 
HP1β T51A+I161E  
+ histone H3 
HP1β V23M+I161E 
+ histone H3 
HP1β F45E+I161E 
+ histone H3 
HP1β K33Q+I161E 
+ histone H3 
HP1β R29/30Q+I161E 
+ histone H3 
NaCl Concentration 
0.3 M   0.6 M  0.75 M 
Proteins 
Histone H3 binding 
Proteins 
Histone H3 binding 
0.3 M 0.6 M 0.75 M 0.3 M 0.6 M 0.75 M 
HP1α    HP1β F45E    
HP1β    HP1β N-terminal F45E    
HP1γ    HP1β T51A    
HP1β C-terminal (115-185)    HP1β N-terminal T51A    
HP1β N-terminal (1-115)    HP1β I161E    
HP1β V23M    HP1β I161E+V23M    
HP1β N-terminal V23M    HP1β I161E+K33Q    
HP1β K33Q    HP1β I161E+F45E    
HP1β N-terminal K33Q    HP1β I161E+T51A    
HP1β R29/30Q    HP1β I161E+R29/30Q    
HP1β N-terminal R29/30Q        
 
Table 6 An overview of the results of the GST pull down experiments performed. Several HP1β mutants were tested for 
their binding affinities to histone H3 at increasing NaCl concentrations. An observed binding was depicted as a tick, whereas 
a lost in binding was depicted as an X. 
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3.7 Investigation of the binding affinity of HP1β to histone H3 and H3K9me3 
Having shown the in vitro binding of HP1β and several mutants with histone H3 in high salt 
concentrations, the strength of this interaction was then measured quantitatively. Isothermal 
titration calorimetry was the method of choice as it is the only method that can measure 
biomolecular interactions through the simultaneous determination of all binding parameters 
(n, KD, ΔH and ΔS) in a single experiment. To compare the affinities and to determine which 
mutants retain the ability to bind to histone H3 but not to H3K9me3 (or vice versa), binding 
of HP1β to H3K9me3 tail peptide was also included in this analysis. Full length recombinant 
mouse HP1β and V23M, F45E, T51A and I161E mutant proteins, were expressed in 
bacteria as His-tag fusion proteins and affinity purified using Ni-NTA beads. HP1β proteins 
(and mutants thereof) were put in the sample cell and either recombinant X. laevis histone H3 
or H3K9me3 tail peptide were then injected into the sample cell using the automated syringe 
(see Figure 9 in Materials & Methods). These experiments were performed both at 25 °C and 
37 °C. 
While binding of HP1β to H3K9me3 was always an exothermic (negative ∆H value, peaks of 
the reaction downwards) reaction, binding to histone H3 was endothermic (positive ∆H value, 
peaks of the reaction upwards). The binding affinities of all reactions (Table 7) were 
calculated by the software of the instrument in terms of a Ka value (association constant), and 
this was converted manually into a KD value (dissociation constant, µM) where the affinity of 
the reaction (Ka) and the KD value were inversely proportional (e.g. higher the KD value, lower 
the affinity). All calculations were based on the Gibbs free energy equation: ∆G= -RT  ln Ka = 
∆H - T∆S (∆G is the free energy of binding, R is the gas constant, T is the absolute 
temperature, Ka is the association constant, ∆H is the enthalpy and ∆S is the entropy).  
As shown in table 7, figures 32 and 33, it was found that the binding affinity of wild type 
HP1β to histone H3 was approximately 4 times higher than for the trimethylated lysine 9 tail 
peptide (H3K9me3) at both 25 °C and 37 °C. In the HP1β T51A mutant, the binding to 
histone H3 was slightly stronger than for the H3K9me3 peptide (Table 7, Figures 34 and 35). 
On the other hand, HP1β V23M mutant had a very low affinity for H3K9me3, in line with 
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published data, while still having a high affinity for histone H3 (Table 7, Figures 36 and 37). 
In case of HP1β F45E mutant, data obtained at 25 °C with Histone H3 was not accurate as 
confirmed by an unstable baseline (Figure 39). However, a direct comparison could be made 
at 37 °C, which gave reproducible results; at 37 °C HP1β F45E mutant has lost its affinity for 
the H3K9me3 peptide but retained its high affinity for the recombinant histone H3 (Figures 
38 and 39). The binding affinity of HP1β I161E mutant for histone H3 was almost two 
times higher than its affinity for H3K9me3 peptide, both at 25 °C and 37 °C (Table 7, 
Figures 40 and 41). On the other hand, compared to WT protein, this mutant showed a 
higher (ca. 2 times higher) affinity for the trimethylated lysine 9 peptide at both tested 
temperatures. 
 
 
 
 
 Histone H3 H3K9me3 
KD N ∆H ∆S KD N ∆H ∆S 
25
 °C
 
HP1β 7.6 0.679 2838 32.9 30 1.32 -9152 -9.99 
HP1β T51A 24.5 0.758 7471 46.2 31.9 1.22 -9859 -12.5 
HP1β V23M 7.5 0.834 10500 58.7 189 0.0324 -97550 -310 
HP1β F45E 77.5* 0.678* 3943* 32* 179.5 0.0358 -234600 -769 
HP1β I161E 7.7 1.72 911.7 26.5 14.3 1.21 -8634 -6.8 
37
 °C
 
HP1β 16.4 0.564 14510 68.7 59.5 0.69 -23100 -55.3 
HP1β T51A n.d. n.d. n.d. n.d. 63.3 1 -18760 -41.3 
HP1β V23M n.d. n.d. n.d. n.d. 182.5 0.00387 -1568000 -5040 
HP1β F45E 15 0.451 16030 73.7 344.9 0.173 -66110 -197 
HP1β I161E 19 1.05 10680 56 35 1.31 -10480 -13.4 
 
Table 7 An overview of thermodynamic parameters obtained from the ITC experiments performed. *: data not accurate due 
to unstable baseline, n.d.: experiment not done. KD: dissociation constant (µM), N: number of binding sites, ∆H: the heat of 
binding (enthalpy change, cal/mol), ∆S: entropy change (cal/mol/deg) 
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Figure 32 Binding of wild type HP1β to H3K9me3 tail peptide as measured by isothermal titration calorimetry at 25°C 
(figure on the left) and 37°C (figure on the right). Raw data (upper parts of both figures) and integrated heats of injections 
(lower parts of both figures), with the solid line corresponding to the best fit of the data using “one set of sites” parameter of 
instruments software are shown. 
Figure 33 Binding of wild type HP1β to histone H3 as measured by isothermal titration calorimetry at 25°C (figure on the 
left) and 37°C (figure on the right). Raw data (upper parts of both figures) and integrated heats of injections (lower parts of 
both figures), with the solid line corresponding to the best fit of the data using “one set of sites” parameter of instruments 
software are shown. 
 
 
Chi^2/DoF = 2.162E4 
N                  = 1.32 ±0.0282 Sites 
Ka  = 3.33E4 ±4.16E3 M-1 
Kd  = 30 µM 
ΔH  = -9152 ±353.9 cal/mol 
ΔS  = -9.99 cal/mol/deg 
 
Chi^2/DoF = 1.277E4 
N                  = 0.69 ±0.0349 Sites 
Ka  = 1.68E4 ±1.25E3 M-1 
Kd  = 59.5 µM 
ΔH  = -2.316E4  ±1551 cal/mol 
ΔS  = -55.3 cal/mol/deg 
 
Chi^2/DoF = 2.643E4 
N                  = 0.679 ±0.0448 Sites 
Ka  = 1.31E5 ±4.78E4 M-1 
Kd  = 7.6 µM 
ΔH  = 2838  ±271.1 cal/mol 
ΔS  = 32.9 cal/mol/deg 
 
Chi^2/DoF = 1.59E5 
N                  = 0.564 ±0.0461 Sites 
Ka  = 6.10E4 ±1.40E4 M-1 
Kd  = 16.4 µM 
ΔH  = 1.451E4  ±1616 cal/mol 
ΔS  = 68.7 cal/mol/deg 
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Figure 34 Binding of HP1β T51A mutant to H3K9me3 tail peptide as measured by isothermal titration calorimetry at 25°C 
(figure on the left) and 37°C (figure on the right). Raw data (upper parts of both figures) and integrated heats of injections 
(lower parts of both figures), with the solid line corresponding to the best fit of the data using “one set of sites” parameter of 
instruments software are shown. 
 
 
Figure 35 Binding of HP1β T51A mutant to histone H3 as measured by isothermal titration calorimetry at 25°C (figure on 
the left). Raw data (upper part of figure) and integrated heats of injections (lower part of figure), with the solid line 
corresponding to the best fit of the data using “one set of sites” parameter of instruments software are shown. 
 
 
Chi^2/DoF = 2.034E4 
N                  = 1.22 ±0.0285 Sites 
Ka  = 3.13E4 ±3.63E3 M-1 
Kd  = 31.9 µM 
ΔH  = -9859  ±399.6 cal/mol 
ΔS  = -12.5 cal/mol/deg 
 
Chi^2/DoF = 6.38E4 
N                  = 1.00 ±0.0779 Sites 
Ka  = 1.58E4 ±3.09E3 M-1 
Kd  = 63.3 µM 
ΔH  = -1.876E4  ±2299 cal/mol 
ΔS  = -41.3 cal/mol/deg 
 
Chi^2/DoF = 1.429E5 
N                  = 0.758 ±0.103 Sites 
Ka  = 4.08E4 ±1.68E4 M-1 
Kd  = 24.5 µM 
ΔH  = 7471  ±1447 cal/mol 
ΔS  = 46.2 cal/mol/deg 
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Figure 36 Binding of HP1β V23M mutant to H3K9me3 tail peptide as measured by isothermal titration calorimetry at 25°C 
(figure on the left) and 37°C (figure on the right). Raw data (upper parts of both figures) and integrated heats of injections 
(lower parts of both figures), with the solid line corresponding to the best fit of the data using “one set of sites” parameter of 
instruments software are shown. 
 
 
Figure 37 Binding of HP1β T51A mutant to histone H3 as measured by isothermal titration calorimetry at 25°C (figure on 
the left). Raw data (upper part of figure) and integrated heats of injections (lower part of figure), with the solid line 
corresponding to the best fit of the data using “one set of sites” parameter of instruments software are shown. 
 
 
Chi^2/DoF = 1.348E4 
N                  = 0.0324 ±1.12 Sites 
Ka  = 5.29E3 ±4.76E3 M-1 
Kd  = 189 µM 
ΔH  = -9.755E4  ±3.395E6 cal/mol 
ΔS  = -310 cal/mol/deg 
 
Chi^2/DoF = 2.508E4 
N                  = 0.00387 ±0.757 Sites 
Ka  = 5.48E3 ±3.38E3 M-1 
Kd  = 182.5 µM 
ΔH  = -1.568E6  ±3.068E8 cal/mol 
ΔS  = -5.04E3 cal/mol/deg 
 
Chi^2/DoF = 2.069E5 
N                  = 0.834 ±0.0316 Sites 
Ka  = 1.33E5 ±3.28E4 M-1 
Kd  = 7.5 µM 
ΔH  = 1.051E4  ±578.5 cal/mol 
ΔS  = 58.7 cal/mol/deg 
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Figure 38 Binding of HP1β F45E mutant to H3K9me3 tail peptide as measured by isothermal titration calorimetry at 25°C 
(figure on the left) and 37°C (figure on the right). Raw data (upper parts of both figures) and integrated heats of injections 
(lower parts of both figures), with the solid line corresponding to the best fit of the data using “one set of sites” parameter of 
instruments software are shown. 
 
Figure 39 Binding of HP1β F45E mutant to histone H3 as measured by isothermal titration calorimetry at 25°C (figure on 
the left) and 37°C (figure on the right). Raw data (upper parts of both figures) and integrated heats of injections (lower parts 
of both figures), with the solid line corresponding to the best fit of the data using “one set of sites” parameter of instruments 
software are shown. 
 
 
Chi^2/DoF = 1.434E4 
N                  = 0.0358 ±0.383 Sites 
Ka  = 5.57E3 ±1.79E3 M-1 
Kd  = 179.5 µM 
ΔH  = -2.346E5  ±2.536E6 cal/mol 
ΔS  = -769 cal/mol/deg 
 
Chi^2/DoF = 2869 
N                  = 0.173 ±0.755 Sites 
Ka  = 2.90E3 ±1.20E3 M-1 
Kd  = 344.9 µM 
ΔH  = -6.611E4  ±3.000E5 cal/mol 
ΔS  = -197 cal/mol/deg 
 
Chi^2/DoF = 3.274E4 
N                  = 0.678 ±0.516 Sites 
Ka  = 1.29E4 ±1.17E4 M-1 
Kd  = 77.5 µM 
ΔH  = 3943  ±3887 cal/mol 
ΔS  = 32.0 cal/mol/deg 
 
Chi^2/DoF = 1.992E4 
N                  = 0.451 ±0.0342 Sites 
Ka  = 6.67E4 ±7.73E3 M-1 
Kd  = 15 µM 
ΔH  = 1.603E4  ±1526 cal/mol 
ΔS  = 73.7 cal/mol/deg 
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Figure 40 Binding of HP1β I161E mutant to H3K9me3 tail peptide as measured by isothermal titration calorimetry at 25°C 
(figure on the left) and 37°C (figure on the right). Raw data (upper parts of both figures) and integrated heats of injections 
(lower parts of both figures), with the solid line corresponding to the best fit of the data using “one set of sites” parameter of 
instruments software are shown. 
 
Figure 41 Binding of HP1β I161E mutant to histone H3 as measured by isothermal titration calorimetry at 25°C (figure on 
the left) and 37°C (figure on the right). Raw data (upper parts of both figures) and integrated heats of injections (lower parts 
of both figures), with the solid line corresponding to the best fit of the data using “one set of sites” parameter of instruments 
software are shown. 
 
 
Chi^2/DoF = 1.203E4 
N                  = 1.21 ±0.0128 Sites 
Ka  = 6.99E4 ±5.06E3 M-1 
Kd  = 14.3 µM 
ΔH  = -8634  ±144.0 cal/mol 
ΔS  = -6.80 cal/mol/deg 
 
Chi^2/DoF = 1.061E4 
N                  = 1.31 ±0.0202 Sites 
Ka  = 2.86E4 ±2.39E3 M-1 
Kd  = 35 µM 
ΔH  = -1.048E4  ±296.8 cal/mol 
ΔS  = -13.4 cal/mol/deg 
 
Chi^2/DoF = 2.670E4 
N                  = 1.72 ±0.138 Sites 
Ka  = 1.30E5 ±1.29E5 M-1 
Kd  = 7.7 µM 
ΔH  = 911.7  ±111.8 cal/mol 
ΔS  = 26.5 cal/mol/deg 
 
Chi^2/DoF = 5.197E4 
N                  = 1.05 ±0.0887 Sites 
Ka  = 5.24E4 ±1.03E4 M-1 
Kd  = 19 µM 
ΔH  = 1.068E4  ±1197 cal/mol 
ΔS  = 56.0 cal/mol/deg 
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HP1 proteins are thought to be modulators of chromatin organization in all mammals, yet 
their exact physiological function remains unknown. In a first attempt to elucidate the 
function of HP1β in vivo, the murine Cbx1 gene encoding HP1β was disrupted recently 
(Aucott et al., 2008). The Cbx1 null mutation results in perinatal lethality. The proximate cause of 
death is that the mice cannot breathe due to the defective development of neuromuscular 
junctions within the endplate of the diaphragm; in the absence of contraction of the 
diaphragm the lungs do not expand. Study of other neuronal structures revealed that Cbx1 
null mice exhibit aberrant development of the cerebral cortex and cytological examination of 
neurospheres cultured in vitro from Cbx1 null brains revealed a striking genomic instability. It 
is toward understanding, in concrete cellular and molecular terms, the role of Cbx1 gene 
product, HP1β, in regulating genome stability that is the major focus of this thesis. As 
explained (see Introduction) genomic instability is found in many cancers and is associated 
with the uncontrolled proliferation of cells. To that end, the effects of Cbx1 null mutation on 
telomere function and sister chromatid cohesion have been investigated first. Next, based on 
the known role of HP1 proteins in cellular senescence (see Introduction), the effects of the 
Cbx1 mutation in a sensitized cancer model with the express aim to understand the role of 
HP1β in OIS have been investigated. Finally, alternative ways in which HP1β binds to 
histone H3 have been characterized by measuring the affinity of the different interactions of 
HP1β with histone H3. In this way, it was aimed to define the critical interaction whose loss 
likely results in the Cbx1 null lethal phenotype. 
4.1 The Cbx1 gene and the regulation of genomic stability 
In order to characterise the chromosomal instabilities that were initially observed in Cbx1-/-
neurospheres cultures, a model system was set up, namely the 3T9 assay (Figure 10). This 
allowed us to obtain enough material to characterise the instabilities in more detail; 
neurosphere cultures provide only limited amounts of material for analysis. Accordingly, 
culture of primary MEFs from three genotypes, WT, Cbx1+/- and Cbx1-/-, according to a 3T9 
protocol showed that by passage 16 the WT cells had undergone senescence crisis, while in 
stark contrast, Cbx1+/- and Cbx1-/- MEFs either went through the crisis and continued to 
proliferate or simply continued to proliferate without any sign of having been through crisis. 
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Cytological analysis of early passage cells showed that the instabilities were of several different 
types, including an increased number of telomere-telomere fusions and also premature 
chromosome separations (Figure 11, Table 4). In this thesis the molecular bases of these two 
types of defect were studied further (see below).  
 4.2 Investigation of the effect of Cbx1 null mutation on telomere function 
The presence of telomere-telomere fusions in low passage Cbx1-/- cells strongly indicated that 
the absence of the Cbx1 gene product, HP1β, compromises telomere function. To explore the 
molecular basis of these aberrant fusions further, the H3K9me3-HP1-H4K20me3 epigenetic 
pathway was investigated first. The pathway from H3K9me3 to H4K20me3 via HP1 is 
thought to be important for the assembly of HP1-containing constitutive heterochromatin at 
both centromeres and telomeres (Kourmouli et al., 2004; 2005; Schotta et al., 2004). Disruption of this 
pathway in cells deficient in Suv39h1/h2 HMTases showed decreased levels of H3K9 
trimethylation at telomeres, concomitant with a reduction in binding of HP1 proteins and 
aberrant telomere elongation (Garcia-Cao et al., 2004). Using ChIP assays, no change in the levels 
of H3K9me3, H3K9me2 and H4K20me3 at telomeric heterochromatin was observed 
indicating that the H3K9me3-HP1-H4K20me3 epigenetic pathway is unlikely to be 
disrupted in Cbx1 null cells (Figure 12). Given that the telomeric levels of H3K9me3 remain 
the same, the interaction site for HP1 proteins is intact. Thus, the remaining two HP1 
isoforms, HP1α and HP1γ, might bind and compensate for the loss of HP1β. Because both 
HP1α and HP1γ can also bind the H4K20 methyltransferases Suv4-20h1/2, they can in turn 
recruit these methyltransferases and thus maintain trimethylation of lysine 20 on histone H4. 
To address the question of whether the telomeric fusions and end associations observed in the 
chromosomes of Cbx1-/- MEFs were due to a disruption of the protective shelterin complex, 
immunofluorescence and ChIP assays were undertaken which allowed the investigation of 
specific changes in members of the shelterin complex. As explained (see Introduction) 
mammalian telomeres are protected from being sensed as DNA damage by the “shelterin” 
protein complex, which is a complex of 6 interacting proteins that form a protective cap at the 
end of mammalian chromosomes. Disruption of this protective protein complex results in the 
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“uncapping” of telomeres and triggers DNA damage response accompanied by non-
homologous end joining and consequent telomere-telomere fusions (de Lange, 2005). The six 
shelterin subunits include TRF1, TRF2, TIN2, RAP1, TPP1 and POT1. Among these 
proteins, POT1 and TPP1 play important roles in the protection of chromosome ends 
(Baumann and Price, 2010). POT1 binds to single stranded TTAGGG repeats present at the 3’ 
overhang and in the D-loop of the so-called T-loop configuration. In the mouse there are two 
paralogues of POT1: POT1a and POT1b. Disruption of either gene in mouse embryonic 
ﬁbroblasts results in reduced proliferation, a severe telomeric DNA damage response (TIFs or 
telomere dysfunction-induced foci), chromosome reduplication, increased sister telomere 
recombination and resection of the telomeric C-strand to give long G-overhangs (Hockemeyer et 
al., 2006 and Wu et al., 2006). TPP1 connects POT1 with TIN2 through its centrally-located POT1 
interaction domain and depletion of TPP1 leads to removal of all detectable POT1 from 
telomeres. Notably, impaired TPP1 function leads to unprotected telomeres and telomere 
length phenotypes as seen in POT1-deficient cells (Hockemeyer et al., 2007, Lazzerini and de Lange, 
2007, Liu et al., 2004, Xin et al., 2007 and Ye et al., 2004). 
Investigation of possible mis-localisation of TPP1, POT1a and POT1b proteins in Cbx1 null 
cells showed that there was little difference in the localizations of these proteins in G1 
interphase nuclei taken from Cbx1-/- MEFs compared to WT (Figure 14). While it is not 
possible to draw concrete conclusions simply by inspection of the (macro) cellular 
distributions of these two shelterin proteins, ChIP grade antibodies that can be reliably used 
to look at the biochemical interaction of these proteins with telomeric chromatin were, as yet, 
unavailable. Because of the availability of good ChIP grade antibodies, two other members of 
the shelterin complex, TRF1 and TRF2, were studied using ChIP assay. TRF1 and TRF2 are 
constitutively present at telomeres and the proportion of TRF1 and TRF2 loaded on 
telomeres is important for telomere length regulation. Notably, mouse HP1β has been shown 
to interact with SALL1 and TRF1 protein (Netzer et al., 2001). Extensive cell-based in vitro 
studies using overexpression of TRF1 alleles have suggested a role for TRF1 as a negative 
regulator of telomere length (van Steensel and de Lange, 1997; Smogorzewska et al., 2000; Ancelin et al., 2002). 
TRF1 has other functions apart from being involved in telomere physiology because the 
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blastocyst stage lethality found in TRF1 null mice is not the result of any changes in telomere 
length or telomere capping (Karlseder et al., 2003). In tissue culture cells, TRF1 deficiency has also 
been shown to lead to telomere aberrations including fusions and multitelomeric signals in 
cultured ES cells (Okamoto et al., 2008). TRF1-/- MEFs also show abundant telomere fusions, 
particularly, sister telomere fusions, as well as the occurrence of multi-telomeric signals 
(Martínez et al., 2009). In the ChIP assays performed, no change was found in the amount of 
TRF2 at the telomeres and but there was a reduction of TRF1 binding to Cbx1-/- telomeres. 
This reduction in TRF1 protein at the telomere might explain the effect of the Cbx1-/- 
mutation on telomere length, which will be discussed next. 
It has been known for some time that a minimum length of TTAGGG repeats is required for 
the proper telomere function (Capper et al., 2007). Telomere length is maintained by telomerase, a 
reverse transcriptase that adds telomeric repeats de novo after each cell division, counteracting 
the end-replication problem in those cell types in which it is expressed (Chan and Blackburn, 2002; 
Collins and Mitchell, 2002). The physical association of telomerase to the telomere can be affected 
by the overexpression of HP1β in human cells, which results in reduced association of human 
telomerase reverse transcriptase with the telomere and a higher frequency of end-to-end 
chromosomal fusions (Sharma et al., 2003). These data indicate a critical role for HP1β in 
maintaining mammalian telomeric heterochromatin. This also appears to be true for HP1 
homologues from other species. In fission yeast, various mutations that alleviate telomeric 
silencing and heterochromatin formation have no or limited effects on telomere length, 
including the inactivation of genes encoding Swi6 (HP1 homologue), Clr4 (Suv39h 
homologue) and other components of the RNAi machinery (Ueno et al., 2004; Ekwall et al., 1996; Hall 
et al., 2003). In fruit fly, on the contrary, HP1 proteins have been shown to negatively regulate 
the transposition-based mechanism of telomere elongation (Perrini et al., 2004). In mice, cells 
lacking Suv39h1/h2 HMTases show decreased levels of H3K9 trimethylation at telomeres, 
concomitant with aberrant telomere elongation (Garcia-Cao et al., 2004). Telomere length is also 
similarly deregulated in cells that lack all three members of the pRb family (García-Cao et al., 
2002).  
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In order to determine whether depletion of HP1β in mouse cells has an effect on the telomere 
length, FLOW-FISH analysis on early and late passage WT and Cbx1-/- MEFs was 
undertaken. This analysis revealed that there was very little or no difference in the telomere 
lengths of early passage WT and Cbx1-/- cells. However, at late passage, the Cbx1-/- cells had 
telomeres that were much longer (~20 kb) than the WT telomeres (Figure 16). The fact that 
the telomeres were longer in late passage Cbx1-/- cells (and not in early passage ones) is 
indicative of a likely increase in telomere length in response to the Cbx1 deficiency with each 
cell cycle. As for the molecular mechanism, the observation that TRF1 protein levels in early 
passage Cbx1-/- MEFs were decreased (Figure 12), taken together with the published result 
that TRF1 is a known negative regulator of telomere length (van Steensel and de Lange, 2000), leads 
to a model where the lack of HP1β results in reduction in TRF1 and a concomitant increased 
access of telomerase to telomeric sequences, resulting in an increased telomere length. Future 
experiments would include a more detailed analysis of the passage number at which telomeres 
of Cbx1-/- cells start to increase in length. The fact that Cbx1-/- MEFs escape senescence 
around passage 16 is suggestive of a critical stage that might trigger telomere elongation. 
These experiments could be combined with DNAse I hypersensitivity assays to determine 
whether telomere elongation in Cbx1-/- cells is accompanied by greater accessibility of the 
telomeric sequences. 
4.3 The Cbx1 null mutation and sister chromatid cohesion 
Sister chromatid cohesion is required during mitosis in order to align the chromosomes at the 
spindle equator at metaphase and thereby enable segregation to precede normally with equal 
distribution of sister chromatids to the daughter nuclei. In the absence of cohesion, 
segregation is aberrant, leading to premature separation of chromosomes and concomitant 
aneuploidy in daughter cells (Bernard et al., 2001). Sister chromatid cohesion is mediated by a set 
of evolutionarily conserved proteins that form a complex known as cohesin (Onn et al., 2008). 
This complex consists of 4 proteins, SMC1, SCC1, SCC3 and SMC3. The timely release of 
cohesion from duplicated chromosomes is required for accurate chromosome segregation 
during mitosis. This release is tightly regulated by the spindle assembly checkpoint (SAC) 
that prevents progression to anaphase if chromosomes remain unattached to mitotic spindles. 
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A critical, conserved component of SAC is BUB1; BUB1 is required for targeting other SAC 
proteins to the kinetochore. Another key protein that is important for proper chromosome 
segregation is the shugoshin (SGO1) protein that prevents the removal of centromeric 
cohesin during mitotic prophase and ensures sister chromatid cohesion is maintained before 
bidirectional attachment to the mitotic spindle (Kitajima et al., 2005). 
There has been conflicting data in the literature regarding the role of HP1 proteins in 
maintaining sister chromatid cohesion. Initial reports in S. pombe showed that Swi6 (HP1 
homologue) not only functions in pericentromeric heterochromatin silencing, but also recruits 
cohesin, which is important for centromeric sister chromatid cohesion and kinetochore 
biorientation (Bernard et al., 2001; Nonaka et al., 2002). Swi6 was also shown to interact with Psc3 (an 
SCC3 homolog) by both co-immunoprecipitation and yeast two hybrid assays (Nonaka et al., 
2002). There are also other reports which state that it is the cohesin loading factor SCC2, 
rather than cohesin, which interacts with HP1 (Fischer et al., 2009; Serrano et al., 2009; Lechner et al., 2005; 
Zeng et al., 2009). Human HP1α and S. pombe Swi6 were also found to interact with SGO1 and 
this interaction was shown to be important for SGO1 localization at centromeres in early 
mitosis, where it plays a role in cohesin retention and sister chromatid cohesion (Yamagishi et al., 
2008). In human cells treated with an siRNA against HP1α, SGO1 localization was abolished 
and the centromeric cohesion was largely dissociated in the SGO1-lacking chromosomes 
(Yamagishi et al., 2008). Besides SGO1 has also been shown to directly interact with GST-tagged 
HP1α, HP1β and HP1γ indicating a role for HP1 proteins in the localization of SGO1 
(Serrano et al., 2009).  
By contrast in Suv39h1/h2 double-knockout mouse embryonic fibroblasts (Koch et al., 2008), 
where both H3K9 trimethylation and HP1 proteins are much reduced, no reduction in 
cohesin association at centromeres was observed. Furthermore, in another study, depletion of 
HP1 proteins in human cells by siRNA has been shown to have no effect on cohesin 
recruitment (Serrano et al., 2009). 
Using Cbx1-/- MEFs, it was investigated whether the defects in sister chromatid cohesion seen 
in the chromosome spreads from Cbx1-/- MEFs show a difference in distribution of the 
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proteins involved in cohesion, kinetochore attachment and spindle assembly checkpoint 
(SAC). Accordingly, unfixed metaphase spreads from early passage WT and Cbx1-/- MEFs 
were stained for SMC3, BUB1 and SGO1 (Figures 17-19). This analysis has revealed that 
there were no changes in SMC3, BUB1 and SGO1 localization in early passage Cbx1-/- cells 
compared to WT MEFs indicating that either HP1β is unlikely to be involved in the 
recruitment of these kinetochore/cohesion components to the centromeres of mouse cells or 
that its function is redundant, being compensated by the two other HP1 isotypes.  
Although HP1β seems unlikely to be involved in cohesion recruitment to mouse centromeres, 
there is some evidence that the HP1 isotype, human HP1γ, can recruit cohesin, albeit to 
specific chromosomal sites outside of the centromere. At the D4Z4 chromosomal site (D4Z4 
is a 3.3 kb long macrosatellite repeat sequence) binding of HP1γ, in an H3K9me3 dependent 
manner, in turn recruits the cohesion complex (Zeng et al., 2009). Thus, the possibility remains 
that the recruitment of cohesin to mammalian centromeres might require an isotype-specific 
interaction with either of the other two HP1 isotypes other than HP1β. 
4.4 Investigation of the effect of Cbx1 mutation on oncogene-induced senescence (OIS)  
The 3T9 assay also showed that Cbx1 null fibroblasts escape the typical senescence crisis that 
is seen when culturing primary mouse fibroblasts (Figure 10). This result is consistent with 
observations that HP1 proteins are involved in regulating the exit of cells from the cell cycle 
during the progression towards cellular senescence. HP1 proteins interact with the tumour 
repressor pRb, which is a key regulator of the p16INK4A/pRb senescence pathway that has been 
shown to be crucial for SAHF formation (Gil and Peters, 2006; Kim and Sharpless, 2006). Notably, loss 
of pRb function gives rise to phenotypes similar to those found in Cbx1-/- tissue culture cells. 
Embryos lacking pRb function exhibit a genomic instability that is consistent with defects in 
DNA replication and abnormal segregation of chromosomes during mitosis (Kennedy et al., 2000; 
Foijer et al., 2005; Eguchi et al., 2007). In mouse embryonic stem cells the deletion of both pRb alleles 
results in increased chromosomal alterations (Zheng et al., 2002). In MEFs, the inactivation of 
pRb leads to polyploidy (Srinivasan et al., 2007). In mouse hepatocytes, loss of pRb function 
promotes aneuploidy (Mayhew et al., 2005). Similarly, knockdown of pRb in human primary cells 
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has been shown to promote aneuploidy via micronuclei formation (Amato et al., 2009). The 
resemblance of these pRb phenotypes to those observed in Cbx1-/- MEFs opens up the 
possibility that the loss of Cbx1 gene function results in defects downstream from the cellular 
functions of pRb. However, this is, at least for the moment, speculation and remains to be 
proved. 
Related to cellular senescence that occurs during organismal and cellular ageing, senescence 
can also be induced in response to a variety of stresses (Serrano and Blasco, 2001). One of these is 
OIS, which is a tumour suppressor mechanism in primary cells. OIS is mediated by two main 
pathways: the p19ARF/p53 and/or the p16INK4A/pRb (Gil and Peters, 2006; Kim and Sharpless, 2006). It is 
characterised by the acquisition of senescence markers in response to oncogenic stress. 
Typically, OIS has been observed in a variety of mouse and human premalignant tumours and 
these observations have been interpreted as in vivo evidence for OIS acting as a barrier to 
tumorigenesis (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Lazzerini-Denchi et al., 2005; Michaloglou et 
al., 2005). 
In this study, a K-ras model of OIS established by Collado and colleagues was utilised (Collado 
et al., 2005). These colleagues were able to show that the expression of oncogenic K-ras (K-
rasV12) triggered senescence during the early premalignant stages of tumorigenesis that results 
from oncogene expression. As explained, (see Introduction) premalignant (adenomas) as well 
as malignant tumours (adenocarcinomas) were identified in the lungs of these mice and, most 
strikingly, the premalignant lesions in the lung contained abundant senescent cells positive for 
OIS markers (SA-β-gal, p15, p16, Dec1, DcR2 and HP1γ) (Collado et al., 2005). Using this 
model, Cbx1+/- mutation was introduced to investigate whether senescence might be bypassed 
leading to an increased numbers of malignant tumours. Accordingly, K-ras+/V12;RERTn+/ERT; 
Cbx1+/- mice were generated that are heterozygous for the Cbx1 null allele and also possesses 
the inducible K-rasV12 oncogene. These mice were then injected with 4-OHT to induce the 
expression of the K-rasV12 oncogene. In the original reference, these mice have been shown to 
develop severe breathing difficulties and die at around 8 months after birth (Guerra et al., 2003). 
However, in this study, it was found that these mice did not develop a severe breathing 
difficulty after eight months. The experiment was therefore continued and mice were allowed 
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to live longer. The experiment was eventually stopped when some of these mice already had 
reached 22 months of age (see Table 5). There was no difference found in the death rates 
between K-ras+/V12;RERTn+/ERT (WT control) and K-ras+/V12;RERTn+/ERT;Cbx1+/- mice (data 
not shown). The lungs of these mice were then analyzed for the expression of oncogenic K-
rasV12 as well as for the presence of premalignant adenomas and/or malignant 
adenocarcinomas. Sequencing of RT-PCR products amplified from lung tissues revealed that, 
K-rasV12 was expressed in 4 of the experimental and 6 of the control mice at the time the 
tissues were taken (Figure 20). K-ras+/V12;RERTn+/ERT mice induce the expression of 
oncogenic K-rasV12 (upon 4-OHT injection) in only one allele along with the wt allele. In the 
original report, the expression efficiency of K-rasV12 using this inducible system has been 
shown to be 5 % to 15 % in most of the tissues examined and this level of expression was 
sufficient to cause the malignancies observed in the lungs of K-ras+/V12;RERTn+/ERT mice 
(Guerra et al., 2003). The fact that the K-rasV12 oncogene could not be detected in some of the 
lungs analyzed might probably be due to the insensitivity of the sequencing method used for a 
quantitative analysis or that the expression was stronger earlier, soon after induction, and after 
many months the expression might then have been extinguished.  
Histopathological analysis of lung sections was then carried out on the H&E stained lung 
sections. This analysis has revealed malignant adenocarcinomas in the five lungs heterozygous 
for the Cbx1 mutation in which the oncogenic K-rasV12 had been induced, while only one WT 
mouse possessed a very small region of malignant tumour. Analysis of the lung tumours found 
in K-ras+/V12;RERTn+/ERT;Cbx1+/- mice were negative for senescence markers (p16, DcR2) but 
positive for the proliferation marker, pKi-67. The absence of premalignant tumours might be 
due to the genetic background of mice (mixed 129 x Bl/6) or at the time at which the mice 
were killed, they had passed through the premalignant stage and only full-blown tumours 
survived. These data indicate that there may be a limited role for the Cbx1 gene in OIS but 
rather that it acts as a tumour suppressor. This view is supported by the in vitro work, to be 
described next. 
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In order to explore further the role of HP1β in OIS, a well established H-rasV12 oncogene in 
vitro model was utilised (Serrano et al., 1997). In this model, mouse embryonic fibroblasts 
transduced with an H-rasV12 expression plasmid undergo OIS as evidenced by a cessation of 
proliferation and positivity for SA-β-gal staining.  
In this current study, Cbx1-/- MEFs transduced with the H-rasV12 expression vector were 
shown to undergo a proliferation arrest similar to seen in WT MEFs transduced with the 
same vector (Figure 28). Subsequent positive SA-β-gal staining on MEFs 7 days after 
transduction with the H-rasV12 expression vector has also shown that these cells were 
senescent indeed, which indicates that the Cbx1 gene product, HP1β, is unlikely to be 
involved in the OIS response (Figure 29). 
It is known that OIS in primary cells is mediated by the two main tumour suppressor 
pathways: the p19ARF/p53 and/or the p16INK4A/pRb (Gil and Peters, 2006; Kim and Sharpless, 2006). The 
p16INK4A/pRb pathway is crucial for the formation of SAHF, which are highly condensed 
regions of chromatin that develop in cells that will exit the cell cycle and become senescent. 
SAHF are characterised by the accumulation of histone H3 trimethylated at lysine 9 and 
heterochromatin proteins, including heterochromatin protein 1 (HP1), high-mobility group 
A (HMGA) proteins and macroH2A (Narita et al., 2003; Narita et al., 2006; Zhang et al., 2005). In vivo 
and in vitro data described above indicate that HP1β is unlikely to be an important marker of 
OIS. Instead it is likely to be a tumour suppressor that may act downstream of the pRB 
pathway. Very similar lung tumours to those obtained in K-ras+/V12;RERTn+/ERT;Cbx1+/- mice 
have also been observed in pRb/p130 conditional mutant mice carrying a conditional 
oncogenic K-ras allele, whose controlled expression results in the development of high-grade 
lung adenocarcinomas (Ho et al., 2009). Although there are currently no known human diseases 
that are associated with mutations in the Cbx1 gene, changes in its level of expression have 
been reported for many cancers (Dialynas et al., 2008). It has also been demonstrated that 
decreased HP1β expression, correlates with invasive potential in five human melanoma cell 
lines suggesting that HP1β acts as a tumour suppressor in melanoma oncogenesis (Nishimura et 
al., 2006).  
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There is some support for the HP1γ isoform in mediating OIS, probably in SAHF formation. 
Collado et al. have shown that the premalignant adenomas that were formed by the induced 
expression of K-rasV12 oncogene were all positive for HP1γ staining whereas adenocarcinomas 
were negative. In another study, senescent prostatic intraepithelial neoplasia found in the 
AKT1 transgenic mice were also shown to have an increased HP1γ staining, in support of the 
idea that HP1γ is a marker of OIS (Majumder et al., 2008). However, in a contradictory study 
where various human malignant tumours were screened, HP1γ was found to be expressed 
uniformly in the cell nucleus of all cancers examined, including lung adenocarcinomas. 
Furthermore, these same workers were able to demonstrate that siRNA knockdown of HP1γ 
sufficiently stopped the growth of colon cancer cells (Takanashi et al., 2009). In the present study, 
strong HP1γ staining was observed in adenocarcinomas found in the lungs of K-
ras+/V12;RERTn+/ERT;Cbx1+/- mice (Figure 27), arguing against a role for HP1γ in OIS, and 
rather in favour of role as a marker of proliferating cells. 
4.5 The binding of HP1β to histone H3 
A large body of work in various organisms has shown that the presence of HP1 structural 
proteins and trimethylated lysine 9 of histone H3 (H3K9me3) represent the characteristic 
hallmarks of heterochromatin. Similarly, the binding of HP1β to H3K9me3 and Suv39h1 
histone methyltransferase is thought to be the key interaction of HP1β leading to spreading 
of repressive heterochromatic domains (Lachner et al., 2001 and Bannister et al., 2001). In favour of this 
idea, it has been shown that HP1β is mislocalized in cells taken from Suv39h1/h2 double null 
(dn) animals. Rather than being concentrated within constitutive heterochromatin, HP1β is 
found uniformly throughout euchromatic and heterochromatic regions in these Suv39h1/h2 
dn cells (Bannister et al., 2001). However, in the light of recent evidence from biophysical studies a 
more complex picture has emerged which cannot easily be explained by a simple binary 
H3K9me3-HP1β interaction (Festenstein et al., 2003, Cheutin et al., 2003, Schmiedeberg et al., 2004 and Dialynas 
et al., 2007). Another key interaction of HP1β, which has been studied in some detail, is the 
binding to the histone H3 histone-fold domain (Nielsen et al., 2001 and Dialynas et al., 2006). However, 
the essential physiological function of this HP1β-H3 fold interaction still remains to be 
solved. 
Discussion 
94 
 
In the present study, the in vitro interaction of HP1β (and its mutants) with histone H3 has 
been investigated first by GST pull down experiments. Several single/multiple amino acid 
substitutions have been introduced into GST tagged murine HP1β, which were decided upon 
from a review of the literature and aimed at addressing the interaction of HP1β with 
recombinant, unmethylated histone H3. The rationale for the experiments was to incubate 
WT and mutant GST-HP1β proteins with histone H3 in increasing NaCl concentrations so 
that the affinity of the interaction of the mutants with recombinant histone H3 could be 
measured. The mutations introduced into HP1β were valine 23 to methionine (V23M), 
arginine 29 and 30 to glutamine (R29/30Q), lysine 33 to glutamine (K33Q), phenylalanine 
45 to glutamic acid (F45E), threonine 51 to alanine (T51A) and isoleucine 161 to glutamic 
acid (I161E). Valine 23 is thought to be required for binding of the HP1β CD to the 
H3K9me3 peptide (Nielsen et al., 2002). In HP1α the V22M mutation (which corresponds to 
V23M in HP1β) has been shown to be required for histone H3 binding as well (Nielsen et al., 
2001). Similarly, the V26M mutation in D. melanogaster HP1 (which corresponds to V23M in 
HP1β) was also shown to result in a dramatic loss of binding to methylated H3K9 peptide 
(Jacobs et al., 2001). The reason for choosing R29/30Q and K33Q mutations were to reduce the 
overall basic charge of the protein in this evolutionarily conserved region of the protein and to 
use them as controls. The R28/29Q substitutions in HP1α (which correspond to R29/30Q in 
HP1β) have been shown to have no effect on interaction with purified calf thymus histone 
H3 (Nielsen et al., 2001); the corresponding mutations of R29/30Q and K33Q in D. melanogaster 
HP1 have also been shown to have no effect on PEV (Platero et al., 1995). F45 is one of the three 
evolutionarily conserved aromatic residues (Y21, W42 and F45) that form the notional 
aromatic “cage”, into which the positively charged methylammonium functional moiety of 
H3K9me3 fits (Jacobs and Khorasanizadeh, 2002; Nielsen et al., 2002). T51 has been shown to be 
phosphorylated upon DNA damage and play a role in the rapid mobilisation of HP1β in 
euchromatin and heterochromatin (Ayoub et al., 2008). T51 is also known to play a role in the 
interaction with H3K9me3, by the formation of a network of hydrogen bonds between the 
side chains of E53, T51 and W42 of the human HP1β chromodomain. This network of 
hydrogen bonds is disrupted in the T51A mutant (Ayoub et al., 2008, Figure 42). Isoleucine 161 
residue is important in the formation of HP1β dimers; I161E mutation has been shown to 
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inhibit dimerisation of the two CSDs with each other, and disrupt the formation of functional 
HP1β dimers (Brasher et al., 2000). 
This analysis has revealed that together with WT HP1β, all full length recombinant HP1β 
mutants tested were able to pull recombinant histone H3 down in all NaCl concentrations, 
except from I161E mutant which has lost its binding to histone H3 at 0.6 M and 0.75 M 
NaCl (Figure 32, left and right section). This indicates that the CSD is the important module 
for binding to recombinant histone H3, through as a dimer (HP1β dimerisation is disrupted 
by the I161E mutation), although this conclusion may need to be qualified in light of the 
isothermal titration calorimetry results discussed below. The importance of the CSD in H3 
binding was supported by two further observations. First, that an HP1β mutant that lacks the 
CD (named C-terminal HP1β) was capable of binding to histone H3 in all NaCl 
concentrations and, second, that an HP1β mutant lacking the conserved CSD (named N-
terminal HP1β) failed to bind to histone H3 at 0.6 M and 0.75 M salt concentrations. Taken 
together these data showed that the CSD has a strong affinity (greater than the CD) for the 
recombinant histone H3. However, the influence of the CD in binding of the intact protein 
to recombinant H3 cannot be ignored because specific CD mutations in combination with 
the I161E mutation rescue binding at 0.6 M (F45E) and at both 0.6/0.75 M salt (R29/30Q). 
Other pull-down experiments gave results which show that mutations in CD residues do not 
affect binding to recombinant H3 histone. Previously, V22M mutation in HP1α has been 
shown to inhibit histone H3 binding (Nielsen et al., 2001), however, the corresponding V23M 
mutation in HP1β seems to have no effect on binding to histone H3. Similarly, T51A 
mutation in HP1β has been thought to disrupt the binding of His-tagged HP1β to 
H3K9me3 and histone H3 (Ayoub et al., 2008) (Figure 42). The present study, however, clearly 
Figure 42 A model for the interaction of the wild type human 
HP1β chromodomain bound to dimethylated K9 of histone 
H3 (H3K9me2), based on the PDB coordinates 1KNA, 
compared with its T51A mutant. A network of hydrogen 
bonds between the side chains of E53, T51 and W42 of the 
human HP1β chromodomain, marked as yellow dashed lines, 
is disrupted in the T51A mutant. Figure modified from Ayoub 
et al., 2008. 
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has shown that the HP1β T51A mutant remains capable of binding to histone H3 even at 
higher salt concentrations.  
To support and extend the data obtained from GST pull down experiments, the strength of 
HP1β-histone H3 interaction was also determined quantitatively by the isothermal titration 
calorimetry (ITC) technique which enabled the quantitative determination of biomolecular 
interactions and all binding parameters in a single experiment. The binding affinity of HP1β 
to H3K9me3 tail peptide was also measured in parallel as a comparison. The ITC analysis has 
revealed that the binding affinity of wild type HP1β to histone H3 was approximately 4 times 
higher than for the trimethylated lysine 9 tail peptide (H3K9me3) at both 25 °C and 37 °C 
indicating a more critical role for HP1β-histone H3 interaction than its canonical interaction 
with the H3K9me3 determinant of the histone code (Figures 32-33).  
In support of the previous result obtained in the pull down experiments, the binding of the 
HP1β T51A mutant to both histone H3 and H3K9me3 could be proven and the binding 
affinity to histone H3 has been shown to be greater than for the H3K9me3 peptide (Table 7, 
Figures 34 and 35). As expected, HP1β V23M mutant had a very low affinity for H3K9me3, 
in line with published data, while still retaining a high affinity for histone H3 (Table 7, 
Figures 36 and 37). In case of HP1β F45E mutant, it was not possible to accurately measure 
its affinity to histone H3 at 25 °C as a result of an unstable baseline due to an unknown 
reason (Figure 39). However, a direct comparison could be made at 37 °C, which gave 
reproducible results; at 37 °C HP1β F45E mutant has lost its affinity for the H3K9me3 
peptide as expected but retained its high affinity for the recombinant histone H3 (Figures 38 
and 39). The binding affinity of HP1β I161E mutant for histone H3 was almost two times 
higher than its affinity for H3K9me3 peptide, both at 25 °C and 37 °C (Table 7, Figures 40 
and 41). Interestingly, compared to WT protein, this mutant showed a higher (ca. 2 times 
higher) affinity for the trimethylated lysine 9 peptide at both tested temperatures. 
Considering the previous result obtained from GST pull down experiments, it is also 
surprising that the His-HP1β I161E protein had a similarly high affinity to histone H3 as 
WT HP1β which implicates a negligible role for dimerisation of HP1β in its binding to 
histone H3 in this particular technique used. It has been shown that GST tagged fusion 
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proteins are found in homodimers and tend to aggregate, which might have impeded the 
interaction of GST-HP1β I161E mutant with histone H3 in higher salt concentrations (Kaplan 
et al., 1997). 
Taken together, the GST pull down and ITC experiments give a picture of a high affinity 
binding of HP1β to histone H3 histone-fold domain likely through its CSD, which puts 
emphasis on an interaction that has previously received little attention. In contrast, the 
binding of HP1β CD to H3K9me3 determinant of the histone code has been widely accepted 
as the essential function of HP1β in the assembly of heterochromatin domain in the genome. 
Despite its elegant simplicity, the accepted view that the H3K9me3–HP1β interaction is the 
key one for heterochromatin assembly and organismal survival needs modification. Recent 
dynamics studies have revealed a more complex picture that is not readily explained by a 
simple binary H3K9me3–HP1β interaction. Fluorescence recovery after photo-bleaching 
(FRAP) studies in mammalian cells showed that HP1β is a dynamic protein with recovery 
half-lives (t1/2) of 0.5 s – 10 s for euchromatin and 2.5 s – 50 s for heterochromatin (Festenstein et 
al., 2003; Cheutin et al., 2003). Further studies showed that a small fraction (4 % – 7 %) of very slow-
moving HP1 molecules in constitutive heterochromatin could take >1 hour to recover after 
photo-bleaching, a property indicative of tight binding to chromatin (Schmiedeberg et al., 2004; 
Dialynas et al., 2007). Moreover, the existence of several kinetically distinct HP1β species in the 
nucleus has been confirmed by the observation that the nuclear distribution of HP1β varied 
upon cell type examined, micro-environmental conditions and the cellular differentiation state 
(e.g. ES cells possess hyperdynamic HP1 molecules compared with differentiated cells) 
(Meshorer and Misteli, 2006; Ritou et al., 2007; Dialynas et al., 2007). As a consequence of these data and 
supported by genetic studies made in the mouse and in D. melanogaster, it is clear that a new 
conceptual framework is needed to understand the chromatin dynamics of HP1β and that any 
such framework must now extend beyond the canonical H3K9me3–HP1β interaction. The 
fact that Suv39h1/h2-/- mice live and Cbx1-/- die clearly shows that the essential function of 
HP1β must lie outside the Suv39h1/h2-dependent heterochromatic H3K9me3–HP1β 
interaction (Lachner et al., 2001; Aucott et al., 2008). The same situation appears to occur in D. 
melanogaster: flies lacking HP1 (Su(var)2-505 homozygotes) die at the third larval instar stage 
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with no escapers, whereas flies lacking dKMT1A (Su(var)3-906 homozygotes) are viable 
(Eissenberg et al., 1992; Tschiersch et al., 1994). Therefore, the essential function of HP1β proteins 
cannot be readily explained by their role on reading the H3K9me3 determinant of the histone 
code. It might be the high affinity binding of HP1β to the histone H3 histone-fold domain 
that is required for organismal survival. Putting emphasis on this mostly neglected interaction 
would also explain the survival of mice hypomorphic for Cbx1 which have only 10 % of WT 
HP1β protein levels (Dr. Thorsten Bangsow, JWGU, Frankfurt am Main, unpublished). It is 
only if the mouse completely lacks HP1β that it dies at around birth with an associated 
genomic instability characterised by severe chromosomal abnormalities that are indicative of 
pericentric constitutive heterochromatin dysfunction (Aucott et al., 2008). Placing physiological 
importance on the HP1β-H3 histone-fold interaction instead of the H3K9me3–HP1β 
interaction might also provide an alternative explanation for the recent contradictory 
observation which shows that HP1β is recruited to sites of DNA damage independently of 
the H3K9me3 (Ayoub et al., 2008; Luijsterburg et al., 2009; Zarebski et al., 2009; Billur et al., 2010). It is possible 
that this recruitment is via the HP1β-histone H3 histone-fold interaction. The small number 
of studies to date indicates that HP1 recruitment could be one of the earliest molecular events 
in the DNA damage response (Ball and Yokomori, 2009); however it remains too early to speculate 
upon the molecular mechanism(s) of how mammalian HP1 proteins aid repair at sites of 
DNA damage, which is the subject for future research. 
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Abstract 
Heterochromatin protein 1 (HP1) proteins are fundamental units of heterochromatin packaging that are enriched at 
the centromeres and telomeres of nearly all eukaryotic chromosomes. HP1 homologues are found in a variety of 
organisms and are involved in the establishment and maintenance of higher-order chromatin structures by specifically 
recognizing and binding to (tri- and di-) methylated lysine 9 on histone H3. In mammals, there are three HP1 
homologues termed HP1α (Cbx5), HP1β (Cbx1), and HP1γ (Cbx3). Among these three isoforms HP1β is the best 
characterized. Murine HP1β is essential for organismal survival. Cbx1-/- knockout mice are perinatal lethal and exhibit 
aberrant cerebral cortex development, reduced proliferation of neuronal precursors, widespread cell death and edema. 
Cbx1-/- neurospheres cultured in vitro show a dramatic genomic instability.  
This study demonstrates that Cbx1+/- and Cbx1-/- mouse embryonic fibroblasts (MEFs) escape senescence crisis that is 
associated with gross chromosomal aberrations including aneuploidy, premature chromosome separations and 
telomere-telomere fusions. Telomeres of Cbx1-/- MEFs show reduced binding of the shelterin protein TRF1 with no 
change in the cellular localizations of POT1a, POT1b and TPP1 proteins compared to wild type (WT) cells. 
Telomere length analysis revealed that the telomeres of late passage Cbx1-/- MEFs are longer (~20 kb) than the WT 
controls. There was no change in the localization of cohesin protein SMC3, spindle assembly checkpoint protein 
BUB1 and SGO1. In an in vitro model of oncogene-induced senescence (OIS), introduction of Cbx1-/- mutation in 
cells expressing H-rasV12 oncogene did not result senescence bypass. In vivo experiments utilizing the inducible K-rasV12 
oncogene expression in Cbx1+/- mice resulted in increased malignant adenocarcinomas in lungs, which were negative 
for the markers of senescence. Taken together these data indicate that HP1β acts as a tumour suppressor rather than 
mediating senescence in response to oncogenic stress. GST pull down experiments with WT HP1β, HP1β mutants 
and recombinant histone H3 showed that the binding of HP1β to histone H3 is resistant to 0.75 M NaCl 
concentrations and that HP1β chromoshadow domain is sufficient for this interaction. Isothermal calorimetry 
experiments confirmed that the binding affinity of HP1β for recombinant histone H3 was 4 times higher than its 
affinity for H3K9me3. V23M and F45E (“aromatic cage”) mutations in the HP1β chromo domain were also shown to 
inhibit binding to H3K9me3 while retaining binding to histone H3. 
In this study, the role of murine HP1β protein in the regulation of genome stability and senescence has been 
investigated, which provided insights into the role of HP1β in both processes. It has been shown that there is a high 
affinity binding of HP1β to the histone H3 histone-fold domain that is stronger than the affinity to H3K9me3. It is 
proposed that the loss of this high affinity interaction might result in the perinatal lethal phenotype seen in Cbx1-/- 
mice. 
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Zusammenfassung 
Heterochromatin-Protein-1- (HP1-) Proteine sind grundlegende strukturelle Komponenten des Heterochromatins, 
die bevorzugt in den Centromeren und Telomeren fast aller eukaryotischer Chromosomen vorkommen. HP1-
Homologe finden sich in zahlreichen Organismen und sind an der Bildung und Aufrechterhaltung von 
Chromatinstrukturen höherer Ordnung beteiligt. Dazu erkennen und binden sie spezifisch (tri- und di-) methylierte 
Lysin-9-Reste am Histon H3. In Säugern gibt es drei HP1-Homologe, nämlich HP1α (Cbx5), HP1β (Cbx1) und 
HP1γ (Cbx3), von denen HP1β das am besten charakterisierte darstellt. Das murine HP1β ist unabdingbar für das 
Überleben des Organismus. Cbx1-/--Nullmutanten sind perinatal letal und zeigen eine anomale Entwicklung des 
cerebralen Cortex, eine verringerte Proliferation von neuronalen Vorläuferzellen, ausgedehnten Zelltod und Ödeme. In 
vitro kultivierte Cbx1-/--Neurosphären weisen eine signifikante genomische Instabilität auf. 
Diese Arbeit zeigt, dass murine embryonale Fibroblasten (MEF) der Genotypen Cbx1+/- und Cbx1-/- der 
Seneszenzkrise entkommen, die mit erheblichen Chromosomenanomalien einschließlich Aneuploidie, vorzeitiger 
Chromosomenseperation und Telomer-Telomer-Fusionen einhergeht. Telomere von Cbx1-/--MEF zeigen eine 
verringerte Bindung des Shelterin-Proteins TRF1, aber keine Veränderung der zellulären Lokalisation der Proteine 
POT1a, POT1b und TPP1 im Vergleich zu Wildtyp- (WT-) Zellen. Eine Analyse der Telomerlängen ergab, dass die 
Telomere von späten Cbx1-/--MEF-Passagen ~20 kb länger waren als WT-Kontrollen. Es konnten dabei keine 
Änderungen der Lokalisationen des Kohesinproteins SMC3, des Spindelkontrollpunkt-Proteins BUB1 sowie des 
SGO1-Proteins festgestellt werden. In einem In-vitro-Modell der Onkogen-induzierten Seneszenz (OIS) resultierte 
die Einführung der Cbx1-/--Mutation in H-rasV12-Onkogen exprimierende Zellen nicht in einer Umgehung der 
Seneszenz. In-vivo-Experimente mit Hilfe einer induzierbaren K-rasV12-Onkogenexpression in Cbx1+/--Mäusen 
führten zum vermehrten Auftreten maligner Adenokarzinome der Lunge, wobei diese keine Seneszenzmarker 
aufweisen. Zusammengenommen weisen diese Daten darauf hin, dass HP1β keine Induktion der Seneszenz als 
Antwort auf onkogenen Stress bewirkt, sondern vielmehr als Tumorsuppressor fungiert. GST-pull-down-Experimente 
mit WT-HP1β oder HP1β-Mutanten und rekombinantem Histon H3 zeigten, dass die Bindung von HP1β an 
Histon H3 resistent gegenüber einer Konzentration von 0.75 M NaCl ist und dass die Chromoshadow-Domäne 
ausreichend für diese Interaktion ist. Isothermale Kalorimetrie-Experimente zeigten, dass die Bindungsaffinität von 
HP1β zu rekombinantem Histon H3 viermal höher liegt als die Affinität zu H3K9me3. V23M- und F45E- 
(“aromatischer Käfig-”) Mutationen in der HP1β-Chromo-Domäne zeigten weiterhin eine Inhibition der H3K9me3-
Bindung während die Bindung zu Histon H3 erhalten bleibt. 
In dieser Arbeit wurde die Rolle des murinen HP1β-Proteins bei der Regulation der Genomstabilität und Seneszenz 
untersucht, wobei sich Einblicke in die Involvierung von HP1β in beide Prozesse ergaben. Es wurde gezeigt, dass 
HP1β eine hohe Affinität zur histone-fold-Domäne des Histons H3 besitzt, welche über der Affinität zu H3K9me3 
liegt. Hieraus ergibt sich, dass der Verlust dieser hochaffinen Interaktion den perinatal letalen Phänotyp von Cbx1-/--
Mäusen bedingen könnte. 
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Appendix 
Sequences of GST fusion proteins 
Color code :  GST sequence     HP1 sequence    
Full length HP1α in pGEX-4T-1 vector 
DNA sequence: 
ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTTTTGGAATATCTTGAA
GAAAAATATGAAGAGCATTTGTATGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTG
GAGTTTCCCAATCTTCCTTATTATATTGATGGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATA
GCTGACAAGCACAACATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTG
GATATTAGATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTCAAAGTTGATTTTCTTAGCAAG
CTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAACATATTTAAATGGTGATCATGTAACCCAT
CCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACATGGACCCAATGTGCCTGGATGCGTTCCCAAAA
TTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCA
TGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGCTGGTTCCGCGT
GGATCCCCGGAATTCGATAAGCTTGACATGGGAAAGAAGACCAAGAGGACAGCCGACAGCTCTTCTTCAGAGGAT
GAGGAGGAATATGTGGTGGAAAAGGTGTTGGACAGGCGCATGGTTAAGGGGCAAGTGGAATATCTGTTGAAGTGG
AAAGGCTTTTCTGAGGAGCACAATACTTGGGAACCTGAGAAGAACTTGGATTGTCCTGAACTAATTTCTGAGTTT
ATGAAAAAGTATAAGAAGATGAAGGAGGGTGAAAACAATAAGCCCAGGGAGAAATCAGAAGGAAACAAGAGGAAA
TCCAGTTTCTCCAACAGCGCTGATGATATTAAATCTAAAAAAAAGAGAGAGCAAAGCAATGATATCGCTCGGGGC
TTTGAGAGAGGACTGGAACCAGAAAAGATCATCGGAGCAACAGATTCCTGCGGTGACTTAATGTTCTTAATGAAA
TGGAAAGACACAGATGAAGCTGACCTGGTTCTTGCAAAAGAAGCTAACGTGAAGTGTCCACAGATTGTGATAGCA
TTTTATGAAGAGAGACTGACGTGGCACGCATATCCAGAGGATGCGGAAAACAAAGAAAAAGAAAGCGCGAAGAGC
TAA 
 
Amino acid sequence: 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYI
ADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTH
PDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRG
SPEFDKLDMGKKTKRTADSSSSEDEEEYVVEKVLDRRMVKGQVEYLLKWKGFSEEHNTWEPEKNLDCPELISEFM
KKYKKMKEGENNKPREKSEGNKRKSSFSNSADDIKSKKKREQSNDIARGFERGLEPEKIIGATDSCGDLMFLMKW
KDTDEADLVLAKEANVKCPQIVIAFYEERLTWHAYPEDAENKEKESAKS. 
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Full length HP1β in pGEX-3X vector 
DNA sequence: 
ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTTTTGGAATATCTTGAA
GAAAAATATGAAGAGCATTTGTATGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTG
GAGTTTCCCAATCTTCCTTATTATATTGATGGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATA
GCTGACAAGCACAACATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTG
GATATTAGATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTCAAAGTTGATTTTCTTAGCAAG
CTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAACATATTTAAATGGTGATCATGTAACCCAT
CCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACATGGACCCAATGTGCCTGGATGCGTTCCCAAAA
TTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCA
TGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGATCGAAGGTCGT
GGGATCCCCCTGGCGGGTACTATGGGGAAAAAGCAAAACAAGAAGAAAGTGGAGGAGGTACTAGAAGAAGAGGAA
GAGGAATATGTGGTGGAAAAAGTTCTTGATCGGCGAGTTGTCAAGGGCAAGGTGGAATATCTTCTAAAGTGGAAG
GGTTTCTCAGATGAGGACAACACTTGGGAGCCAGAAGAGAATCTGGATTGCCCTGACCTTATTGCTGAGTTTCTA
CAGTCACAGAAAACAGCTCATGAGACAGATAAGTCAGAGGGAGGCAAGCGCAAAGCTGATTCTGATTCTGAAGAT
AAAGGAGAGGAAAGCAAACCAAAGAAGAAGAAAGAAGAGTCAGAAAAGCCACGAGGCTTTGCCCGGGGTTTGGAG
CCAGAGCGGATTATTGGAGCTACTGACTCCAGTGGAGAGCTCATGTTCCTGATGAAATGGAAAAACTCTGATGAG
GCTGACCTGGTCCCTGCCAAGGAAGCCAATGTCAAGTGCCCACAGGTTGTCATATCCTTCTATGAGGAAAGGCTA
ACGTGGCATTCCTACCCCTCAGAGGATGATGACAAAAAAGACGACAAGAATTAG 
 
Amino acid sequence: 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYI
ADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTH
PDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLIEGR
GIPLAGTMGKKQNKKKVEEVLEEEEEEYVVEKVLDRRVVKGKVEYLLKWKGFSDEDNTWEPEENLDCPDLIAEFL
QSQKTAHETDKSEGGKRKADSDSEDKGEESKPKKKKEESEKPRGFARGLEPERIIGATDSSGELMFLMKWKNSDE
ADLVPAKEANVKCPQVVISFYEERLTWHSYPSEDDDKKDDKN. 
Mutants of GST-HP1β: 
V23M  : valine 23 to methionine, GTG to ATG 
R29/30Q  : arginine 29 and 30 to glutamine, CGGCGA to CAACAA 
K33Q  : lysine 33 to glutamine, AAG to CAG 
F45E   : phenylalanine 45 to glutamic acid, TTC to GAA 
T51A  : threonine 51 to alanine, ACT to GCT 
I161E  : isoleucine 161 to glutamic acid, ATA to GAG 
V23M & I161E  : valine 23 to methionine, GTG to ATG and isoleucine 161 to glutamic acid, ATA to 
GAG 
R29/30Q & I161E : arginine 29 and 30 to glutamine, CGGCGA to CAACAA and isoleucine 161 to 
glutamic acid, ATA to GAG 
K33Q & I161E  : lysine 33 to glutamine, AAG to CAG and isoleucine 161 to glutamic acid, ATA to GAG 
F45E & I161E  : phenylalanine 45 to glutamic acid, TTC to GAA and isoleucine 161 to glutamic acid, 
ATA to GAG 
T51A & I161E  : threonine 51 to alanine, ACT to GCT and isoleucine 161 to glutamic acid, ATA to 
GAG 
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Full length HP1γ in pGEX-3X vector 
DNA sequence: 
ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTTTTGGAATATCTTGAA
GAAAAATATGAAGAGCATTTGTATGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTG
GAGTTTCCCAATCTTCCTTATTATATTGATGGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATA
GCTGACAAGCACAACATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTG
GATATTAGATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTCAAAGTTGATTTTCTTAGCAAG
CTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAACATATTTAAATGGTGATCATGTAACCCAT
CCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACATGGACCCAATGTGCCTGGATGCGTTCCCAAAA
TTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCA
TGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGATCGAAGGTCGT
GGGATCCCCCTGGCGGGTACTATGGCCTCCAATAAAACTACATTGCAAAAAATGGGAAAGAAACAAAATGGAAAG
AGTAAAAAAGTTGAAGAGGCAGAGCCTGAAGAATTTGTGGTAGAAAAAGTACTGGACCGTCGTGTAGTGAATGGG
AAGGTGGAGTATTTCCTGAAGTGGAAGGGGTTCACAGATGCTGATAATACTTGGGAACCAGAAGAAAATTTAGAT
TGTCCAGAATTAATTGAAGCATTTCTTAATTCTCAAAAAGCTGGTAAAGAAAAAGATGGTACAAAAAGGAAATCT
TTATCTGACAGTGAATCTGATGATAGCAAATCGAAGAAGAAGAGAGATGCTGCTGACAAACCAAGGGGCTTTGCC
AGAGGTCTCGACCCTGAACGAATAATCGGCGCCACAGACAGCAGCGGAGAGTTAATGTTTCTCATGAAGTGGAAG
GACTCGGACGAGGCCGACTTGGTGCTGGCAAAGGAGGCGAACATGAAGTGTCCTCAGATTGTCATTGCCTTCTAC
GAGGAGCGGCTGACTTGGCATTCTTGTCCTGAAGATGAAGCACAATAA 
 
Amino acid sequence: 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYI
ADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTH
PDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLIEGR
GIPLAGTMASNKTTLQKMGKKQNGKSKKVEEAEPEEFVVEKVLDRRVVNGKVEYFLKWKGFTDADNTWEPEENLD
CPELIEAFLNSQKAGKEKDGTKRKSLSDSESDDSKSKKKRDAADKPRGFARGLDPERIIGATDSSGELMFLMKWK
DSDEADLVLAKEANMKCPQIVIAFYEERLTWHSCPEDEAQ. 
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C-terminal HP1β in pGEX-3X vector 
DNA sequence: 
ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTTTTGGAATATCTTGAA
GAAAAATATGAAGAGCATTTGTATGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTG
GAGTTTCCCAATCTTCCTTATTATATTGATGGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATA
GCTGACAAGCACAACATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTG
GATATTAGATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTCAAAGTTGATTTTCTTAGCAAG
CTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAACATATTTAAATGGTGATCATGTAACCCAT
CCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACATGGACCCAATGTGCCTGGATGCGTTCCCAAAA
TTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCA
TGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGATCGAAGGTCGT
GGGATCCCCCTGGCGGGTACTCGGGGTTTGGAGCCAGAGCGGATTATTGGAGCTACTGACTCCAGTGGAGAGCTC
ATGTTCCTGATGAAATGGAAAAACTCTGATGAGGCTGACCTGGTCCCTGCCAAGGAAGCCAATGTCAAGTGCCCA
CAGGTTGTCATATCCTTCTATGAGGAAAGGCTAACGTGGCATTCCTACCCCTCAGAGGATGATGACAAAAAAGAC
GACAAGAATTAG 
 
Amino acid sequence: 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYI
ADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTH
PDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLIEGR
GIPLAGTRGLEPERIIGATDSSGELMFLMKWKNSDEADLVPAKEANVKCPQVVISFYEERLTWHSYPSEDDDKKD
DKN. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
122 
 
N-terminal HP1β in pGEX-4T-3 vector 
DNA sequence: 
ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTTTTGGAATATCTTGAA
GAAAAATATGAAGAGCATTTGTATGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTG
GAGTTTCCCAATCTTCCTTATTATATTGATGGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATA
GCTGACAAGCACAACATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTG
GATATTAGATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTCAAAGTTGATTTTCTTAGCAAG
CTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAACATATTTAAATGGTGATCATGTAACCCAT
CCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACATGGACCCAATGTGCCTGGATGCGTTCCCAAAA
TTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCA
TGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGCTGGTTCCGCGT
GGATCCAGAAAGCTGGCGGGTACTATGGGGAAAAAGCAAAACAAGAAGAAAGTGGAGGAGGTACTAGAAGAAGAG
GAAGAGGAATATGTGGTGGAAAAAGTTCTTGATCGGCGAGTTGTCAAGGGCAAGGTGGAATATCTTCTAAAGTGG
AAGGGTTTCTCAGATGAGGACAACACTTGGGAGCCAGAAGAGAATCTGGATTGCCCTGACCTTATTGCTGAGTTT
CTACAGTCACAGAAAACAGCTCATGAGACAGATAAGTCAGAGGGAGGCAAGCGCAAAGCTGATTCTGATTCTGAA
GATAAAGGAGAGGAAAGCAAACCAAAGAAGAAGAAAGAAGAGTCAGAAAAGCCACGAGGCTTTGCCCGGGTCGAC
TCGAGCGGCCGCATCGTGACTGACTGA 
 
Amino acid sequence: 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYI
ADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTH
PDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRG
SRKLAGTMGKKQNKKKVEEVLEEEEEEYVVEKVLDRRVVKGKVEYLLKWKGFSDEDNTWEPEENLDCPDLIAEFL
QSQKTAHETDKSEGGKRKADSDSEDKGEESKPKKKKEESEKPRGFARVDSSGRIVTD. 
 
Mutants of GST-N-terminal HP1β 
V23M  : valine 23 to methionine, GTG to ATG 
R29/30Q  : arginine 29 and 30 to glutamine, CGGCGA to CAACAA 
K33Q  : lysine 33 to glutamine, AAG to CAG 
F45E   : phenylalanine 45 to glutamic acid, TTC to GAA 
T51A  : threonine 51 to alanine, ACT to GCT 
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Sequences of His fusion proteins 
Color code: Hexahistidine tag sequence     HP1 sequence    
Full length HP1β in pQE-30 vector 
DNA sequence: 
ATGAGAGGATCGCATCACCATCACCATCACGGATCCATGGGAAAAAAGCAAAACAAGAAGAAAGTGGAGGAGGTA
CTAGAAGAAGAGGAAGAGGAATATGTGGTGGAAAAAGTTCTTGATCGGCGAGTTGTCAAGGGCAAGGTGGAATAT
CTTCTAAAGTGGAAGGGTTTCTCAGATGAGGACAACACTTGGGAGCCAGAAGAGAATCTGGATTGCCCTGACCTT
ATTGCTGAGTTTCTACAGTCACAGAAAACAGCTCATGAGACAGATAAGTCAGAGGGAGGCAAGCGCAAAGCTGAT
TCTGATTCTGAAGATAAAGGAGAGGAAAGCAAACCAAAGAAGAAGAAAGAAGAGTCAGAAAAGCCACGAGGCTTT
GCCCGGGGTTTGGAGCCAGAGCGGATTATTGGAGCTACTGACTCCAGTGGAGAGCTCATGTTCCTGATGAAATGG
AAAAACTCTGATGAGGCTGACCTGGTCCCTGCCAAGGAAGCCAATGTCAAGTGCCCACAGGTTGTCATATCCTTC
TATGAGGAAAGGCTAACGTGGCATTCCTACCCCTCAGAGGATGATGACAAAAAAGACGACAAGAATTAGAAGCTT
AATTAG 
 
Amino acid sequence: 
MRGSHHHHHHGSMGKKQNKKKVEEVLEEEEEEYVVEKVLDRRVVKGKVEYLLKWKGFSDEDNTWEPEENLDCPDL
IAEFLQSQKTAHETDKSEGGKRKADSDSEDKGEESKPKKKKEESEKPRGFARGLEPERIIGATDSSGELMFLMKW
KNSDEADLVPAKEANVKCPQVVISFYEERLTWHSYPSEDDDKKDDKN. 
 
Mutants of His HP1β 
V23M : valine 23 to methionine, GTG to ATG 
F45E  : phenylalanine 45 to glutamic acid, TTC to GAA 
T51A : threonine 51 to alanine, ACT to GCT 
I161E : isoleucine 161 to glutamic acid, ATA to GAG 
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Results from collaborations are outlined when discussing the respective data 
 
Telomere FISH and Giemsa Staining 
was done in collaboration with Prof. T. Pandita (WUSOM, St. Louis, USA) 
 
Transient expression of EGFP fusion proteins and immunofluorescence staining 
was done in collaboration with Dr. K. Okamoto (Scripps, San Diego, USA) 
 
FLOW-FISH analysis 
was done in collaboration with Dr. U. Brassat/Prof. T. Brummendorf (UKE, Hamburg, 
Germany) 
 
Retroviral transduction of RAS and proliferation assay 
was done in collaboration with Dr. M. Balabanov/Prof. T. Brummendorf (UKE, 
Hamburg, Germany) 
 
 
